Psychoeducation with problem-solving (PEPS) therapy

for adults with personality disorder: a pragmatic

randomised controlled trial to determine the clinical

effectiveness and cost-effectiveness of a manualised

intervention to improve social functioning by McMurran, Mary et al.
McMurran, Mary and Crawford, Mike J. and Reilly, Joe 
and Delport, Juan and McCrone, Paul and Whitham, 
Diane and Tan, Wei and Duggan, Conor and 
Montgomery, Alan A. and Williams, Hywel C. and 
Adams, Clive E. and Jin, Huajie and Lewis, Matthew and 
Day, Florence (2016) Psychoeducation with problem-
solving (PEPS) therapy for adults with personality 
disorder: a pragmatic randomised controlled trial to 
determine the clinical effectiveness and cost-
effectiveness of a manualised intervention to improve 
social functioning. Health Technology Assessment, 20 
(52). ISSN 1366-5278 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/44805/1/PEPS%20Personality%20Disorder%20HTA
%2020162052.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 20 ISSUE 52 JULY 2016
ISSN 1366-5278
DOI 10.3310/hta20520
Psychoeducation with problem-solving (PEPS) therapy 
for adults with personality disorder: a pragmatic 
randomised controlled trial to determine the clinical 
effectiveness and cost-effectiveness of a manualised 
intervention to improve social functioning
Mary McMurran, Mike J Crawford, Joe Reilly, Juan Delport, Paul McCrone, 
Diane Whitham, Wei Tan, Conor Duggan, Alan A Montgomery,  
Hywel C Williams, Clive E Adams, Huajie Jin, Matthew Lewis  
and Florence Day on behalf of the PEPS Trial Collaborative Group

Psychoeducation with problem-solving
(PEPS) therapy for adults with personality
disorder: a pragmatic randomised
controlled trial to determine the clinical
effectiveness and cost-effectiveness of a
manualised intervention to improve
social functioning
Mary McMurran,1* Mike J Crawford,2 Joe Reilly,3,4
Juan Delport,5 Paul McCrone,6 Diane Whitham,7
Wei Tan,7 Conor Duggan,1,8 Alan A Montgomery,7
Hywel C Williams,7 Clive E Adams,1 Huajie Jin,6
Matthew Lewis5 and Florence Day7 on behalf of the
PEPS Trial Collaborative Group
1Institute of Mental Health, University of Nottingham, Nottingham, UK
2Centre for Mental Health, Imperial College London, London, UK
3School of Medicine, Pharmacy & Health, Centre for Integrated Health Care
Research, Durham University, Durham, UK
4Tees, Esk & Wear Valleys NHS Foundation Trust, Middlesbrough, UK
5Centre for Psychological Therapies, Cwm Taf University Health Board,
Mountain Ash, UK
6Institute of Psychiatry, King’s College London, London, UK
7Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
8Partnerships in Care, Nottingham, UK
*Corresponding author
Declared competing interests of authors: Hywel Williams is Deputy Director of the National Institute
for Health Research (NIHR) Programme and chairperson of the Health Technology Assessment (HTA)
Commissioning Board. From 1 January 2016 he became Programme Director for the HTA programme.
The NIHR HTA programme funded this study; however, Professor Williams was not involved in that
funding decision.
Disclaimer: This report contains transcripts of interviews conducted in the course of the research and
contains language that may offend some readers.
Published July 2016
DOI: 10.3310/hta20520

This report should be referenced as follows:
McMurran M, Crawford MJ, Reilly J, Delport J, McCrone P, Whitham D, et al. Psychoeducation
with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised
controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised
intervention to improve social functioning. Health Technol Assess 2016;20(52).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.058
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: nihredit@southampton.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 08/53/06. The contractual start date
was in February 2010. The draft report began editorial review in November 2014 and was accepted for publication in December 2015. The
authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and
publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on
the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a
commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials
and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical 
School, UK
Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School,  
University of Warwick, UK
Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK
Ms Tara Lamont Scientific Advisor, NETSCC, UK
Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society,  
Newcastle University, UK
Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK
Professor John Norrie Health Services Research Unit, University of Aberdeen, UK
Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: nihredit@southampton.ac.uk
Professor Geoffrey Meads Professor of Health Sciences Research, Health and Wellbeing Research and
Development Group, University of Winchester, UK
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK
Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Psychoeducation with problem-solving (PEPS) therapy for
adults with personality disorder: a pragmatic randomised
controlled trial to determine the clinical effectiveness and
cost-effectiveness of a manualised intervention to improve
social functioning
Mary McMurran,1* Mike J Crawford,2 Joe Reilly,3,4 Juan Delport,5
Paul McCrone,6 Diane Whitham,7 Wei Tan,7 Conor Duggan,1,8
Alan A Montgomery,7 Hywel C Williams,7 Clive E Adams,1 Huajie Jin,6
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3School of Medicine, Pharmacy & Health, Centre for Integrated Health Care Research,
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4Tees, Esk & Wear Valleys NHS Foundation Trust, Middlesbrough, UK
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6Institute of Psychiatry, King’s College London, London, UK
7Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK
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*Corresponding author mary.mcmurran@nottingham.ac.uk
Background: If effective, less intensive treatments for people with personality disorder have the potential
to serve more people.
Objectives: To compare the clinical effectiveness and cost-effectiveness of psychoeducation with
problem-solving (PEPS) therapy plus usual treatment against usual treatment alone in improving
social problem-solving with adults with personality disorder.
Design: Multisite two-arm, parallel-group, pragmatic randomised controlled superiority trial.
Setting: Community mental health services in three NHS trusts in England and Wales.
Participants: Community-dwelling adults with any personality disorder recruited from community mental
health services.
Interventions: Up to four individual sessions of psychoeducation, a collaborative dialogue about
personality disorder, followed by 12 group sessions of problem-solving therapy to help participants learn a
process for solving interpersonal problems.
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Main outcome measures: The primary outcome was measured by the Social Functioning Questionnaire
(SFQ). Secondary outcomes were service use (general practitioner records), mood (measured via the Hospital
Anxiety and Depression Scale) and client-specified three main problems rated by severity. We studied the
mechanism of change using the Social Problem-Solving Inventory. Costs were identified using the Client
Service Receipt Inventory and quality of life was identified by the European Quality of Life-5 Dimensions
questionnaire. Research assistants blinded to treatment allocation collected follow-up information.
Results: There were 739 people referred for the trial and 444 were eligible. More adverse events in the
PEPS arm led to a halt to recruitment after 306 people were randomised (90% of planned sample size);
154 participants received PEPS and 152 received usual treatment. The mean age was 38 years and 67%
were women. Follow-up at 72 weeks after randomisation was completed for 62% of participants in the
usual-treatment arm and 73% in the PEPS arm. Intention-to-treat analyses compared individuals as
randomised, regardless of treatment received or availability of 72-week follow-up SFQ data. Median
attendance at psychoeducation sessions was approximately 90% and for problem-solving sessions was
approximately 50%. PEPS therapy plus usual treatment was no more effective than usual treatment alone
for the primary outcome [adjusted difference in means for SFQ –0.73 points, 95% confidence interval (CI)
–1.83 to 0.38 points; p= 0.19], any of the secondary outcomes or social problem-solving. Over the
follow-up, PEPS costs were, on average, £182 less than for usual treatment. It also resulted in 0.0148 more
quality-adjusted life-years. Neither difference was statistically significant. At the National Institute for Health
and Care Excellence thresholds, the intervention had a 64% likelihood of being the more cost-effective
option. More adverse events, mainly incidents of self-harm, occurred in the PEPS arm, but the difference
was not significant (adjusted incidence rate ratio 1.24, 95% CI 0.93 to 1.64).
Limitations: There was possible bias in adverse event recording because of dependence on self-disclosure
or reporting by the clinical team. Non-completion of problem-solving sessions and non-standardisation of
usual treatment were limitations.
Conclusions: We found no evidence to support the use of PEPS therapy alongside standard care for
improving social functioning of adults with personality disorder living in the community.
Future work: We aim to investigate adverse events by accessing centrally held NHS data on deaths and
hospitalisation for all PEPS trial participants.
Trial registration: Current Controlled Trials ISRCTN70660936.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 52.
See the NIHR Journals Library website for further project information.
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Plain English summary
A personality disorder is a pattern of beliefs and behaviour that causes distress and difficulties to boththe affected person and others. We conducted a well-designed evaluation of a treatment called
psychoeducation with problem-solving (PEPS) to see if it improved social functioning, which is how well
people get on in their day-to-day lives. Psychoeducation involves up to four sessions of an individual
talking with a mental health professional about their diagnosis of personality disorder and what it means
for them. Participants are then offered 12 group sessions to learn a problem-solving approach to overcome
some of their difficulties. We recruited 306 adults and divided them randomly (by chance) to receive PEPS
plus usual treatment or usual treatment alone. We planned to recruit 340 people but it was noticed that
people receiving PEPS had more adverse events, such as hospital admissions, than those who did not and
so we stopped recruiting people early. About 12 months after the end of treatment we found no
differences in social functioning between those who received PEPS and those who did not. There were no
differences on any other measures – cost of services, quality of life, mood or problem severity. There were
more adverse events reported in the PEPS group, but this difference could be as a result of chance. We
found no evidence to support the use of PEPS therapy alongside standard care within the NHS to improve
social functioning of adults with personality disorder living in the community.
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Scientific summary
Background
Personality disorder (PD) is one of the most prevalent forms of mental health problem, and is associated
with substantial health-care and social costs. Despite this, there is relatively little reliable evidence on the
effectiveness of treatments for PD.
Many treatments for PD are intensive and of long duration, which limits the amount of services that can be
provided. Testing the clinical effectiveness and cost-effectiveness of shorter interventions is important if
more people with PD are to be treated. Additionally, interventions that can be used with any PD have the
potential for more efficient service delivery. In treating groups of people with mixed PDs, the treatment
target necessarily needs to be a problem common to all. One core feature of all PDs is the experience of
problems with social and interpersonal functioning. Social problem-solving therapy is one viable and
empirically supported approach. Meta-analyses of problem-solving therapy outcome studies document its
effectiveness for people with a wide range of mental health problems.
A combined psychoeducational intervention aimed at clarifying the PD diagnosis, identifying associated
problems and leading into group problem-solving therapy has been developed. Psychoeducation with
problem-solving (PEPS) therapy was evaluated with adults with PD in the community, in an exploratory
trial. In this trial, those treated with PEPS therapy showed better social functioning, as measured by the
Social Functioning Questionnaire (SFQ), at the end of treatment than those in a wait-list control group.
Here, we present the results of a multisite randomised controlled trial of PEPS therapy.
Objectives
The study aimed to determine if PEPS therapy in addition to usual treatment compared with usual
treatment alone for people with PD resulted in improved social functioning at follow-up 72 weeks
after randomisation.
In addition, we planned to:
l assess the costs and cost-effectiveness of PEPS therapy compared with usual treatment alone
l examine the effects on scheduled and unscheduled use of services
l examine the effect on mood
l evaluate participants’ perceived effects of the intervention
l evaluate referrers’ perceived effects of the intervention
l examine the process of change by testing the hypotheses:
¢ that psychoeducation improves the therapeutic relationship
¢ that social problem-solving therapy improves social problem-solving abilities
l conduct a qualitative investigation of the receipt of PEPS in practice to identify the views of
service users.
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Methods
Setting
Community mental health services in three NHS trusts in England and Wales.
Participants
Eligible participants were aged ≥ 18 years, living in the community and proficient in spoken English and
had capacity to provide informed consent. At the point of randomisation, participants were required to
have one or more probable PDs identified through the International Personality Disorder Examination
completed at screening. Exclusion criteria were a primary diagnosis of major functional psychosis,
insufficient degree of literacy, comprehension or attention to be able to engage in trial therapy and
assessments, engagement in a specific programme of psychological treatment for PD or likely to start such
treatment during the trial period, and participation in any other trial.
Interventions
This was a two-arm trial comparing PEPS therapy in addition to usual treatment with usual treatment only.
PEPS therapy is a combination of individual psychoeducation followed by group problem-solving therapy.
Psychoeducation consists of up to four sessions of information and dialogue about PDs, as experienced
by the individual and as assessed by the clinician. The aims are to build rapport, improve knowledge
and motivate participants for problem-solving therapy. Problem-solving therapy is a 12-session group
intervention designed to help people learn a strategy for solving interpersonal problems. Usual treatment
was not specified.
Training
The PEPS intervention was specified in treatment manuals, containing information about the theory
underpinning the treatment, the content of sessions, and the duration and frequency of sessions.
Therapists were qualified mental health nurses or psychology graduates with clinical experience.
Therapists were centrally trained by experienced clinicians, and regular supervision was provided.
Audiotapes of treatment delivery were scrutinised by the trainers to ensure that each therapist was adhering
to the treatment specification. Competence checklists were constructed for this assessment. Cut-off scores
for competence were agreed in advance and therapists were assessed for competence in delivering the
treatment. None of the therapists failed to meet the competence criteria on any of the measures.
Randomisation
Randomisation was based on a computer-generated pseudo-random code using random permuted blocks
of randomly varying size, created by the Nottingham Clinical Trials Unit in accordance with their standard
operating procedure and held on a secure server. Allocation was stratified by recruiting centre and sex.
Blinding
Participants, mental health workers delivering the interventions and participants’ usual-care teams
were aware of the treatment allocation. Most of the outcome data were obtained from self-report
questionnaires from patients who were not blind to treatment allocation. However, outcome measures
were administered by research assistants blinded to treatment allocation, and data entry and analyses were
conducted blind to allocation.
Outcomes
l The primary outcome of social functioning was measured by the SFQ, an eight-item self-report
questionnaire with scores ranging from 0 to 24. A lower score is more desirable.
l Costs and cost-effectiveness were based on the Client Service Receipt Inventory and the European
Quality of Life-5 Dimensions (EQ-5D) questionnaire, a health status measure used to generate
quality-adjusted life-years (QALYs).
SCIENTIFIC SUMMARY
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l Scheduled and unscheduled use of services was based on information in general practitioner records,
with emergency department visits and attendances at crisis resolution teams designated unscheduled.
l Mood was measured by the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report
questionnaire with scores ranging from 0 to 42. Higher scores are less desirable.
l Referrers’ perceived effects of the intervention were assessed using the Global Assessment of
Functioning (GAF), a rating scale used to rate the social, occupational and psychological functioning of
adults from low (score 1) to superior (score 100).
l Participants were asked to specify three main problems they wished to change and rate these on
severity on a scale from not at all distressing (0) to very distressing (10).
l Therapeutic relationship was assessed using the Working Alliance Inventory – Short Revised (WAI-SR), a
12-item scale rated by both client and therapist to assess agreement on the tasks and goals of therapy,
and the bond between client and therapist, with a range of scores between 12 (poor) and 48 (good).
l Social problem-solving abilities were measured by the Social Problem-Solving Inventory – Revised: Short
Version (SPSI-R), a 25-item self-report questionnaire that measures problem-solving orientations and
styles. A total social problem-solving score ranges from 0 to 25, with a higher score being more desirable.
Sample size
Allowing for 30% attrition, we estimated that 340 participants would be needed to detect a 2-point
difference (standardised effect size of 0.44) on the SFQ with 80% power and 1% two-sided alpha.
Analysis plan
Clinical effectiveness
The primary between-group comparison for the primary outcome was implemented using a multivariable
linear regression model following the intention-to-treat principle with multiple imputation of the missing
data. The analysis was adjusted by outcome at baseline and stratification variables and allowed for
potential clustering by problem-solving group in the PEPS arm. Sensitivity analyses were conducted as
follows: (1) intention to treat without imputation of missing data; (2) further adjustment of baseline
variables with marked imbalance between arms; and (3) estimating the impact of adherence to
intervention on treatment effect.
Analysis of secondary outcomes, health-service use and adverse events was conducted using a similar
approach as for the primary outcome, dependent on the outcome type and without imputation of missing
data. The exception to this was the SPSI-R total score, which was analysed using repeated measures by
including both SPSI-R score at 24 and 72 weeks.
Cost-effectiveness
The cost of the PEPS intervention was estimated using information on the core resources required to
deliver the individual and group sessions, and estimating specific costs for those inputs. Health service use
was measured using the Client Service Receipt Inventory. Cost data are frequently skewed; therefore,
bootstrapped estimates were planned so that mean costs could be compared while imposing no prior
assumptions regarding the data distribution. The EQ-5D was used to measure health-related quality of life,
with utility scores attached to each health state used to generate QALY gains over the follow-up period
(using area under the curve methods and assuming a linear change between any two adjacent time
points). Baseline data were analysed using a regression model to identify variables significantly associated
with cost. If PEPS resulted in higher costs and better outcomes, then incremental cost-effectiveness ratios
were to be computed. Uncertainty around these was explored using cost-effectiveness planes. In addition,
cost-effectiveness acceptability curves were generated using the net benefit approach in order to
determine the likelihood that the intervention was the most cost-effective option. These probabilities were
subsequently used to generate the cost-effectiveness acceptability curves.
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Results
A difference in the number of reported adverse events caused concern about the safety of PEPS therapy
and led to an early cessation of recruitment after 306 people had been randomised: 154 in the PEPS arm
and 152 in the usual-treatment arm.
Follow-up at 72 weeks after randomisation was completed for 62% and 73% in the usual-treatment and
PEPS arms, respectively. In addition to a greater proportion of completers, duration of follow-up among
non-completers was also greater in the PEPS arm, which resulted in a total of 178 and 203 person-years of
follow-up in the usual-treatment and PEPS arms, respectively.
Median attendance at the individual psychoeducation sessions was approximately 90% and for
problem-solving group sessions was around 50%. Regarding group sessions, 47% (n= 63) received a
partial intervention (i.e. ≤ 5 group sessions) and 53% (n= 70) received the intervention as per protocol
(i.e. ≥ 6 group sessions). Complier average causal effect (CACE) analysis suggests that compliance increases
the effect, but none of the sensitivity analyses supports different conclusions from the primary analysis.
Psychoeducation with problem-solving therapy plus usual treatment was no more effective than usual
treatment alone on the primary outcome [adjusted difference in means for SFQ –0.73 points, 95%
confidence interval (CI) –1.83 to 0.38 points; p= 0.19]. No difference was found in scheduled service use
(adjusted incidence rate ratio 0.91, 95% CI 0.69 to 1.21; p= 0.54), unscheduled service use (adjusted
incidence rate ratio 0.87, 95% CI 0.60 to 1.26; p= 0.47), HADS score (adjusted difference in means –1.2,
95% CI –4.2 to 1.8; p= 0.44) or on severity ratings of three main problems (adjusted difference in means
–0.3, 95% CI –1.0 to 0.5; p= 0.48). Insufficient data precluded analyses of the GAF. There was no
difference in the total SPSI-R score (adjusted difference in means 0.14, 95% CI –0.53 to 0.82; p= 0.68) or
on any of the subscales. Insufficient data precluded analyses of the WAI. By the final follow-up, the mean
costs for the usual-treatment group were £182 higher than for the PEPS group, but the difference was
not significant. Similarly, the PEPS group had higher QALYs (adjusted difference in mean gains from
baseline to end point 0.015), but the difference was not significant.
By the end of the trial, both the number of reported adverse events, including serious adverse events, and
the number of people experiencing them were greater in the PEPS arm. Statistical analysis that allows for
the higher follow-up in the PEPS arm shows a tendency for PEPS participants to experience more adverse
events, although the results are inconclusive (adjusted incidence rate ratio 1.24, 95% CI 0.93 to 1.64).
Discussion
We found no evidence to support the use of PEPS therapy alongside standard care for improving the social
functioning of adults with PD living in the community. This differs from the pilot study, in which significant
improvement was found in the primary outcome of social functioning, measured, as in this trial, by the
SFQ. The trial reported here was superior in its design and methods: it was multisite, there was a larger
number of participants providing greater precision of estimated between-group differences, the follow-up
period was considerably longer and the methods of imputing missing data were more sophisticated.
Hence, greater confidence can be placed in these results. More adverse events, mainly incidents of
self-harm, occurred in the PEPS arm but the difference was not significant. There may have been bias in
recording adverse events because more people in the PEPS arm were followed up and for longer.
SCIENTIFIC SUMMARY
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Recently, evidence has been accruing from trials that structured clinical management achieves equally
good outcomes as specific treatments for PD. It may be that specialist treatments benefited primarily by
minimising harm, possibly through preventing unco-ordinated care. In the PEPS trial, treatment was
delivered as a stand-alone therapy rather than being integrated into a co-ordinated package of care.
This may have been a serious shortcoming. One possible explanation for the higher number of reported
adverse events in the treatment arm is that the treatment stopped without any structured follow-up, thus
leaving participants unsupported after a period of treatment. To have one’s support withdrawn may be
more damaging than to have had little or no support in the first place.
Conclusion
Psychoeducation with problem-solving therapy should not be promoted for people in mental health
services who are diagnosed with PD, at least not in the absence of a structured, comprehensive clinical
care package. Harm is most likely to be caused by leaving people unsupported after the conclusion of brief
interventions rather than by PEPS itself, with some evidence for this being the CACE analysis showing that
more uptake of treatment leads to better outcomes. Use of any brief problem-solving interventions in
practice should be conducted only with rigorous collection of data on adverse effects, in the context of the
need for better awareness and measurement of adverse events in psychotherapy practice as a whole.
Overall, participants in this trial were heavy users of health services, costing approximately £8000 per
annum (based on baseline data). This is reflected in low quality of life, with QALYs of approximately
0.57 over the entire follow-up (out of a possible 1.5 QALYs). It is important to continue to seek effective
management and treatment for this group of individuals.
Trial registration
The trial is registered as ISRCTN70660936.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Aims
The study aimed to determine if psychoeducation with problem-solving (PEPS) therapy in addition to usual
treatment for people with personality disorder (PD) results in improved social functioning 72 weeks after
randomisation (approximately 12 months after the end of treatment), compared with treatment as
usual alone.
In addition, we intended to:
l assess the costs and cost-effectiveness of PEPS therapy in addition to usual treatment compared with
usual treatment alone
l examine the effects on scheduled and unscheduled use of services
l examine the effect on mood, as measured by the Hospital Anxiety and Depression Scale (HADS)
l evaluate referrers’ perceived effects of the intervention using the Global Assessment of
Functioning (GAF)
l evaluate participants’ perceived effects of the intervention in relation to the severity of the
self-identified three most important problems
l examine the process of change by testing the hypotheses:
¢ that psychoeducation improves the therapeutic relationship
¢ that social problem-solving therapy improves social problem-solving skills
l conduct a qualitative investigation of the receipt of PEPS therapy in practice to identify the views of
service users.
Scientific background
Personality disorder
Personality disorder is one of the most common mental health problems, and it is associated with
substantial health-care costs.1–3 Compared with those with no PD, people with PD show higher rates of
premature mortality,4 greater engagement in health-compromising behaviours such as substance abuse,1
greater levels of general health problems5 and more use of health-care services.6 PD is also associated with
financial difficulties and problems maintaining jobs,5 marital dissatisfaction and intimate partner violence,7
crime8 and poor quality of life.9 These matters make a strong case for treating people with PD.
Despite this, there is relatively little reliable evidence on the effectiveness of treatments for PD. Systematic
reviews of all psychosocial treatments for PD identified only 27 randomised controlled trials (RCTs)
published up to 200610,11 and only a few trials have been published since then.12,13 The majority of studies
are underpowered and most related to one specific PD – borderline PD. Chambless and Hollon’s14
criterion for a treatment to be considered effective is that there should be at least two independent,
well-conducted RCTs or single-case experiments. Only one therapy meets this criterion; dialectical
behaviour therapy is more effective than usual treatment for reducing suicide attempts, service use and
borderline symptomatology in borderline PD, although positive effects decay over time.12 However, other
cognitive and behavioural interventions are supported by single RCTs.
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Many treatments for PD are intensive and of long duration, which limits the number of services that can be
provided. Hence, the great majority of people who may benefit from psychological treatments do not
receive them. Testing the clinical effectiveness and cost-effectiveness of shorter interventions is important if
more people with PD are to be treated. Additionally, interventions that can be used with any PD have the
potential to alleviate the burden on clinical services that can be created if specific types of PD need to be
identified for treatment allocation, and if groups of service users with specific PDs need to be gathered for
treatment to commence. In treating groups of people with mixed PDs, the treatment target necessarily
needs to be a problem common to all.
One core feature of all PDs is the experience of problems with social and interpersonal functioning.15–17
One relatively brief skills-training approach to improving problem-solving that has been evaluated
specifically with people with borderline PD is the Systems Training for Emotional Predictability and Problem
Solving (STEPPS) programme.18 STEPPS is a 20-week group treatment programme for individuals with PD
and others within that person’s system, such as family members, partners, friends and health-care
professionals. STEPPS focuses on psychoeducation, emotion management training and behaviour
management training. One RCT19 found that borderline symptoms were significantly more improved in
those in a STEPPS group (n= 65) than in those who received treatment as usual (n= 59); however, this
difference was no longer apparent at the 1-year follow-up. Improvements in secondary outcomes (including
GAF, negative affectivity, depression, impulsiveness) and symptoms were also significantly greater for the
STEPPS group post treatment but not at the 1-year follow-up. In another RCT,20 those who completed
STEPPS (n= 33) were compared with those who received treatment as usual (n= 33), with no significant
group differences in PD or other psychological symptoms at the 6-month follow-up, although the STEPPS
group showed a significantly greater improvement in overall quality of life. There are clearly improvements
to be made to problem-solving approaches for people with PD in terms of enhancing and sustaining
outcomes and, as mentioned, offering a problem-solving approach to people with PDs other than
borderline is a more practical prospect. Social problem-solving therapy is one viable and empirically
supported alternative.
Social problem-solving therapy
Good social problem-solving is one component of social competence.21,22 Social problem-solving is defined as
‘the self-directed cognitive-affective-behavioural process by which an individual attempts to identify or
discover solutions to specific problems encountered in everyday living’23 (p.11). There is abundant evidence of
an association between social problem-solving deficits and problems related to PD.24–27 People with PD report
less desirable scores on all scales of the Social Problem-Solving Inventory – Revised: Short Version (SPSI-R)28
compared with a sample of mature students,22 and people high on borderline traits show poorer social
problem-solving abilities than those with lower borderline traits, particularly when experiencing negative
emotions.29 This information suggests that social problem-solving therapy may benefit people with PD.
Problem-solving therapy is suited to people with PD because the focus is on improving social functioning
and reducing personal distress, which are considered to be of paramount importance in the treatment of
PD.30 The aim in problem-solving therapy is to help people to recognise their strengths and limitations, and
to work with these to learn new skills that will enable them to cope more effectively with life’s problems.
Problem-solving therapy works to decrease the person’s negative problem orientation and develop positive
orientation, without which therapy is unlikely to be effective.31
Engaging people with PD in treatment is a major challenge.32,33 The social problem-solving approach
enhances engagement by offering an accessible framework for change, supporting people in the
experience of successful problem-solving and encouraging independence rather than reliance on therapy.
Furthermore, the preliminary psychoeducation component of PEPS therapy aims to educate, build
rapport and motivate people for problem-solving therapy.34 PDs and their impact are discussed in a
collaborative dialogue and problems that may be worked on in subsequent group sessions are identified.
Psychoeducation has shown good effects with people with borderline PD, showing significantly greater
declines in general impulsivity and the storminess of close relationships over 12 weeks than in those who
did not receive psychoeducation.35
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Meta-analyses of problem-solving therapy outcome studies document its effectiveness for people with a
wide range of mental health problems.31,36,37 Detained PD offenders were identified as performing poorly in
all aspects of social problem-solving compared with offenders with no PD and non-offenders.38,39 A pilot
study of a psychoeducational intervention aimed at clarifying the offenders’ PD diagnosis and identifying
associated problems led to an increase in patients’ knowledge about PD and improved the therapeutic
alliance.34 A brief problem-solving therapy was evaluated with this client group, finding that social
problem-solving abilities improved post therapy and that this improvement was sustained at a 6-month
follow-up.40 A social problem-solving intervention has also been evaluated with women in a secure setting,
with improvements after treatment in risk and health,41 and with people at high risk of suicide, showing
reduced suicidal ideation over those receiving treatment as usual.42
Psychoeducation with problem-solving therapy
A combined PEPS therapy was evaluated with community adults with PD in a Phase 2 exploratory trial.43
Overall, this sample had the lowest social problem-solving scores in comparison with mature students,
prisoners and PD offenders.44 At the end of treatment, compared with a wait-list control group, those
treated with PEPS therapy showed better social functioning, as measured by the Social Functioning
Questionnaire (SFQ).45 Analyses were conducted to examine the hypothesised mechanism of change,
namely that improved social problem-solving leads to improved social functioning.46 These analyses
indicated that all aspects of social problem-solving improved over the course of PEPS therapy and, that
controlling for baseline level of social functioning, the most important predictor of improvement in social
functioning was a reduction in negative problem orientation (i.e. people felt less threatened by problems
and more confident in their ability to solve problems). This exploratory study has been identified as
important in four ways.47,48 First, the intervention was brief and, hence, is likely to be more acceptable to
patients and services. Second, PEPS therapy was delivered in clinical settings, hence its likely effectiveness
in everyday practice was indicated. Third, PEPS therapy was offered to people with any PD or combination
of PDs, so it was inclusive rather than exclusive. Finally, non-specialist staff delivered PEPS therapy; hence it
would be possible to deliver it relatively cheaply. In addition, a Delphi study of patients’ views of PEPS
therapy indicated that it was perceived as acceptable and useful.49
Overall, PEPS therapy has the potential to contribute to the Department of Health’s agenda that PD should
no longer be a diagnosis that excludes people from services.50 It is an intervention in which staff can easily
be trained and, thus, has the potential to make a significant contribution to building workforce capacity.51
Here, we present the results of an adequately powered, multisite RCT.
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Chapter 2 Methods
Design
The PEPS trial was a two-arm, parallel-group, pragmatic randomised controlled superiority trial comparing
PEPS therapy plus treatment as usual with treatment as usual alone. Participants were individually
randomised at a ratio of 1 : 1, and stratified by sex and centre.
An economic analysis was conducted alongside the trial to determine the costs and cost-effectiveness of
PEPS therapy compared with treatment as usual (see Chapter 5). In addition, a qualitative component
sought to explore participants’ experiences of PEPS therapy and treatment as usual (see Chapter 6).
Study setting and participants
Study participants were recruited from three NHS trusts providing mental health services in central and
north-west London, South Wales and the North-East of England.
We recruited participants from mental health services including community mental health teams (CMHTs),
crisis resolution teams, primary care liaison teams, psychology services and on discharge from inpatient care.
Eligibility criteria
At the point of randomisation participants were required to have one or more PD, including a PD not
otherwise specified, identified through the International Personality Disorder Examination (IPDE) completed
as part of the study-specific procedures at the screening visit. In addition, eligible participants were aged
≥ 18 years, living in the community (including residential or supported care settings) and proficient in
spoken English and had capacity to provide informed consent.
Exclusion criteria were a primary diagnosis of major functional psychosis, insufficient degree of literacy,
comprehension or attention to be able to engage in trial therapy and assessments, engagement in a
specific programme of psychological treatment for PD or likely to start such treatment during the trial
period and participation in any other trial.
Identification of participants
Participants were identified by their mental health team. The initial approach about the study was made by
a member of the potential participant’s mental health team, who sought verbal agreement from the
potential participant to meet with the research team to discuss the study. Referral to the research team
was made according to local procedures at each site.
All potential participants referred to the research team were recorded on the Participant Screening and
Enrolment Log, whether or not they were enrolled in the trial.
Recruitment
Potential participants providing verbal agreement were referred to the research team who assessed
eligibility according to the available clinical information, and invited potentially eligible participants to
consider taking part in the trial. Potential participants were provided with written and verbal information
about the trial and were given a minimum of 24 hours to consider whether or not to participate.
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All participants joining the study provided written, informed consent. Participants were free to withdraw
from the study at any time without giving a reason. If participants declined to complete follow-up
assessments when originally approached, the researcher sought verbal consent to contact them again at a
later stage to see if they were willing to complete the assessments.
Recruitment strategy
The identification and recruitment of participants was actively managed at each site to reduce potential
delays and group waiting times. Problem-solving group start dates were determined in advance, allowing
a time-limited baseline and randomisation period to be specified, based on recommended minimum and
maximum waiting times before commencement of treatment and between the individual and group
components of PEPS therapy. The specifications were that psychoeducation should be completed a
maximum of 4 weeks before the problem-solving group started. The maximum wait between
randomisation and the group starting should be 10 weeks and the minimum should be 5 weeks.
This enabled completion of the individual treatment sessions and first follow-up prior to the start of the
problem-solving group.
Within each recruitment phase there was an approximate 5-week period within which baseline
assessments and randomisation were completed for participants in a particular recruitment phase.
Randomisation was completed as soon as possible after baseline assessments and in all cases this should
have been done within 1 week.
A minimum starting group size of six was recommended. During the randomisation period, local teams
aimed to randomise a minimum of 12 participants to ensure an adequate minimum starting group size.
It was recommended that starting group sizes should generally be no more than 10 participants. However,
local teams could use discretion in determining the appropriate group starting size according to local
circumstances, current waiting times and recruitment rates.
Screening
To confirm eligibility for the trial the following screening measures were undertaken before randomisation:
1. The presence of PD was confirmed using the IPDE.52 The IPDE is a 99-item, semistructured interview
that allows both diagnostic and dimensional scores to be extracted for each PD according to either
Diagnostic and Statistical Manual of Mental Disorders (DSM)53 or International Classification of
Diseases54 criteria. DSM criteria were used in this trial. Each item is scored as the behaviour or trait
being absent or normal (score 0), exaggerated or accentuated (score 1), or at the criterion level or
pathological (score 2). Diagnostic scores were calculated in accordance with the scoring manual.
A minimum of one ‘probable’ score on any diagnostic category including PD not otherwise specified
was required to be eligible for the trial.
2. Adequate literacy was required to engage in trial therapies and assessments. In the majority of cases
this was assessed by the investigator or authorised designee in conjunction with the participant’s
usual-care team. Adequate literacy was determined in discussion with the participant and their clinical
team, based on the ability to participate in the trial therapy and assessments. The Basic Skills Agency’s,
Fast Track 20 Questions55 was available as an additional screening measure to aid assessment of
literacy if required, but was not used. Study recommendations were that a score of ≥ 3 on the literacy
component of the Fast Track 20 Questions indicated that additional consideration may be required,
but did not prohibit further involvement in the trial. The final decision about inclusion or exclusion
was made by the therapist in consultation with the referrer, the client and, if necessary, the site
coinvestigator or site clinical supervisor.
METHODS
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Interventions
This was a two-arm trial comparing PEPS therapy in addition to treatment as usual with treatment as
usual only.
Psychoeducation with problem-solving therapy
Psychoeducation with problem-solving therapy is a complex cognitive–behavioural intervention that
integrates individual and group therapies. There are two distinct components – individual psychoeducation
and group problem-solving therapy – with optional individual support sessions.
Psychoeducation
Psychoeducation consists of up to four sessions delivered by a mental health worker trained to administer
the procedure. The number of sessions depends on the duration of sessions and the speed at which
the participant can comfortably work through the session content. Although the guidance is to work in
1-hour sessions, some participants prefer to have longer and less frequent sessions to maintain the flow of
the content.
The sessions are conducted as a one-to-one collaborative dialogue and are designed to fulfil both general
and specific functions. In general, the aims are to build rapport with participants and enhance their
motivation for the subsequent problem-solving therapy. This is done specifically by asking participants their
views on how their personality leads to problems in interpersonal relationships and social functioning,
introducing them to and discussing their PD diagnoses, and explaining how therapy can help people
ameliorate their problems.
Interviewers follow a set procedure described in a facilitator’s manual (see Appendix 1). Participants are
first asked about their understanding of personality and any personality-related problems that they
experience in a brief interview consisting of six questions:
1. What does the word ‘personality’ mean to you?
2. Do you think your personality causes you problems? In what way?
3. Do you think your personality causes problems for other people? In what way?
4. Would you like to change the way you handle problems?
5. Some people are diagnosed as having a PD. Do you know what a PD is?
6. Have you ever been told you might have a PD?
Information on personality and PD is then provided, following an information sheet explaining the concept
of personality in terms of it being the way people typically think, feel and behave, and PD being personality
styles that persistently cause difficulties and distress. The suggestion that problem-solving therapy can help
ameliorate problems is then introduced. Participants are asked to complete a checklist of what problems
they experience in relation to their PD. The interviewer completes a checklist that takes the individual
through their PD diagnoses, as identified prerandomisation using the IPDE,52 which is a structured clinical
assessment. The interviewer and the participant discuss information about the individual’s personality
problems from both perspectives. Participants are then guided to identify specific problems that they want
to change, and prioritise those to be addressed in the subsequent problem-solving therapy sessions.
The interviewer summarises the progress made in psychoeducation and logs the problems to be addressed
in problem-solving therapy on a summary pro forma. This summary is used to convey the information
to the problem-solving therapy facilitators. The content of psychoeducation is also summarised in a
personalised booklet (see Appendix 2) that the participant is given to keep.
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Problem-solving therapy
Problem-solving therapy is a 12-session manualised (see Appendix 3) group intervention designed to teach
people a strategy for solving interpersonal problems. Problem-solving therapy is delivered by two mental
health professionals trained to administer the therapy. The recommended starting group size was between
6 and 10 participants, but local sites were advised to use discretion so that when trial recruitment was
slow, groups could start without undue delay; actual group sizes were between 5 and 12 participants.
Sessions lasted approximately 2 hours, divided into 75 minutes of problem-solving work, a 15-minute
break and 30 minutes of problem-solving work.
In each session, one participant worked through an actual problem that was identified in collaboration with
one of the group facilitators prior to the group session. The problem selected could be an emotional or
interpersonal problem, rather than a practical problem, and would be one that was current and important
but not excessively distressing or unsuited to sharing in a time-limited group. Participants were then guided
to learn the steps of the problem-solving process, based on the work of D’Zurilla and Nezu:56,57
(a) orientation – identifying negative feelings and using these as a cue for initiating the
problem-solving process
(b) problem definition – defining their problem clearly and accurately, breaking down large problems into
smaller, more manageable ones
(c) goal-setting – setting specific goals for change
(d) generating alternatives – generating solution options
(e) decision-making – considering the consequences of each option to themself and others in both the
short and the long term
(f) action-planning – selecting potentially effective options and organising these into a means-end
action plan.
Participants were then expected to implement the action plan and were offered optional fortnightly
individual support sessions throughout the 12-week problem-solving group therapy to help with
implementation. Progress with the action plan was reviewed in the next group session.
The problem-solving process is translated into colloquial questions, which are shown in Table 1, along with
the formal stages of the process and the skills learned in each stage.
TABLE 1 The problem-solving process
Question Stage Skills
Feeling bad? Orientation Recognition and understanding of feelings countering impulsivity
What’s my problem? Problem definition Information gathering
Assessing the quality and relevance of information
Breaking down large problems
What do I want? Goal-setting Identification of needs
Setting targets
What are my options? Alternatives Creative thinking
What’s my plan? Decision-making Challenging dysfunctional beliefs
Challenging antisocial attitudes
Anticipation of outcomes
Forward planning
How did I do? Evaluation Recognise and reward success
Recognise and address obstacles
METHODS
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Throughout this process, attention was paid to improving optimism and hope for change, which is
identified as of equal importance to problem-solving skills. This was done by helping participants experience
success in problem-solving through guiding them through the problem-solving process, giving them support
in their efforts to solve problems, identifying their strengths and highlighting problem-solving successes.
The process of problem-solving through addressing the key questions was recorded on a flip chart as
the session progressed. The flip chart could be written by a group member or one of the facilitators,
depending on the abilities of group members. This material was then transcribed to A4 sheets, which
were given to the participant for his or her records, and a copy retained for the facilitators’ records.
Individual support sessions of 1-hour duration were offered fortnightly to help the individual carry out
problem-solving action plans. Additionally, participants were encouraged to work through problems
independently outside sessions in order to generalise the new skills. A worksheet was provided to assist
with independent working.
Problem-solving therapy was provided in mixed- or single-sex groups, depending on the stage of the trial
(described in Changes to the intervention during the trial), the number and suitability of referrals received,
and participant preference. Participants allocated to PEPS therapy were expected to attend every session,
and regular attendance was encouraged in accordance with normal clinical practice. A record of
attendance at sessions was maintained for all participants. Participants were not withdrawn from trial
therapy for reasons of poor attendance. Owing to variable group attendance rates, a prespecified
minimum attendance at group treatments was defined for participants to be considered to have received
therapy per protocol. The agreed hypothesis was that attending ≥ 6 of the maximum 12 group sessions
of problem-solving therapy would be associated with improved outcomes on the SFQ.
Changes to the intervention during the trial
Within the trial, problem-solving groups were originally intended to be single sex. This was to ensure
consistency with the pilot study and in response to preferences expressed by service user representatives
advising on the design of the study during protocol development. However, the requirement for single-sex
groups was found to cause delays while awaiting the accrual of sufficient participants to form a group.
This was a particular issue for male participants because fewer men were referred to the study.
After consulting with the Trial Steering Committee (TSC), the study team took the decision to allow
problem-solving therapy to be offered in mixed-sex groups. The reasons for this were:
1. Mixed-sex groups are routine practice in community-based clinical services already offering
PEPS therapy.
2. Mixed-sex groups may help to reduce waiting times and delays between recruitment
and randomisation.
3. Mixed-sex groups can provide clinical benefits (e.g. helping participants to address issues with relating
to people of the opposite sex).
An amendment was submitted to the Research Ethics Committee to introduce this change in August 2011,
approximately halfway through the recruitment period. Following implementation of this amendment,
allocation to mixed- or single-sex groups was made in accordance with usual clinical practice, incorporating
participant preference where possible.
Treatment as usual
Usual treatment was provided by participants’ usual-care teams in accordance with normal clinical practice.
No restrictions were placed on access to other treatments during the trial period, although engagement in
a specific programme of psychological treatment for PD was an exclusion criterion applied at the point
of enrolment.
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The original protocol included a standardised form of treatment as usual as the control. Shortly after the
start of the recruitment period, it became apparent that there was substantial variability in the level and
type of care provided to people with PD at each of the participating sites. Many potential participants were
being assessed by mental health services and discharged without treatment. To exclude these people
would seriously compromise recruitment to the trial. For this reason, the study team could not impose a
standardised form of treatment as usual on the referring clinical services. The study team felt that this issue
was likely to become more pressing as NHS cuts at the time caused CMHTs to reduce services. As a result,
it was agreed that the trial should compare PEPS therapy with treatment as usual in whatever form that
took, and the planned requirement for a standardised form of treatment as usual was removed from the
protocol in August 2010. The standardised form of treatment as usual, outlined in the original protocol,
was recommended as a minimum standard of care but this was not imposed on clinical services referring
participants to the trial.
Treatment fidelity
Manualised assessment and treatments
The IPDE schedule, psychoeducation and problem-solving therapy are all comprehensively manualised.
Training and supervision
Therapists were qualified mental health nurses or psychology graduates with clinical experience. All IPDE
assessors attended training in administering and scoring the structured interview from a qualified and
highly experienced clinician and researcher. Each lead clinician who delivered psychoeducation and
problem-solving therapy was trained to conduct the intervention. Problem-solving therapy groups were
facilitated by two facilitators. Most cofacilitators also attended training in delivery of the intervention;
however, on the rare occasions that this was not possible, groups could be cofacilitated by a facilitator
who had not completed the training, provided that they were fully briefed by the lead therapist and were
aware of the limitations of their involvement. A minimum of one fully trained and assessed facilitator
was present at every group session.
Psychoeducation training was delivered after IPDE training and consisted of informing therapists of the
rationale for psychoeducation, explaining the delivery mode of an educational dialogue and familiarising
therapists with the materials and their sequence of delivery. Problem-solving therapy training consisted of
3 days in which groups of participants were given the theory, outcome evidence and role-play practice.
In each case (IPDE, psychoeducation and problem-solving), training followed an existing training protocol.
Training was conducted centrally by experienced clinicians and researchers. After training, regular
supervision was provided, both centrally and locally.
Competence checks
Audiotapes of treatment delivery were scrutinised by the trainers to ensure that each therapist was
adhering to the treatment specification. Competence checklists were constructed for this assessment
(see Appendices 4–6). These specified the key activities for conducting the IPDE and delivering
psychoeducation and problem-solving sessions according to the intended treatment model. Cut-off scores
for competence were agreed in advance and therapists were assessed for competence in delivering the
treatment. None of the therapists failed to meet the competence criteria on any of the measures. Having
assessed the therapists as competent to deliver the treatment according to the model and the protocol,
no further checks were made. This was considered to reflect actual clinical practice in which staff are
trained in a procedure and, if they meet the standards set by the trainers, they commence practice and the
quality of their continued practice is monitored through supervision.
METHODS
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Fidelity checks
Treatment fidelity was assessed in three ways:
1. Measuring adherence to protocol implementation (e.g. frequency and duration of treatment sessions).
2. Assessing adherence to therapy, as specified in the treatment manual.
3. Clinical supervision.
Adherence to psychoeducation was self-rated by the therapist after the end of all psychoeducation
sessions, using a standard protocol (see Appendix 7). Adherence to problem-solving group sessions was
rated by experienced clinicians, based on a sample of audiorecorded sessions.
Outcome measures
Primary outcome
The primary outcome was social functioning as measured by the SFQ.45 This is an 8-item self-report scale,
on which each item is scored from 0 to 3. The total SFQ score ranges from 0 to 24. A reduction
(i.e. an improvement) of ≥ 2 points on the SFQ at the 72-week follow-up was the specified clinically
significant change.
Secondary effectiveness outcomes
1. Scheduled and unscheduled health-service use collected through a retrospective review of mental
health service and general practitioner (GP) records.
2. Mood, measured by the HADS,58 a 14-item self-report questionnaire with scores in the range of 0 to
42, and on which higher scores are less desirable.
3. The referring clinician’s judgement of the participant’s overall level of psychosocial functioning assessed
by the GAF.53
4. The client’s assessment of severity, on a scale from not at all distressing (0) to very distressing (10),
of the three problems they considered most important (three main problems).
Process measures
The following measures were intended as measures of the processes of change during PEPS therapy:
1. Therapeutic relationship was assessed using the Working Alliance Inventory – Short Revised (WAI-SR),59
a 12-item scale rated by both client and therapist to assess agreement on the tasks of therapy,
agreement on the goals of therapy, and the bond between client and therapist, with a range of scores
between 12 (poor) and 48 (good).
2. Social problem-solving abilities were measured by the SPSI-R,28 a 25-item self-report questionnaire that
measures problem-solving orientations and styles, with five items in each of the five subscales: positive
problem orientation, negative problem orientation, rational problem-solving, impulsivity/careless style
and avoidance style. Effective social problem-solving is indicated by higher scores on positive problem
orientation, rational problem-solving and the SPSI-R, and lower scores on negative problem orientation,
impulsivity/careless style and avoidance style. A total social problem-solving score ranges from 0 to 25,
in which a higher score is more desirable.
Health economic outcomes
1. Receipt and cost of services were collected using the Client Service Receipt Inventory (CSRI).60
2. Quality of life was assessed by the European Quality of Life-5 Dimensions (EQ-5D),61 a health status
measure used to generate quality-adjusted life-years (QALYs).
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Participants’ views and experiences
Qualitative semistructured interviews were completed with participants allocated to PEPS therapy after
psychoeducation and after problem-solving therapy to seek participants’ views on treatment. Further
interviews were completed with all participants after the final follow-up to seek participants’ views on the
experiences of PEPS therapy and usual treatment.
Safety and tolerability measures
Adverse events occurring in trial participants were recorded and monitored. For the purposes of this trial,
a recordable adverse event was defined as any of the following:
l death for any reason
l inpatient hospitalisation for any reason
l any other serious, unexpected adverse event.
Adverse events were reported for all participants from consent to trial completion or early withdrawal from
trial follow-up. If a participant withdrew from treatment but agreed to remain in trial follow-up, data
collection, including adverse event reporting, continued in accordance with the protocol.
Premature withdrawal from the trial therapies or follow-up was reported, with reasons for withdrawal
documented when these were given.
Statistical methods
Statistical analysis
The analysis and reporting of the trial was in accordance with Consolidated Standards of Reporting Trials
(CONSORT) guidelines.62–65 Analyses were detailed in a statistical analysis plan, which was finalised prior
to completion of data collection and database lock. All analyses were conducted using Stata version 13
(StataCorp LP, College Station, TX, USA).
Preliminary analyses
Descriptive statistics of demographic and clinical measures were used to examine the balance between the
randomised arms at baseline.
Primary analysis
The primary analysis compared the mean SFQ score between PEPS and usual treatment at the 72-week
postrandomisation follow-up, adjusted for baseline SFQ score and stratification variables (centre and sex),
and implemented using maximum likelihood-based generalised linear modelling. The primary analysis
compared individuals as randomised, regardless of treatment actually received or if 72-week follow-up SFQ
data were observed (intention-to-treat principle). The effect is presented as an adjusted difference in
means, 95% confidence intervals (CIs) and p-value for the comparison.
Imputation of missing primary outcome data
The pattern of missing data was investigated by examining variables recorded at baseline that were
associated with ‘missingness’ of SFQ score at the 72-week follow-up. Multiple imputation and analysis
of multiple imputed data sets were conducted using ‘mi’ procedures in Stata. The imputation model
contained site, age, sex, ethnicity, social status, PD category (simple or complex), SFQ at baseline and
24 weeks, baseline EQ-5D health state score, baseline HADS score, baseline SPSI-R score and baseline
three main problems score, and 20 data sets were imputed.
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Missing item data
For all outcomes that are a scale comprising a number of items, the following procedure was undertaken
when > 0% and ≤ 15% of items were missing:
l Step 1: calculate the scale mean for each participant (denoted by m1 for those with > 0% and ≤ 15%
of items missing).
l Step 2: calculate the mean of scale means for participants with complete scale data only (denoted
by M1).
l Step 3: calculate each item mean for all participants with observed data for that item (denoted by S1).
l Step 4: for each item, calculate M1 – S1 (denoted by d).
l Step 5: impute missing item data using m1 – d.
When > 15% of items were missing, the total scale score was regarded as missing and imputed using
multiple imputation.
Clustering in psychoeducation with problem-solving arm
In this trial there were two potential sources of clustering in the PEPS arm only: by therapist in the first
treatment phase and by the problem-solving therapy group in the second treatment phase. Data for the
former were not available for some participants, or else treatment in the first phase was delivered by a
single therapist per centre. Furthermore, any clustering effect was expected to be dominated by the latter.
Therefore, we obtained clustered sandwich estimates of variance by specifying the ‘cluster’ option in all
regression models, which relaxes the assumption that all observations are independent.
Sensitivity analyses
We conducted the following sensitivity analyses of the primary outcome:
1. Repeated the primary analysis with additional adjustment for any variables displaying marked imbalance
between the arms at baseline.
2. Repeated the primary analysis restricted to those participants with observed primary outcome data at
72 weeks.
3. To examine treatment efficacy, complier average causal effect (CACE) estimates66 were calculated using
instrumental variable regression methods for those participants in the PEPS arm who received the
intervention in line with the treatment protocol. The definition of treatment received as per protocol
was having completed psychoeducation according to the therapist assessment and attended a
minimum of six of the group problem-solving sessions.
Subgroup analyses
Although no subgroup analyses were specified a priori, we conducted two exploratory subgroup
analyses by including appropriate interaction terms in the regression model for the primary outcome.
We investigated whether or not there was any evidence of differential effects of treatment on SFQ score
at 72 weeks according to (1) study site (central and north-west London, South Wales and North-East
England); (2) PD category (simple, complex); and (3) borderline PD diagnosis at baseline.
Secondary outcomes
Analysis of secondary outcomes was conducted using a similar approach as for the primary outcome,
except that missing data were not imputed, and choice of regression model and presentation of the
estimated between-group effect was dependent on outcome type (continuous, binary, ordinal, rate).
We used proportional odds logistic regression for ordinal data and we checked the goodness-of-fit
assumption for the Poisson regression analysis of count data using the Pearson test. Descriptive data are
presented for each time point, but formal comparisons were only conducted for 72-week data. The
exception to this is the SPSI-R total score, for which a repeated measures analysis was conducted including
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
13
data at both the 24- and 72-weeks follow-up to examine whether any treatment effects were sustained
or emerged later. This was tested formally with an interaction term between treatment group and time in
the model, and in the absence of any evidence of a time effect, a repeated measures analysis generates an
average effect size over the duration of follow-up.
Between-group differences in health-care service use and adverse events were estimated using binomial/
Poisson regression modelling and allow for multiple events per individual.
Interim analysis
No formal interim analyses for effectiveness were planned or undertaken, however, unblinded data were
periodically reviewed by the Data Monitoring and Ethics Committee (DMEC) during routine meetings.
Sample size
The sample size calculation for the study was based on the primary hypothesis that those randomised to
PEPS therapy in addition to usual treatment would have improved social functioning at 72 weeks after
randomisation compared with those randomised to usual treatment only. We powered the trial to detect a
difference of 2 points on the SFQ score (standardised effect size of 0.44). This is agreed to be a clinically
significant and important difference.67 We based our sample size estimate on a conservative (i.e. largest)
estimate of standard deviation (SD) of 4.53 points.
To detect a difference in mean SFQ score of 2 points with a two-sided significance level of 1% and
power of 80%, with equal allocation to two arms, would require 120 patients in each arm of the trial.
In anticipation of a 30% loss to follow-up at 72 weeks after randomisation, we planned to randomise
340 participants (170 in each arm).
Randomisation
Following recruitment and completion of screening and baseline assessments, participants were randomly
allocated to receive PEPS therapy in addition to usual treatment or usual treatment alone at a ratio of 1 : 1.
Randomisation was based on a computer-generated pseudo-random code using random permuted blocks
of randomly varying size, created by the Nottingham Clinical Trials Unit (NCTU), in accordance with its
standard operating procedure and held on a secure server. The randomisation was stratified by recruiting
centre and sex. The sequence of treatment allocations was concealed until recruitment, data collection and
all other trial-related assessments were complete.
The investigator, or an authorised designee, accessed the treatment allocation for each participant by
means of a remote, internet-based randomisation system developed and maintained by the NCTU.
Allocation was therefore fully concealed from recruiting staff.
Study procedures
Preparatory phase
Site initiation visits were completed prior to the start of recruitment to ensure that all site staff were
trained in the protocol and study-specific procedures.
Visit schedule
The duration of follow-up was 72 weeks post randomisation. The study schedule is shown in Figure 1.
Data collection
Follow-up visits were completed in person or by telephone. To improve response rates at the final follow-up,
the SFQ was posted to participants who could not be contacted by another means.
METHODS
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The majority of data were collected through the use of standardised, self-report assessment measures
completed by participants during scheduled follow-up visits. Research staff involved in data collection were
provided with guidance on the principles of standardised assessment and on the specific measures
employed in the trial. Assessments were self-completed by participants or read aloud to participants by the
researcher if required. In this case, questions were read out verbatim and were not reworded. No test
feedback was given to participants.
The Service Use Record Check was completed by the research assistants after the final assessment
measures had been collected. Service use data were collected from GP and mental health records
retrospectively for the duration of the trial, according to a data collection manual that outlined procedures
for accessing GP records, procedures for dealing with incomplete or inconsistent data, and definitions of
key terms; standardised data collection forms were used (see Appendix 8).
Screening
Baseline and randomisation
PEPS in addition to TAU
Psychoeducation
Semistructured interview
First follow-up (approximately 5–10 weeks after randomisation)
HADS, three main problems, WAI
TAU only
Problem-solving therapy
Semistructured interview
Second follow-up (approximately 24–26 weeks after randomisation)
EQ-5D, SFQ, CSRI, GAF, HADS, three main problems, SPSI-R
Third follow-up (approximately 40 weeks after randomisation)
CSRI
Trial update: a telephone call to maintain contact and update on trial progress
Final follow-up (72 weeks after randomisation)
EQ-5D, SFQ, CSRI, GAF, HADS, three main problems,
 SPSI-R, semistructured interview
FIGURE 1 Schedule of visits. TAU, treatment as usual.
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Blinding
In pragmatic trials of this type, as in usual clinical practice, it is not possible to blind participants or
clinicians to whether they are in the intervention or control arm of the trial; therefore, participants, mental
health workers delivering the interventions and participants’ usual-care teams were aware of the treatment
allocation. Most of the outcome data were obtained from self-report questionnaires from participants
who were not blind to treatment allocation. However, outcome measures were administered by research
assistants blinded to treatment allocation in order to reduce assessment bias as far as possible. Data
analysts remained blinded to allocation during the study by having access to only aggregate data and no
access to data that could reveal treatment arm, such as course attendance. Final analyses were conducted
using treatment labels A/B, with allocation decodes released only after completion of analyses. Data that
could reveal allocation were analysed following release of allocation decodes.
At the start of each follow-up, participants were reminded of the importance of not disclosing their
treatment allocation to the research assistant using a suggested unblinding script (see Appendix 9).
If the research assistant was inadvertently unblinded to treatment allocation before completing the final
follow-up, a record of the incident of unblinding was made. Researchers also reported whether or not they
were aware of the treatment allocation at the time of completing the primary end-point assessments.
Owing to changes in personnel over the course of the trial, in some cases, end-point assessments were
conducted by researchers who were not unblinded. A record was made of the blinding status of the
researcher conducting the final follow-up data collection.
Payments to participants
Participants reaching the final follow-up were offered a non-contingent voucher payment in recognition
of their contribution to the trial. Contact with the participant at the final follow-up was sufficient for
provision of the voucher (i.e. payment was not contingent on completion of the final follow-up
assessments). This voucher payment was introduced in an amendment in April 2013, approximately
halfway through final follow-up completion.
Reimbursement of travel expenses incurred in relation to attendance at research appointments was
offered, and travel expenses incurred by participants in conjunction with the treatments provided in the
trial were paid in accordance with normal clinical practice at the local sites.
Patient and public involvement
Two service users were involved in the protocol development and in the preparation of the participant
information sheet and consent form. Service user representatives on the Trial Management Group (TMG),
TSC and DMEC contributed to the management and oversight of the trial.
Research governance
The study was conducted in accordance with the principles of good clinical practice and the Research
Governance Framework for Health and Social Care.68
Ethics
Ethical approval for the study, including amendments, was given by the South Wales Research Ethics
Committee (reference number 09/WSE03/48).
The final approved protocol was version 6.0, dated 3 April 2013. The original approved protocol was
version 1.0, dated 18 September 2009. For a summary of amendments implemented during the trial see
Appendix 10.
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Oversight
A number of committees were assembled to ensure the proper management and conduct of the trial, and
to uphold the safety and well-being of participants. The general purpose, responsibilities and structures of
the committees were described in the protocol, with separate charters developed for the independent
oversight committees.
The TMG comprised members of the study team and met regularly throughout the trial to oversee the
day-to-day management of the trial. The TMG met approximately once a month for the duration of the
trial, with meetings held face to face and by teleconference for those unable to attend in person. The TMG
reviewed recruitment and data completion rates, as well as identifying and addressing any issues arising
during the course of the trial.
Independent oversight of trial conduct was provided by the TSC and DMEC.
The independent TSC monitored, reviewed and supervised the progress of the trial. The TSC also
monitored pooled data to consider safety and efficacy indications, and considered reports from the DMEC.
An independent DMEC was established, with access to unblinded data, to provide independent reviews
and recommendations to the TSC regarding continuation of the study in light of potential treatment
effect. The DMEC was advisory to the TSC. During routine conduct of the trial, the DMEC was the only
group with access to unblinded data. The DMEC reviewed unblinded data at routine meetings held during
the course of the trial. The data that were presented included listings of reported adverse events and
reported hospitalisations collected from the CSRI.
For the schedule of meetings of the DMEC and TSC see Appendix 11.
Safety monitoring
Local procedures were implemented at each site to ensure adverse events were recognised and reported,
including asking participants about adverse events during each contact and asking the participant’s clinical
team to inform the site principal investigator if an adverse event was identified. The participant’s responsible
clinician was also contacted by letter to request information on adverse events throughout the trial.
In addition, in the event of loss to follow-up, the participant’s clinical team and/or GP were contacted to
alert the responsible clinician to the participant’s loss to follow-up and to request information on any
unreported adverse events to ensure that safety data remained accurate and up to date. All adverse events
were reported to the trial co-ordinating centre within 24 hours of the study team becoming aware of them.
Adverse event reports were reviewed on receipt at the co-ordinating centre, and were assessed for
relatedness and expectedness by the chief investigator in accordance with the National Research Ethics
Service guidance on adverse event reporting in trials that do not include medicines. To guide this
assessment, the adverse event form collected information on all possible and suspected causes identified
from the available clinical information, including clinical notes and participant self-report. A categorical
assessment of ‘relatedness to the trial’ was also made by the person reporting the event.
Adverse events were also classified by the person reporting them according to whether or not there were
indications of ‘psychological antecedents’. Events that were deemed to have psychological antecedents were
defined as mental health-related events. Mental health-related events were further categorised as follows:
l self-harm, including drug or alcohol overdose
l deterioration in mental health
l suicidal ideation
l suicide or attempted suicide
l planned/respite hospital admission
l other (specify).
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The primary classification only was recorded. Adverse events were classified by the person reporting the
event on the basis of the information available at the time (e.g. through participant self-report or clinical
notes). For example, attempted suicide was recorded when this was the reason given by the participant,
and it does not necessarily relate to the severity of harm caused or evidence of clear intent (i.e. events
recorded as ‘attempted suicide’ are not necessarily life-threatening).
All adverse events were routinely reported to the Research Ethics Committee, DMEC and TSC as part of
the regular reporting requirements. In addition, serious adverse events that were deemed to be both
related to administration of any of the trial procedures and that were not identified as expected
occurrences were subject to expedited reporting to the Research Ethics Committee, as required by the
National Research Ethics Service guidance for studies that are not clinical trials of investigational medicinal
products in the UK.
METHODS
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Chapter 3 Early stopping of recruitment and
delivery of the trial intervention
The decision to stop recruitment and trial therapy
On 29 October 2012, following the fourth meeting of the DMEC, the DMEC chairperson wrote to the TSC
notifying the TSC of a safety alert in the PEPS trial based on an untoward pattern of serious adverse
events. The DMEC had done some investigations but had been unable to satisfy themselves of whether
this finding might or might not have been treatment related. The DMEC recommended further
investigations to clarify the safety and tolerability of the treatment and advised that randomisation to the
trial be suspended until this had been further investigated. The DMEC did not recommend stopping
the treatment of people currently in the trial, as they considered that the potential risks of harm in
discontinuing treatment were not justified at that stage. Following subsequent correspondence and
discussions between the two committees, during which the TSC reviewed the recommendations of the
DMEC and the unblinded data on which they were based, the TSC agreed that a safety concern could
not be ruled out, but made different recommendations to those advocated by the DMEC. The TSC
communicated the following decisions to the chief investigator and trial co-ordinating centre in a letter
dated 6 November 2012:
l No further patients should be randomised into the PEPS trial.
l Patients who were currently in treatment in the trial should no longer receive trial treatment within the
parameters of the trial treatment protocol.
l To fulfil the duty of care to patients who have completed the treatment phase of the trial the trial team
should consider how to inform patients of the possibility of harm.
l Trial data should continue to be collected and all patients followed up as per protocol.
A number of clinical concerns were raised by the PEPS trial team between 10 and 12 November 2012, and
the study team felt that a challenge to the decision to stop trial treatment was warranted. In the absence
of precedent in this situation, the following process was proposed by the trial co-ordinating centre and
agreed by all parties, including the funder:
l A joint meeting of TSC and trial team would be held.
l The TSC would explain their decisions and rationale behind them.
l The study team would present their concerns.
l Chaired discussion between all parties.
l The TSC would convene a closed meeting to consider the challenge and agree its response.
These discussions took place at a face-to-face meeting held on 15 November 2012. The meeting was
hosted by the NCTU and chaired by a senior member of the NCTU, who was not otherwise involved
in the trial. The closed TSC meeting was held on 19 November 2012. Immediately following this meeting,
the TSC wrote to the study team to confirm the unanimous decision of the TSC to uphold its original
decision. Following this confirmation, the study team took immediate steps to action the implementation
plan that had been previously agreed during the meeting held on 15 November 2012 and in
subsequent correspondence.
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Stopping recruitment and trial therapy
On receipt of the notification of the initial decision from the TSC on 6 November 2012, the following
interim actions were taken immediately by the chief investigator and trial co-ordinating centre:
l The online randomisation system was suspended on 6 November 2012 to ensure that no further
participants would be randomised.
l The TMG, other coinvestigators, the trial funder and the trial sponsor were notified immediately.
l A holding statement, approved by the TSC and sent on their behalf, was circulated to recruiting sites
on 8 November 2012. Site principal investigators were asked to disseminate the holding statement
to site staff and to stop any further recruitment of participants with immediate effect on
8 November 2012.
Delivery of the trial therapy was suspended where it was possible to do so without undue disruption
(e.g. postponing appointments). At this stage, steps were not taken to permanently discontinue treatment
or inform participants until the implications had been fully considered and a clinically appropriate action
plan, with support and alternative treatment arrangements, was in place.
A brief search and consultation failed to find any previous examples of cessation of recruitment and
treatment because of a safety alert in a trial of this type. Therefore, the process of stopping recruitment
and delivery of trial therapy meant that additional, specific procedures were developed in collaboration
between the TMG, TSC and NCTU with reference to clinical guidelines and accepted good practice.
Regular communication was maintained during the planning and implementation to review progress and
agree the next steps.
Informing participants and clinicians of the trial changes
Everyone affected by the trial changes was provided with information by the research team. A written
information sheet was provided. Participants who were ‘active’ in the trial (i.e. recently referred or in the
treatment phase) were provided with additional information and support regarding their ongoing care. A
separate, simplified version of the information sheet was available for participants in the follow-up period.
Clinical teams and referring clinicians were informed of the trial changes. They received the same
information as participants, and were offered additional guidance on ‘frequently asked questions’ and
sources of additional support and advice, should they be required to respond to queries or concerns
from participants.
A letter was sent to the responsible clinician within mental health services and the GPs for all participants
involved in the trial to inform them of the changes to the trial.
Participants and clinical teams were informed of the changes to the study as a matter of urgency. It was
considered essential that all those affected by the changes were informed by the research team first,
before this information was in the public domain.
The provision of information to people affected by the trial changes was completed on a staged basis so
that the processes used and information provided could be informed by early feedback from participants
and clinical teams. However, the process of informing people affected by the trial changes was time
limited and all those affected by the changes were notified within a reasonable time scale. Whenever
possible, this was within 4 weeks.
EARLY STOPPING OF RECRUITMENT AND DELIVERY OF THE TRIAL INTERVENTION
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Updated consent
No further trial-specific procedures (e.g. continuation of the IPDE, sessions with a PEPS therapist or
follow-up assessments) were completed with participants until they had been informed of the trial
changes. Participants in the trial were asked to sign an updated consent form to confirm receipt of the
new information and indicate their ongoing agreement to participate in the trial. Verbal consent was
accepted for continuation of follow-up assessments completed by telephone, although written consent
forms were also requested.
Issues relating to participants
When the decision to stop recruitment and delivery of the trial therapy was made, 306 participants had
been randomised. The number of participants at each stage of the trial is shown in Table 2.
Randomised to psychoeducation with problem-solving therapy and active in
the treatment phase of the trial
Participants who had been randomised to receive PEPS therapy and were currently in the treatment phase
of the trial were informed of the trial changes as soon as practically possible, and arrangements were
made to ensure that the delivery of PEPS therapy was stopped in a clinically appropriate way. The TSC
had confirmed that their recommendation to stop trial treatment did not advocate an abrupt stopping.
Delivery of trial treatment in accordance with the protocol should cease; however, there was scope to
meet with participants to explain the situation and to involve them in decisions about a structured and
clinically appropriate end to trial treatment. What was clinically appropriate depended on the stage of PEPS
therapy and the needs of individual participants. This was a clinical judgement made by the site principal
investigator in consultation with clinicians involved in the trial, the participant’s usual clinical team and the
participant, as appropriate. To underpin what was clinically appropriate we referred to national guidelines
on treatment of PD. There are two National Institute for Health and Care Excellence (NICE) guidelines
on the treatment and management of PD: one for borderline PD69 and one for antisocial PD.70 Both
emphasise the importance of endings and transitions. As a result, the study team identified a need to liaise
with clinical teams to identify what support they could offer and how the investigators and trial therapists
could assist.
Randomised, active in follow-up
Participants currently in follow-up were informed of the trial changes at their next scheduled follow-up
appointment if this was due within 4 weeks. Participants were informed by letter before their next
scheduled appointment, if this was necessary, to prevent an undue delay. Participants informed of the trial
changes by letter were provided with contact details and invited to contact the study team should they
have any queries or wish to discuss this further.
TABLE 2 Number of participants and trial stage at stoppage
Stage of the trial Number of participants
Randomised to PEPS therapy and active in the treatment phase of the trial 19
Randomised, active in follow-up 210
Randomised, completed trial follow-up 54
Randomised, withdrawn before completion 23
Active in screening phase 38
Referred but not yet started study-specific procedures 42
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Active in screening phase
Participants who had not yet been randomised but were active in the screening phase of the trial were
also informed promptly. Participants in the middle of the IPDE were given the choice to stop or continue
this. Participants who completed the IPDE were offered feedback on the results of the IPDE, in accordance
with the existing procedure for doing this at the end of the trial (this is distinct from the provision
of psychoeducation).
Referred but not yet started study-specific procedures
There was a number of people who had not completed any study-specific procedures at the time of
stopping, although some had given consent to join the trial. The research team contacted these people to
thank them for their interest in the study and to inform them that recruitment to the trial had stopped.
Randomised, completed trial follow-up or withdrawn before completion
In addition, participants who were in follow-up and those who had completed their involvement with
the trial (completed final follow-up or withdrew before completion) were informed and supported, as
appropriate. Arrangements were made to contact participants who had completed their involvement in the
trial and those who withdrew before completion. These participants were informed by letter and provided
with a written information sheet.
The following people were not directly informed of the trial changes by the research team:
l people who were referred to the PEPS trial, but were excluded before consent or declined
to participate
l participants who consented and withdrew before randomisation
l participants who consented, but were not eligible for randomisation following screening.
Additional support for study staff
Study-wide guidance documents were prepared and maintained to ensure that everybody involved in
informing participants and clinical teams, and responding to queries, including those responsible for
staffing the trial helpline, had access to relevant written information to support them in this role.
Initially, local sites made arrangements for a limited local helpline to address queries and concerns from
participants and clinical teams promptly. Arrangements for a trial-wide helpline were made, in the event
that demand should exceed local capacity.
A press release was prepared and agreed by all parties so that a clear statement could be made in the
event that the media picked up on the trial stoppage.
The national helpline and press statement were not used.
Documentation of the process
The process of informing participants and of stopping the delivery of PEPS therapy was clearly documented.
Feedback given by participants was recorded to inform the ongoing process and ensure that lessons could
be learned.
In addition to recording what information was provided and when, sites were also asked to document any
questions, comments or concerns raised by participants and clinical teams, and to provide feedback to the
trial co-ordinating centre on the issues raised.
EARLY STOPPING OF RECRUITMENT AND DELIVERY OF THE TRIAL INTERVENTION
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Participants’ views on trial stoppage
Feedback was reviewed to identify learning points and enable reflection on the processes used in the trial
and during implementation of the trial changes.71 Specific feedback was received and documented from
37 participants from all trial stages. A number of recurring views were identified. Among the most
frequently reported were that an initial increase in distress was expected when engaging in psychological
therapies; stopping PEPS therapy led to a concern over the lack of alternative treatment options; that there
were alternative interpretations of the finding that more adverse events were recorded in the PEPS group;
and that therapy delivered within the trial could have been improved (e.g. needed to be longer).
There were no complaints about how the trial changes were implemented.
Urgent safety measure
A substantial amendment (substantial amendment 08 dated 26 November 2012) sought retrospective
approval from the Research Ethics Committee for implementation of the trial changes as an urgent safety
measure. The procedure for informing participants and clinical teams, and supporting documents were
submitted for ethical review and approval in parallel to implementation. Approval was received in
December 2012.
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23

Chapter 4 Results
Recruitment
Study recruitment commenced in August 2010. Between August 2010 and November 2012, 739 people
were referred to the trial for assessment of eligibility. Of these, 444 people were initially assessed as
eligible and provided consent to join the trial. The reasons for non-participation were not willing to provide
consent (n= 113), not eligible (n= 49), unable to contact following referral to the trial (n= 106) and not
recruited because of the early stoppage (n= 27). The reasons participants were deemed not eligible for
enrolment are given in Table 3.
One hundred and thirty-eight people provided consent to join the trial but withdrew or were excluded
before randomisation. The reasons for withdrawal/exclusion before randomisation are presented in Table 4.
Of the participants who consented but were not randomised, 67% were female and the average age was
38 years.
TABLE 4 Withdrawal/exclusion before randomisation
Withdrawal/exclusion before randomisation Total number of participants
PD diagnosis not confirmed by IPDE 32
Insufficient literacy identified at screening 1
Participant withdrew consent 34
Unable to contact 23
Early stopping of recruitment 48
Total withdrawn/excluded before randomisation 138
TABLE 3 Reasons for non-enrolment
Not eligible for enrolment in the trial Total number of participants
Responsible clinician did not consider person had PD 7
Primary diagnosis of psychosis 3
Insufficient spoken English 1
Insufficient literacy, comprehension or attention 3
Receiving other psychological treatment for PD 22
Other 13
Total not eligible for enrolment in the trial 49
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Participant flow
The CONSORT diagram in Figure 2 summarises the assessments completed at each time point.
Referred to PEPS team
(n = 739)
• Declined, n = 113
• Not eligible, n = 49
• Unable to contact, n = 106
• Early stopping, n = 27
Consented
(n = 444)
• Withdrew consent, n = 34
• Not eligible, n = 33
• Unable to contact, n = 23
• Early stopping, n = 48
Randomised
(n = 306)
Usual treatment
(n = 152)
• Received allocated 
   intervention, n = 152 (100%)
PEPS
(n = 154)
• Received allocated 
   intervention as per protocol,
   n = 70 (45%)
• Received partial intervention, 
   n = 78 (51%)
• Did not receive intervention, 
   n = 6 (4%)
First 
follow-up 
at 5 weeks
• Followed up, n = 110 (72%)
• Not followed up, n = 42 (28%)
   • Withdrew consent, n = 6
   • Not done,a n = 36
• Followed up, n = 136 (88%)
• Not followed up, n = 18 (12%)
   • Died, n = 1
   • Withdrew consent, n = 2
   • Not done, n = 15
Second 
follow-up at
24 weeks
• Followed up, n = 93 (61%)
• Not followed up, n = 59 (39%)
   • Withdrew consent, n = 10
   • Not done, n = 49
• Followed up, n = 117 (76%)
• Not followed up, n = 37 (24%)
   • Died, n = 1
   • Withdrew consent, n = 3
   • Not done, n = 33
Final
follow-up at
72 weeks
• Followed up, n = 94 (62%)
• Not followed up, n = 58 (38%)
   • Withdrew consent, n = 21
   • Not done, n = 37
• Followed up, n = 113 (73%)
• Not followed up, n = 41 (27%)
   • Died,b n = 4
   • Withdrew consent, n = 10
   • Not done, n = 27
FIGURE 2 The CONSORT diagram. a, Not done is a combination of those participants who did respond to contact
and those who chose not to attend the follow-up for that particular follow-up; b, two of the deaths occurred
before and two after the trial was stopped.
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Follow-up at 72 weeks after randomisation was completed for 62% and 73% in the usual treatment and
PEPS arms, respectively. Follow-up rates for each time point by centre were as follows:
l first follow-up: central and north-west London 75%, South Wales 89%, North-East England 80%
l second follow-up: central and north-west London 61%, South Wales 73%, North-East England 74%
l final follow-up: central and north-west London 66%, South Wales 76%, North-East England 62%.
The median (first quartile, third quartile) time between consent and randomisation was 6.1 (2.3, 11.9)
weeks, and was 2.0 (1.0, 3.9) weeks between randomisation and first therapy session (PEPS only).
The mean times between randomisation and the first follow-up was 8.0 (SD 5.1) weeks, second follow-up
was 28.8 (SD 6.9) weeks and final follow-up was 80.3 (SD 10.1) weeks.
Baseline characteristics of randomised participants
Table 5 summarises the randomised groups at baseline. Of the 306 participants, 230 (75%) were women
and the mean age was 38.2 years (SD 10.9 years). The only variable with a notable imbalance between
the arms at baseline was type of PD, with a greater proportion in the PEPS arm defined as complex
(60% compared with 49% in the usual-treatment arm).
Table 6 shows baseline demographic and outcome variables further categorised by follow-up at 72 weeks
and trial arm. Participants who completed the trial were slightly older, more likely to be female and
more likely to have never worked or be long-term unemployed. There was no strong suggestion that
different types of participants were followed up in the two trial arms, although white participants were
over-represented among completers in the usual-treatment arm, while those with PD classified as simple
were over-represented among completers in the PEPS arm.
TABLE 5 Summary of participant characteristics at baseline by trial arm
Variable
Treatment arm
Usual treatment (n= 152) PEPS (n= 154)
Age at randomisation (years), mean (SD) 37.8 (11.0) 38.6 (10.9)
Sex, n (%)
Female 115 (76) 115 (75)
Male 37 (24) 39 (25)
Age left full-time education (years), mean (SD) 16.9 (3.3) 17.2 (3.7)
Highest educational attainment, n (%)
None 29 (19) 24 (16)
GCSE 16 (10) 22 (14)
A-level 45 (30) 35 (23)
Vocational 10 (7) 10 (7)
Degree 32 (21) 36 (23)
Other 20 (13) 25 (16)
Missing 0 2 (1)
continued
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TABLE 5 Summary of participant characteristics at baseline by trial arm (continued )
Variable
Treatment arm
Usual treatment (n= 152) PEPS (n= 154)
Ethnicity, n (%)
White 127 (83) 129 (84)
Mixed 9 (6) 6 (4)
Black Caribbean 6 (4) 5 (3)
Black African 0 2 (1)
Black other 2 (1) 0
Asian Indian 1 (2) 0
Asian other 1 (1) 0
Other 6 (4) 12 (8)
Socioeconomic status, n (%)
Never worked and long-term unemployed 96 (63) 105 (68)
Routine and manual occupations 28 (18) 20 (13)
Intermediate occupations 13 (9) 9 (6)
Managerial and professional occupations 15 (10) 20 (13)
IPDE type (definitive), n (%)
Paranoid 16 (11) 13 (8)
Schizoid 1 (1) 4 (3)
Schizotypal 0 0
Antisocial 31 (20) 23 (15)
Borderline 90 (59) 93 (60)
Histrionic 6 (4) 2 (1)
Narcissistic 3 (2) 1 (1)
Avoidant 56 (37) 57 (37)
Dependent 7 (5) 4 (3)
Obsessive–compulsive 20 (13) 14 (9)
PD not otherwise specified 10 (7) 14 (9)
PD,a n (%)
Simple PD 77 (51) 61 (40)
Complex PD 75 (49) 93 (60)
A-level, advanced level; GCSE, General Certificate of Secondary Education.
a The simple/complex categories are based on Tyrer and Johnson,72 in which simple refers to one or more PDs in one DSM
cluster and complex refers to two or more PDs in two or more clusters.
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TABLE 6 Summary of participant characteristics at baseline by trial arm and trial completion status
Variable
Non-completer Completera
Usual treatment
(n= 58)
PEPS
(n= 41)
Usual treatment
(n= 94)
PEPS
(n= 113)
Age at randomisation (years), mean (SD) 36.2 (10.9) 37.0 (11.3) 38.9 (11.0) 39.1 (10.7)
Sex, n (%)
Female 38 (65) 27 (66) 77 (82) 88 (78)
Male 20 (35) 14 (34) 17 (18) 25 (22)
Age left full time education (years), mean (SD) 17.1 (3.8) 16.4 (2.8) 16.8 (2.9) 17.5 (3.9)
Highest educational attainment, n (%)
None 11 (19) 6 (15) 18 (19) 18 (16)
GCSE 7 (12) 4 (10) 9 (10) 18 (16)
A-level 18 (31) 12 (29) 27 (29) 23 (20)
Vocational 5 (9) 2 (5) 5 (5) 8 (7)
Degree 12 (20) 8 (19) 20 (21) 28 (25)
Other 5 (9) 7 (17) 15 (16) 18 (16)
Ethnicity, n (%)
White 44 (76) 34 (83) 83 (88) 95 (84)
Mixed 6 (11) 4 (10) 3 (3) 2 (2)
Black Caribbean 4 (7) 1 (2) 2 (2) 4 (3)
Black African 0 0 0 2 (2)
Black other 2 (3) 0 0 0
Asian Indian 0 0 1 (1) 0
Asian other 0 0 1 (1) 0
Other 2 (3) 2 (5) 4 (4) 10 (9)
Socioeconomic status, n (%)
Never worked and
long-term unemployed
32 (55) 27 (66) 64 (68) 78 (69)
Routine and manual occupations 13 (23) 4 (10) 15 (16) 16 (14)
Intermediate occupations 7 (12) 4 (10) 6 (6) 5 (4)
Managerial and professional occupations 6 (10) 6 (14) 9 (10) 14 (13)
PD, n (%)
Simple PD 28 (48) 13 (32) 49 (52) 48 (42)
Complex PD 30 (52) 28 (68) 45 (48) 65 (58)
Baseline SFQ score
Mean (SD) 14.9 (4.9) 14.7 (4.1) 14.0 (4.2) 15.1 (4.0)
Median (first quartile, third quartile) 15 (12, 19) 14 (11, 18) 14 (11, 17) 15 (13, 18)
continued
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Duration of follow-up
Follow-up was greater in the PEPS arm at every time point (see Figure 2). Overall, 68% of participants were
followed up at the 72-week primary end point. In addition to a greater proportion of completers, duration
of engagement with the trial among non-completers was greater in the PEPS arm (Table 7). This resulted in
a total of 178 and 203 person-years of follow-up in the usual-treatment and PEPS arms, respectively.
Uptake of psychoeducation with problem-solving therapy
Table 8 summarises how much PEPS intervention was offered to, and attended by, trial participants
allocated to receive it. Median attendance at the individual psychoeducation sessions was approximately
90%, dropping to around 50% for the problem-solving therapy group sessions. Seventy (45%)
participants completed the PEPS intervention as per protocol. The size of PEPS problem-solving therapy
groups formed at randomisation and followed up at 72 weeks is reported in Table 9, along with estimated
intracluster correlation coefficients for primary and secondary outcomes.
TABLE 7 Summary of participation duration by trial arm and trial completion status
Time active in PEPS trial
Treatment arm
Usual treatment PEPS
Non-completer
(n= 58)
Completer
(n= 94)
Non-completer
(n= 41)
Completer
(n= 113)
Mean number of weeks (SD) 30.0 (25.7) 80.2 (9.8) 36.7 (23.4) 80.3 (10.4)
TABLE 6 Summary of participant characteristics at baseline by trial arm and trial completion status (continued )
Variable
Non-completer Completera
Usual treatment
(n= 58)
PEPS
(n= 41)
Usual treatment
(n= 94)
PEPS
(n= 113)
Baseline HADS score
Mean (SD) 27.1 (8.1) 28.6 (5.7) 27.7 (7.3) 27.0 (7.7)
Median (first quartile, third quartile) 28.5 (21, 33) 28 (24, 33) 28 (23, 34) 28 (23, 32)
Baseline EQ-5D health status score
Mean (SD) 43.2 (23.9) 44.3 (20.4) 40.4 (23.5) 44.6 (23.0)
Median (first quartile, third quartile) 45 (25, 60) 45 (30, 59) 39.5 (20, 60) 40 (30, 60)
Baseline SPSI-R score
Mean (SD) 6.8 (3.1) 6.2 (3.1) 6.9 (3.4) 6.5 (3.0)
Median (first quartile, third quartile) 6.2 (4.6, 8.6) 6 (4.2, 8.2) 7.2 (4.3, 9.1) 6.6 (4.4, 8.6)
Baseline three-problem average score
Mean (SD) 8.7 (1.1) 9.0 (1.0) 8.7 (1.1) 8.6 (1.1)
Median (first quartile, third quartile) 9 (8, 9.7) 9 (8.7, 10) 9 (8, 9.7) 8.7 (8, 9.3)
A-level, advanced level; GCSE, General Certificate of Secondary Education.
a Completer is defined as someone who attended final follow-up at 72 weeks after randomisation and had primary
outcome available.
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TABLE 8 Uptake of PEPS therapy
Session types
Number
offered
Number
attended
Proportion
offered/attended
Psychoeducation sessions
Mean (SD) 3.4 (0.7) 3.0 (1.0) 0.9 (0.3)
Median (first quartile, third quartile) 3 (3, 4) 3 (3, 4) 1 (0.8, 1)
Problem-solving group sessions
Mean (SD) 11.8 (0.8) 5.2 (4.0) 0.5 (0.3)
Median (first quartile, third quartile) 12 (12, 12) 6 (2, 9) 0.6 (0.3, 0.8)
Number of participants offered problem-solving sessions,
n (%)
133 (100)
Non-attenders, n (%) 20 (15)
Attended 1–5 sessions, n (%) 43 (32)
High attenders (minimum six sessions), n (%) 70 (53)
Individual support sessions
Mean (SD) 4.2 (1.9) 2.3 (1.8) 0.5 (0.4)
Median (first quartile, third quartile) 5 (3, 6) 2 (1, 4) 0.5 (0.2, 0.8)
TABLE 9 Intracluster correlation coefficients for outcomes at 72 weeks in PEPS arm according to therapy group
Outcome at 72 weeks’ follow-up Estimated intracluster correlation coefficient (95% CI)
SFQ 0.07 (0 to 0.24)
HADS 0.11 (0 to 0.29)
SPSI-R 0.01 (0 to 0.17)
Three main problems 0.01 (0 to 0.15)
Size of cluster in problem-solving group
As formed on randomisation
Number of groups 18
Median (25th quartile, 75th quartile) 6.5 (6, 8)
Minimum, maximum 5, 12
Followed up at 72 weeks
Number of groups 18
Median (25th quartile, 75th quartile) 5 (5, 6)
Minimum, maximum 1, 10
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Primary outcome
Primary analysis
Based on observed data, the mean SFQ score at 24 weeks was 13.5 points (SD 4.5 points), and for usual-care
and the PEPS arm was 13.8 points (SD 4.5 points); the corresponding mean scores at 72 weeks were
13.9 points (SD 5.3 points) and 13.5 points (SD 4.8 points), respectively. However, the primary analysis was
conducted based on multiple imputation of missing data.
There was no evidence of any clinically important difference between the arms based on the primary
analysis (Table 10). Across the whole sample, the mean difference in SFQ score between baseline and the
72-week follow-up was –0.94 points (95% CI –1.54 to –0.32 points).
Sensitivity analyses
There was no strong evidence of a between-group difference in the primary outcome from any of the
sensitivity analyses (Table 11). As expected, the estimated treatment effect of PEPS among compliers was
greater than that from the primary analysis, as were analyses based only on participants with observed
data at 72 weeks. The lower confidence limits for these analyses exceed the prespecified minimum
clinically important difference in SFQ score of two points. Although the primary analysis excludes any
effect, a clinically important benefit of treatment cannot, therefore, be completely ruled out, particularly
among participants who undertake all of the psychoeducation treatment phase and at least six group
problem-solving sessions.
TABLE 10 Primary analysis: SFQ score (points) at 72 weeks’ follow-up
SFQ score
Treatment arm
Adjusteda difference in meansb 95% CI p-value
Usual treatment
(n= 152)
PEPS
(n= 154)
Baseline, meanc (SE) 14.3 (0.4) 15.0 (0.6) – – –
24 weeks, mean (SE) 13.9 (0.4) 13.7 (0.4) – – –
72 weeks, mean (SE) 13.8 (0.5) 13.5 (0.4) –0.73 –1.83 to 0.38 0.19
SE, standard error.
a Adjusted by baseline SFQ score, study centre and sex.
b Estimated difference in means, 95% CIs and p-values based on multiple imputation of missing data.
c Based on imputed data.
TABLE 11 Sensitivity analysis of primary outcome
Analysis type Adjusted difference in means 95% CI p-value
(1) Primary analysis (MI) –0.73 –1.83 to 0.38 0.19
(2) As (1) with adjustment for baseline PD type –0.72 –1.78 to 0.34 0.18
(3) As (1), CACE estimate –1.60 –3.96 to 0.76 0.18
(4) Observed outcome data –1.07 –2.24 to 0.09 0.07
(5) As (4), CACE estimate –2.15 –4.39 to 0.09 0.06
MI, multiple imputation.
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Blinding
Unblinding of the researcher was reported for 48 (23%) participants who provided SFQ scores at the
72-week follow-up (Table 12). Mean scores were similar among participants in both arms whether or not
unblinding was reported. This is unsurprising given that the SFQ is self-completed by participants.
Subgroup analyses
There was no evidence that the effect of PEPS compared with usual treatment differed according to study
centre, category of PD at baseline or borderline PD diagnosis at baseline (Table 13).
TABLE 12 Summary of primary outcome by unblinding status at final follow-up at 72 weeks
SFQ at 72 weeks by unblinding of researcher at final follow-up
Treatment arm
Usual treatment (n= 94) PEPS (n= 113)
Unblinded
Mean (SD) 13.9 (4.2) 14.2 (4.4)
n 12 36
Blinded
Mean (SD) 13.9 (5.4) 13.1 (4.9)
n 82 77
TABLE 13 Subgroup analysis of SFQ score (points) at 72 weeks by site and PD category
SFQ score
Treatment arm
Interaction
coefficienta 95% CI p-valueUsual treatment PEPS
72 weeks by site
Central and north-west London,
meanb (SE)
13.2 (0.8) 13.0 (0.7)
South Wales, mean (SE) 13.4 (0.9) 13.7 (0.6) –0.37 –3.19 to 2.45 0.30
North-East England, mean (SE) 14.8 (0.7) 13.9 (0.7) –1.34 –3.82 to 1.14
72 weeks by PD category
Simple, mean (SE) 12.5 (0.6) 13.1 (0.7) 0.03 –0.63 to 0.69 0.93
Complex, mean (SE) 15.1 (0.7) 13.8 (0.5)
72 weeks by borderline diagnosis at baseline
Not borderline, mean (SE) 14.6 (0.5) 13.1 (0.5) – – –
Borderline, mean (SE) 12.5 (0.8) 14.1 (0.7) –0.98 –3.24 to 1.27 0.39
SE, standard error.
a Estimated based on multiple imputation, adjusted for baseline SFQ score, study centre and sex.
b Based on imputed data.
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Secondary outcomes
Hospital Anxiety and Depression Scale
Table 14 summarises the HADS total score at all outcome assessment visits, and the estimated
between-group difference at 72 weeks. There was no evidence of any difference between PEPS and
usual treatment, although the 95% CIs were wide and includes a potentially clinically important effect
(i.e. 1.5 points) in either direction.73
Three main problems
Table 15 summarises the three main problems mean scores at each time point and the estimated
between-group difference at 72 weeks’ follow-up. Table 16 shows reported change at each follow-up
time compared with previous assessment, and ordinal logistic regression of rated change at 72 weeks.
Mean scores were reduced in both arms over time and overall, 108 (55%) participants reported some
improvement at 72 weeks but there was no evidence of any difference between PEPS and usual treatment
in either measure.
TABLE 14 Hospital Anxiety and Depression Scale
HADS score
Treatment arm
Adjusteda difference in means 95% CI p-valueUsual treatment PEPS
Baseline, mean (SD) 27.5 (7.5) 27.4 (7.2) – – –
5 weeks, mean (SD) 25.4 (9.8) 24.5 (7.9) – – –
24 weeks, mean (SD) 25.1 (8.6) 23.7 (8.7) – – –
72 weeks, mean (SD) 22.3 (11.8) 21.0 (10.9) –1.2 –4.2 to 1.8 0.44
a Adjusted by baseline HADS score, study centre and sex.
TABLE 15 Three main problems
Three main
problems score
Treatment arm
Adjusteda difference in means 95% CI p-valueUsual treatment PEPS
Baseline, mean (SD) 8.7 (1.1) 8.7 (1.1) – – –
5 weeks, mean (SD) 7.7 (2.3) 7.8 (1.7) – – –
24 weeks, mean (SD) 7.5 (2.1) 7.1 (2.1) – – –
72 weeks, mean (SD) 6.6 (2.8) 6.3 (2.8) –0.3 –1.0 to 0.5 0.48
a Adjusted by baseline three main problems score, study centre and sex.
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Global Assessment of Functioning
Global Assessment of Functioning was included as a means of collecting data on the referring clinicians’
rating of change during the trial. However, during the course of the trial it became apparent that GAF
completion rates were poor. The reasons for this were explored with site staff and identified as:
l participants being discharged from secondary care services and therefore there not being a suitable
clinician involved in their care to provide this rating
l participants in services may not have a regular care team/care co-ordinator
l even for participants for whom a care co-ordinator/regular clinical team is available, GAF scores are
difficult to obtain. One reason for the low returns is resource issues within mental health services
generally (e.g. budget cuts and job losses), which make any non-essential activities difficult to
complete. Another may be lack of familiarity with the rating tool.
TABLE 16 Three main problems rating change
Three main problems score
Treatment arm
Adjusteda odds ratio 95% CI p-valueUsual treatment PEPS
5 weeks, n (%) N= 110 N= 136
Very much improved 3 (3) 1 (1)
Much improved 11 (10) 22 (16)
Minimal improvement 21 (19) 59( 43)
No change 29 (26) 35 (26)
Minimally worse 16 (14) 4 (3)
Much worse 14 (13) 2 (1)
Very much worse 6 (5) 3 (2)
24 weeks, n (%) N= 93 N= 116
Very much improved 5 (5) 9 (8)
Much improved 10 (11) 26 (22)
Minimal improvement 26 (28) 38 (33)
No change 24 (26) 23 (20)
Minimally worse 8 (9) 7 (6)
Much worse 12 (13) 6 (5)
Very much worse 6 (6) 3 (2)
72 weeks, n (%) N= 90 N= 108
Very much improved 8 (9) 13 (12)
Much improved 17 (19) 27 (25)
Minimal improvement 19 (21) 24 (22)
No change 19 (21) 16 (15) 0.65 0.38 to 1.12 0.12
Minimally worse 3 (3) 3 (3)
Much worse 10 (11) 11 (10)
Very much worse 7 (8) 4 (4)
a Adjusted by baseline three main problems score, study centre and sex.
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Continued efforts were made to obtain a rating from the original referrer or other member of the
participant’s clinical team. The TMG agreed in advance that a minimum of 80% completion rate at
baseline and 50% completion at follow-up would be required to enable a valid analysis of GAF data to be
made. These rates were not achieved.
Mechanism of change
Working Alliance Inventory – Short Revised
The WAI examines the development of treatment alliance and was used to assess the effectiveness of the
psychoeducation component in developing treatment alliance. The WAI is intended to be completed by
clients and therapists. In the trial, the therapist form was completed by the PEPS therapist for participants
allocated to PEPS therapy and a member of the participants’ usual-care team for participants receiving
treatment as usual only. Participants were asked to complete the WAI client form in relation to the
working alliance with the relevant clinician. However, for the same practical reasons as listed above for
the GAF, completion rates were poor and did not reach the prespecified level required for a valid analysis.
Social Problem-Solving Inventory – Revised: short version
Table 17 summarises the SPSI-R total score at all outcome assessment visits and the estimated
between-group difference in total score based on a repeated measures analysis that includes data from
both 24 and 72 weeks’ follow-up. There was no evidence of any difference between PEPS and usual
treatment. Analyses for each of the five SPSI-R subscales follow the same approach and found no evidence
of any treatment effect (data not shown).
Service use
Table 18 summarises participants’ use of health services during the trial. Data were available for 140 (91%)
and 126 (83%) participants in the PEPS and usual-treatment arms, respectively. There were 2041 contacts
with health services from 135 individuals in the PEPS arm, compared with 2064 from 116 individuals
allocated to usual treatment. When converted to annual rates, this equated to a mean of approximately
10 contacts per person per year. There was no evidence of any differences between groups in total
health-service use, use of emergency or crisis services, or whether classified as scheduled or unscheduled.
When unclassified health service contacts were reassigned as either scheduled or unscheduled, there was
a higher proportion of scheduled contacts in the PEPS arm than in the usual treatment arm (Table 19).
However, 95% CIs were wide and included the null, indicating no strong evidence that participants in the
two groups differed in scheduled use of health services.
TABLE 17 Social Problem-Solving Inventory – Revised: short version
SPSI-R score
Treatment arm Repeated measures
Usual treatment PEPS Adjusteda difference in means 95% CI p-value
Baseline, mean (SD) 6.9 (3.3) 6.4 (3.0) – – –
24 weeks, mean (SD) 8.0 (3.6) 7.7 (3.5) – – –
72 weeks, mean (SD) 8.2 (4.0) 8.0 (4.0) 0.14 –0.53 to 0.82 0.68
a Adjusted by baseline SPSI-R score, study centre, sex and visit.
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TABLE 18 Service use
Service use
Treatment arm
Adjusteda IRR 95% CI p-value
Usual treatment
(N= 126)
PEPS
(N= 140)
Overall service use, n contacts
(n individuals)
Scheduled 921 (87) 970 (106)
Unscheduled 604 (80) 547 (94)
Unclassified 539 (93) 524 (118)
Total 2064 (116) 2041 (135)
GP contacts, n contacts (n individuals) 1649 (80) 1521 (98)
Emergency department, n contacts
(n individuals)
151 (47) 142 (55)
Hospital admissions, n contacts
(n individuals)
48 (26) 83 (34)
Hospital outpatient appointment,
n contacts (n individuals)
8 (5) 19 (11)
Mental health service, n contacts
(n individuals)
Crisis resolution service 30 (20) 55 (28)
A&E liaison service 6 (6) 12 (11)
Other mental health service 172 (106) 209 (120)
Overall service use for emergency
department, hospital admission, crisis
resolution and A&E liaison service,
n contacts (n individuals)
Scheduled 34 (27) 49 (29)
Unscheduled 195 (54) 230 (65)
Unclassified 6 (4) 13 (10)
Total 235 (85) 292 (104)
Overall service use, n contacts
(n individuals)
1–9 52 (45) 51 (38)
10–19 32 (27) 50 (37)
20–29 10 (9) 20 (15)
30–39 9 (8) 7 (5)
> 40 13 (11) 7 (5)
Overall service use (annual rate) during
72 weeks after randomisation, mean (SD)
10.6 (11.0) 9.9 (14.3) 0.97 0.77 to 1.22 0.81
Overall service use for emergency
department, hospital admission, crisis
resolution and A&E liaison service
(annual rate), mean (SD)
2.5 (3.1) 2.4 (3.2) 0.97 0.66 to 1.41 0.87
Scheduled service use (annual rate),
mean (SD)
6.5 (7.4) 6.0 (5.5) 0.91 0.69 to 1.21 0.54
Unscheduled service use (annual rate),
mean (SD)
4.4 (6.2) 3.7 (4.3) 0.87 0.60 to 1.26 0.47
A&E, accident and emergency; IRR, incidence rate ratio.
a Adjusted by study centre and sex.
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Adverse events
Twenty-eight individuals reported a total of 35 adverse events following referral to the PEPS trial and
before randomisation. Of these, 14 participants were allocated to each arm, with 14 adverse events
occurring in participants allocated to PEPS and 21 in participants allocated to usual treatment. Following
randomisation, a total of 76 adverse events were reported by 39 individuals allocated to usual treatment
and 117 events were reported by 60 individuals allocated to PEPS (Table 20).
Four deaths were reported during the study: two were due to natural causes and two were suicides.
All four participants were allocated to the PEPS arm. The nature and circumstances of these deaths did not
seem related to the therapy.
During the trial, one serious adverse event was reported that had a suspected relationship to the trial and
was not listed in the protocol as an expected occurrence. This was a non-fatal overdose resulting in an
overnight hospital admission, which was precipitated by a number of stressors including anxiety about
group work in relation to forthcoming PEPS therapy. This event was reported to the Research Ethics
Committee, DMEC and TSC. A briefing was issued to all site staff reminding them of the importance of
identifying anxiety in relation to group work and supporting participants with this, as appropriate.
Table 20 provides further details of hospitalisations, self-harm, and other mental health-related
adverse events.
Table 21 shows the results of between-group analyses of reported adverse events. There were
approximately 13% more participants in the PEPS arm who reported at least one adverse event, equivalent
to an approximate 50% relative increase. However, when the difference in total follow-up between the
arms is accounted for, this figure of 50% was attenuated to approximately 30%, with 95% CIs that span
the null. Results of the analysis of total number of adverse events were similar, with an approximately 20%
greater reported event rate in the PEPS arm, with a 95% CI that includes the null.
TABLE 19 Sensitivity analyses of service use
Assignment of service use type
Treatment arm
Adjusteda
risk ratio 95% CI p-valueUsual treatment PEPS
Overall service use if unclassified
assigned as scheduled, n health service
contacts (%) [n individuals]
Scheduled 1460 (71) [117] 1494 (73) [134]
Unscheduled 604 (29) [80] 547 (27) [94] 0.99 0.93 to 1.06 0.77
Overall service use if unclassified
assigned as unscheduled, n health
service contacts (%) [n individuals]
Scheduled 921 (45) [87] 970 (47) [106]
Unscheduled 1143 (55) [108] 1071 (53) [125] 1.05 0.92 to 1.19 0.46
a Adjusted by study centre, sex, service type and allowing for multiple events per individual.
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TABLE 20 Adverse event reports summary post randomisation
Adverse event report categories
Treatment arm
Usual treatment (N= 152) PEPS (N= 154)
Participants with any adverse event, n (%) 39 (26) 60 (39)
All adverse event reports,a n events (n individuals)
Hospitalisation 62 (33) 100 (51)
Deathb 0 4 (4)
Other 14 (12) 13 (12)
Total 76 (39) 117 (60)
Participants with multiple hospitalisations, n (%)
1 19 (58) 29 (56)
2 6 (18) 13 (26)
3 3 (9) 3 (6)
4 4 (12) 2 (4)
5 0 1 (2)
6 1 (3) 0
7 0 2 (4)
9 0 1 (2)
Mental health-related adverse event reports, n events (n individuals)
Planned/respite hospital admission 2 (2) 1 (1)
Self-harm including drug or alcohol overdose 27 (16) 42 (24)
Suicide or attempted suicide 4 (3) 7 (7)
Deterioration in mental health 3 (2) 9 (7)
Suicidal ideation 6 (6) 8 (6)
Other 3 (3) 4 (4)
Total 45 (26) 71 (37)
Participants with multiple self-harm reports, n (%)
1 11 (69) 16 (67)
2 2 (12) 3 (12)
3 1 (6) 1 (4)
4 1 (6) 3 (12)
5 1 (6) 1 (4)
a Some participants reported more than one type of adverse event.
b Two of the deaths were from natural causes and two were suicide.
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TABLE 21 Between-group comparisons of number of individuals with at least one adverse event and the total
number of reported adverse events
Adverse events
RD, % (95% CI) RR (95% CI) IRR (95% CI)
Crude Adjusteda Crude Adjusteda Crude Adjusteda
Based on number
of individuals
(usual treatment,
n= 39; PEPS,
n= 60)
13.3
(2.9 to 23.7)
13.0
(2.9 to 23.1)
1.52
(1.09 to 2.12)
1.52
(1.09 to 2.13)
1.35
(0.89 to 2.07)
1.37
(0.91 to 2.05)
Based on number
of adverse events
(usual treatment,
n= 76; PEPS,
n= 117)
– – – – 1.35
(1.00 to 1.83)
1.24
(0.93 to 1.64)
IRR, incidence risk ratio; RD, risk difference; RR, relative risk.
a Adjusted by site and sex.
Notes
The total amount of follow-up was unequal between trial arms: usual care= 9279 and PEPS= 10,579 person-weeks
(178 and 203 person-years, respectively).
IRR analysis for number of adverse events allows for ≥ 1 adverse event per individual.
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Chapter 5 Health economics analysis
Objectives
Any new intervention requires the use of scarce health-care resources and so conducting economic
evaluations to assess cost-effectiveness is crucial. Economic evaluations of interventions for PD are few in
number, although cost-effectiveness analyses of specific therapies, psychotherapy more generally and
whole programmes have been conducted.74–76 The objectives of the economic evaluation in this study were:
1. to measure and describe the 6-month health-care and societal costs (with a detailed breakdown of
care, benefits, lost employment, etc.) of participants in the PEPS trial at randomisation, and their
association with clinical and demographic characteristics
2. to measure, describe and compare patterns of service utilisation by participants at second follow-up
(post treatment, 24–26 weeks), third follow-up (week 40) and fourth follow-up (week 72) across the
two groups (PEPS and usual treatment)
3. to compare care costs (health care and societal) at second, third and fourth follow-up
4. to assess the cumulative cost–utility of PEPs compared with usual treatment at second, third and fourth
follow-up.
Methods
Analyses were detailed in an economics analysis plan, which was finalised prior to completion of data
collection and database lock.
Use of health services, employment effects and welfare benefits
Comprehensive data were collected on all health, social care and other relevant services used by individual
study members using a tailored version of the CSRI.60 The CSRI was used at baseline and at second, third
and fourth follow-ups, with information provided via participant self-report. The baseline interview covered
resource use for the previous 6 months, while the subsequent interviews covered resource use since the
last interview. The CSRI included the following broad categories of information:
l contacts with health- and social-care professionals
l use of day care services
l use of inpatient care
l contacts with criminal justice/legal services
l medication
l education and time absent from studies
l employment and time off work
l welfare benefits.
Cost calculations
The costs of each resource item were calculated using the best available unit cost estimates (see Appendix 12)
and reported in 2012/13 prices. The cost of the PEPS intervention was estimated using information on the
core resources required to deliver the individual and group sessions, and estimating specific costs for those
inputs (see Appendix 13). Costs were calculated using data on the number of therapy sessions received
by each participant. Lost employment costs for those in employment will be calculated by combining time off
work with daily earnings. The value of benefits received was calculated but these are transfer payments and
so were not included with the service or lost employment costs.
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Quality-adjusted life-years
The EQ-5D was used to measure health-related quality of life. This consists of five domains (mobility,
self-care, usual activities, pain/discomfort and anxiety/depression). Each of these received a score of 1, 2 or
3 corresponding to ‘no problems’, ‘moderate problems’ and ‘major problems’. Utility scores were attached
to each health state based on these scores (a table of utility values has been produced by the Centre for
Health Economics, University of York77). These utility scores were used to generate QALY gains over the
follow-up period using area-under-the-curve methods and assuming a linear change between any two
adjacent time points.
Analyses
Cost data are frequently skewed and this can lead to incorrect p-values and CIs when making comparisons
between groups. To address this, we used a bootstrapped regression model, which makes no assumptions
about the data distribution. Baseline data were analysed using a regression model to identify variables
significantly associated with cost. If PEPS resulted in higher costs and better outcomes, then incremental
cost-effectiveness ratios were to be computed. Uncertainty around these was explored using
cost-effectiveness planes. To construct these, four regression models were run using 10,000 bootstrapped
resamples. The models used service costs and QALYs at second and final follow-up as the dependent
variables. The independent variables were the group identifier and the baseline measure of cost or utility
score. The 10,000 coefficients for the group identifier variable are 10,000 estimates of the cost/outcome
differences and these were plotted against each other. The planes show the probability of the PEPS group
having (i) lower costs and better outcomes, (ii) higher costs and better outcomes, (iii) lower costs and
worse outcomes, and (iv) higher costs and worse outcomes than supportive care alone. In addition,
cost-effectiveness acceptability curves were generated using the net benefit approach in order to
determine the likelihood that the intervention was the most cost-effective option. There is a theoretical,
but unknown, value (represented by the term λ) that society would place on a 1-unit QALY gain as
measured by the EQ-5D. Net benefit can be defined as:
NB = (λ × E)− SC, (1)
where NB is net benefit, E is effectiveness (i.e. QALY gains compared with baseline) and SC is service costs.
For example, if for a particular patient the QALY gained during the follow-up period is 0.05 and if their
service cost is £400, then we can calculate their net benefit if we know λ. If λ= £0 then the net benefit is
–£400, whereas if λ= £10,000 then the net benefit is £100. Net benefits for all patients were estimated by
assuming different values for λ ranging between £0 and £50,000 in £5000 increments. A regression
model was then used to determine the mean difference in net benefit between usual-treatment and PEPS
groups for every value of λ. For each model, 10,000 regression coefficients for the group identifier variable
were generated using bootstrapping and the proportion of these that were greater than zero indicated
the probability that PEPS was cost-effective (i.e. it resulted in a mean incremental net benefit greater than
zero). These probabilities were subsequently used to generate the cost-effectiveness acceptability curves.
Results
Service-use data are summarised in Table 22. In the 6 months before baseline assessment, over 90% of
patients had GP contacts and these occurred approximately every month. Over half also had contacts with
psychiatrists and around one-quarter of patients in both groups had inpatient admissions. Most other
services were used by relatively few patients. Overall, there were few noticeable differences between the
two groups at baseline, although the group randomised to PEPS did have more contacts with home
treatment/crisis team members.
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During the period between baseline assessment and second follow-up, the vast majority of patients again
had contact with GPs. In both groups, there was a reduction in contact with GPs, psychiatrists, home
treatment/crisis team members, social workers and mental health nurses. Fewer were admitted to hospital.
The only key difference between groups was in the use of a social worker, with 24% of patients in the
PEPS group having contact, compared with 17% of patients in the usual-treatment group. However, the
amount of contact with social workers was much higher in the usual-treatment group than the PEPS
group, indicating a greater intensity of use.
Between the second and third follow-ups, there was a continued reduction in contact with home
treatment/crisis team members and mental health nurses in both groups. Contact with GPs, psychiatrists
and social workers was reduced in the PEPS group, but this trend was not observed in the usual-treatment
group. Between the third and final follow-ups, there was a slight increase in contact with GPs, psychiatrists
and home treatment/crisis team members in the PEPS group, which also saw a small increase in inpatient
care. No noticeable changes in service use were observed in the usual-treatment group.
Mean service costs are presented in Table 23. At baseline, mean costs were highest for inpatient care,
followed by contact with psychiatrists, GPs and social workers. Inpatient and GP costs were higher for
the usual-treatment group, and the psychiatrist and social worker costs were higher for the PEPS group.
However, the variation around the means was substantial, as indicated by the SDs. Total health-care costs
were significantly higher for women than for men by an average of £2044 and were higher by an average
of £5431 if the patient had a non-specified PD.
Between baseline and the second follow-up, mean costs were again highest for the use of inpatient care,
contacts with psychiatrists, GPs and social workers. For all of these four services, costs were higher in the
usual-treatment group than in the PEPS group; the cost difference was especially high for inpatient care
(usual treatment, £1430; PEPS, £847) and contacts with social workers (usual treatment, £658; PEPS, £187).
Between the second and third follow-ups, the costs of inpatient care, psychiatrists and GPs were still higher
for the usual-treatment group. Costs of social worker contacts were similar between the groups. Finally,
between the third and final follow-ups, costs of psychiatrists and GPs were higher for the usual-treatment
group, while the costs of inpatient care and social workers were higher for the PEPS group.
The total cost of all health-care services at baseline was £265 higher in the usual-treatment group than in
the PEPS group (Table 24). This cost difference widened at the second and third follow-ups in favour of
PEPS; however, the 95% CI shows the difference to be non-significant. By the final follow-up, the mean
costs were £1174 higher for the usual treatment group than for the PEPS group, after adjusting for
differences in baseline costs. However, the SDs were large and this difference was also non-significant.
When the cost of the PEPS intervention was considered, the total costs for the PEPS group increased
to £7727 per patient for the entire follow-up period, which is still lower than the total cost of the
usual-treatment group (£8072 per patient). After adjustment for baseline, the cost for the PEPS group
was £182 less than for the usual-treatment group.
At the 72-week follow-up, the SFQ score (the primary clinical outcome) is slightly in favour of the PEPS
group, although the difference is not statistically significant (p= 0.19). Therefore, in a technical sense,
PEPS was seen to be dominant as it resulted in lower service costs and an improved SFQ score. However,
this does not take uncertainty around these estimates into account.
The utility values derived from the EQ-5D are shown in Table 25. At baseline assessment and at the second
follow-up, the mean utility scores were slightly higher in the usual-treatment group. At the final follow-up,
the mean utility score was slightly higher in the PEPS group. However, none of these differences was
statistically significant.
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Quality-adjusted life-years generated using the area under the curve method are shown in Table 26.
The mean QALY gain between baseline and second follow-up was 0.2161 for the usual-treatment group
and 0.2108 for the PEPS group. However, the difference adjusting for baseline utility score was 0.0557
in favour of the PEPS group. By the final follow-up, the QALY gain in the usual-treatment group was
0.5706 and 0.5616 in the PEPS group. The adjusted difference was 0.0148 in favour of PEPS.
In a technical sense, PEPS was seen to be dominant as it resulted in lower total costs and a greater QALY gain,
after adjusting for baseline. However, this does not take uncertainty around these estimates into account.
The cost-effectiveness plane showing cost (including service costs for both groups and intervention cost for
PEPS group only) and QALY differences at second follow-up is shown in Figure 3. At the second follow-up,
62.4% of the resamples showed lower costs and a greater QALY gain for the PEPS group while 30.6% of
resamples showed lower costs and a lower QALY gain. Only 4.8% of the resamples showed higher costs
and more QALYs for PEPS, and 2.2% showed higher costs and a lower QALY gain. The cost-effectiveness
plane for the QALY gain and cost differences by final follow-up is presented in Figure 4. The most likely
scenario with 36.8% of resamples was that PEPS resulted in lower costs and greater QALYs. Higher costs
and more QALYs were revealed in 28.1% of resamples. Lower costs and fewer QALYs were shown by
17.9% of resamples and higher costs and fewer QALYs by 17.2%. Clearly, the level of uncertainty is
substantial over the entire follow-up.
TABLE 24 Total mean (SD) health-care service costs excluding intervention (2012/13, £)
Health-care service
use period
Treatment arm
Difference adjusted for
baseline (95% CI)Usual treatment PEPS
6 months to baseline 4178 (5780) 3913 (5834) –
Baseline to second follow-up 3391 (7255) 2296 (4081) –1051 (–2470 to 367)
Baseline to third follow-up 5334 (8434) 3870 (5692) –1391 (–3112 to 331)
Baseline to fourth follow-up 8072 (10,598) 6777 (10,550) –1174 (–3720 to 1371)
TABLE 25 Mean (SD) utility scores at baseline assessment, second and final follow-up
Assessment time point
Treatment arm, mean utility score (SD)
p-valueUsual treatment PEPS
At baseline 0.3647 (0.3664) 0.3422 (0.3505) 0.6194
At second follow-up 0.4050 (0.3529) 0.3731 (0.3709) 0.4868
At final follow-up 0.3825 (0.3718) 0.3895 (0.3668) 0.8802
TABLE 26 Mean quality-adjusted life-years (SD) gained between baseline and second follow-up, and between
baseline and final follow-up
Assessment time point
Treatment arm, mean QALY (SD)
Difference adjusted for
baseline utility (95% CI)Usual treatment PEPS
Baseline and second follow-up 0.2161 (0.1961) 0.2108 (0.2158) 0.0057 (–0.0215 to 0.0328)
Baseline and final follow-up 0.5706 (0.4624) 0.5616 (0.5142) 0.0148 (–0.0622 to 0.0919)
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The cost-effectiveness acceptability curve for the whole follow-up period is shown in Figure 5. Even if
society was not willing to attach any monetary value to QALY gains there would remain a likelihood of
58% that PEPS is the most cost-effective option. As a unit improvement is valued at higher levels, this
likelihood increases. Although we do not know the true societal value that should be placed on a QALY
gain, NICE uses a threshold in the region of £20,000–30,000. Between these two levels there is a
63.6–64.2% likelihood that PEPS is the more cost-effective option.
The above analyses focus on health-care costs. However, it is likely that people with PD will incur higher
cost of criminal justice service as a result of their condition. Two types of criminal justice service were
considered in this analysis: police contact and nights detained in a police cell. The use and costs of both
services are shown in Tables 27 and 28. Costs of police contact were similar in the two groups. Although
relatively few patients spent nights detained in a police cell, the cost was high. It can be seen that the cost
was greatest for the PEPS group before baseline assessment (£211 per patient), but this cost was reduced
during the follow-up period.
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Information on the number of days lost from work as a result of health problems (absenteeism) and the
cost impact of absence from work is given in Tables 29 and 30. The data relate only to those in
employment, the assumption being that, given the level of unemployment in the economy, long-term
absence from work does not result in lost output because others are employed instead. Lost work time
was experienced by a small number of patients, but the costs were substantial. The lost employment costs
were also similar between groups at baseline. These costs then fell for the PEPS group, but remained
stable for the usual-treatment group.
Conclusion
The analyses presented in this chapter have focused on costs and cost-effectiveness. Over the follow-up
period, costs were slightly lower in the PEPS group. There was substantial uncertainty in this result, as
shown by the wide CIs. Utility scores derived from the EQ-5D were very low (average scores were typically
around 0.4). The analyses demonstrated that QALY gains were very similar in the two groups, but with
a very slight advantage in favour of the PEPS intervention after controlling for baseline differences.
Technically, the PEPS intervention was ‘dominant’ in that it resulted in lower average costs and greater
QALY gains. However, the uncertainty around both estimates means that, at a NICE threshold of
£20,000–30,000, there is a 64% likelihood that the intervention is the more cost-effective option.
Given all the information available, PEPS is somewhat more cost-effective but much caution is required in
interpreting this result. We have not considered the logistics of implementation and that may outweigh the
benefits from the intervention.
TABLE 28 Mean (SD) service costs of criminal justice service (2013, £)
Service
Time point
6 months to baseline
Baseline to second
follow-up
Second to third
follow-up
Third to final
follow-up
Usual
treatment PEPS
Usual
treatment PEPS
Usual
treatment PEPS
Usual
treatment PEPS
Police contact 16 (33) 34 (110) 10 (34) 17 (90) 12 (69) 12 (48) 18 (73) 16 (60)
Nights detained
in a police cell
25 (165) 211 (2137) 4 (38) 6 (50) 21 (229) 25 (252) – 31 (322)
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TABLE 30 Mean (SD) cost of lost employment (2012/13, £)
Cost
Time point
6 months to baseline
Baseline to second
follow-up
Second to third
follow-up
Third to final
follow-up
Usual
treatment PEPS
Usual
treatment PEPS
Usual
treatment PEPS
Usual
treatment PEPS
Production lossa 664 (2848) 654 (2698) 205 (1032) 411 (2567) 274 (1566) 40 (196) 238 (1158) 79 (344)
a Lost production cost for whole sample.
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Chapter 6 Qualitative analysis
Objectives
The purpose of this analysis was to search for themes across the PEPS qualitative data set, which consisted
of reports compiled by researchers of participant responses to semistructured interviews, conducted
according to interview schedules developed for the study (see Appendices 14–17). These data were
gathered at:
l first follow-up (after psychoeducation), on the effects of psychoeducation (n= 87)
l second follow-up (after problem-solving therapy), on the effects of problem-solving therapy (n= 61)
l final follow-up (at 72 weeks), on experiences of usual treatment (n= 41) or PEPS therapy (n= 47).
The data were analysed using a thematic analysis.78 Thematic analysis was chosen because of its ability to
richly describe a large number of data by drawing out key points and presenting them in an easily
accessible format,78 and it has been used to investigate engagement issues in people with PD.79
Theoretical position
A pragmatic, flexible, inductive, thematic analysis was undertaken to provide largely face-value feedback
on participant experience of the interventions, as described above. All semistructured interviews (n= 236)
were included in this analysis. As the primary aim of the thematic analysis was to meet the objectives of
the PEPS study, the focus was to provide a rich and nuanced reflection on participants’ experiences of
usual treatment and PEPS as well as to explore, in as much detail as the data permitted, their perceived
benefits or bad effects of the treatments under investigation.
Method
The interview transcripts were read by two researchers (ML and JD), who familiarised themselves with the
entire data set being analysed. ‘Best’ answers to the research questions were captured in the form of
selected excerpts or quotes as an initial step in the analysis. Through an iterative process, these quotes
were organised into recurring patterns or themes. Finally, the themes identified separately were merged or
differentiated and checked to ensure that there was good evidence for them.
In doing this, the following ‘lenses’ influenced the selection process: the notion of ‘prevalence’
(how frequently the idea occurred across the data set was an organising principle, although with the
caveat that more instances does not necessarily mean that they are more important); and a notion of
‘keyness’ (the extent to which a quote or excerpt captured something important to the research question).
Themes
Feedback after psychoeducation
Psychoeducation followed the use of the IPDE to ensure that the individual was eligible for the study, and
consisted of up to four sessions of an individual collaborative dialogue designed to build rapport with
participants, inform them about their PD diagnosis and discuss its effects on interpersonal relationships and
social functioning. The analysis found five themes pertaining to the individual psychoeducation sessions,
which are summarised in Box 1 and then elaborated.
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Theme 1: a collaborative one-to-one process
In general, participants felt that psychoeducation had been a professional, constructive, well-structured
discussion about their diagnosis and its implications for their social functioning and problem-solving.
I’ve found them useful to help me identify some of my patterns, and also enjoyable. Put things
into context.
01/098
The [psychoeducation] sessions were simple to understand, not overelaborate – using simple down to
earth speak. Everyone would benefit from learning.
03/080
Although I have been in therapy a long time and inpatient in various institutions and also seen many
psychiatrists over the last 16 years this is the first time I’ve talked to anyone about my diagnosis. In
therapy we talked about me and occasionally make reference to it. With psychiatrists it is always about
symptoms. This has been reassuring to properly talk to someone about BPD [borderline PD] – a new
context. Psychoeducation is definitely the main factor, without that phase the group sessions would not
have worked. People would not have returned to the group sessions without the initial one to one.
01/099
Being supportive and somebody really listening to your feelings helps me feel secure and worthy as a
person, that someone takes the time to listen.
02/009
I have become more curious and intrigued about my diagnosis. Finding out more about me. I can
recognise and rationalise others’ behaviour and personality, so feel more able to understand them.
I’m trying to apply this to me where I can.
03/024
Good to talk about things and have things explained.
01/148
I’ve got hope that I can deal with some of the things we have discovered in the sessions.
02/014
. . . contact with someone who was interested and understood the problems [was helpful]. I learned
about PD generally and about the relation to my own problems and how they affect my relationship
with others and my reactions to problems.
03/27
We learnt that I’ve got a PD, which has just been categorised as depression – hard to put into words.
Found it helpful to breakdown what my problems are.
02/099
BOX 1 Themes relating to psychoeducation
Themes
1. Collaborative one-to-one process.
2. Provided improved knowledge of traits and understanding of individual relevance and application.
3. Emotional impact and willingness to tolerate this and keep with the process.
4. Positive orientation: optimism, trust and motivation.
5. Barriers to progress: doubts and uncertainties.
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Theme 2: increased or new knowledge of the core concept of ‘trait’
(versus symptom), and a greater understanding of its relevance and
application to the individual themselves
Participants had engaged in a meaningful process of self-understanding and were given a specific
conceptual framework that made sense to them. This brought relief and a sense that they could apply this
knowledge to their recovery:
Learned how my past has affected my personality.
03/01
I don’t feel as isolated; I’m not the only one receiving a PD diagnosis.
03/60
Learnt about my own traits and issues and how it effects me personally.
03/041
[IPDE] was very thought-provoking . . . as I answered some of the questions, I re-evaluated the
scenario, situation.
03/04
Maybe I had in my mind I had a million problems and I’ve learnt it’s all caused by the need to have
things perfect and get everything done. The trait is causing me many problems, I’m being irrational.
It seems more manageable looking at it here, in this way.
02/046
Eye opener, empowering. I learned about my own traits. I am beginning to change . . . I learned that
I am overly dependent.
03/62
I’ve got hope I can deal with some of the things discovered in the [IPDE] sessions.
02/14
. . . pin-pointing traits was helpful.
01/098
It was handy to be informed about other personality disorders.
01/099
What my traits are, the healthy ones and the not so healthy ones.
02/062
It’s not a specific thing with your personality, it’s different things.
02/108
A lot about myself, established ‘triggers’ for my behaviours. Learned that I have the skills to
help myself.
03/04
Everyone has a personality and that disorder happens when a person experiences, perceives, copes or
manages with issues around their feelings and emotions.
03/110
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More about personality disorder. Interesting to have my personality disorder traits reflected back to
me. Reassuring conversation relating to borderline personality disorder.
01/099
The fact that there are so many different types of personality disorder. I was able to put another
perspective on my problems. I always thought it was coming from my depression. I’d never thought
about it in relation to personality before.
01/120
Theme 3: emotional impact and willingness to keep with the process
Participants described the impact of facing and coming to terms with a diagnosis of PD. They described
their own emotional responses to it and their concerns about how others might perceive and treat them.
Things had happened in our lives wherein we were let down by the system – and [but] the onus was
put back onto ourselves for this . . . being described as having a personality disorder. We had failed in
the first instance.
01/133
Triggered some historical memories about [my] father. I have not ‘switched off’ like I normally do –
I have felt more focused.
03/82
Session 2 [psychoeducation] made me tearful. It felt like having the truth slapped in my face. Was
overwhelming seeing all the boxes I had actually ticked. My mum has been a great support whilst in
this study. I have got to spend more time with her, which brought us closer and she understands
me better.
01/38
. . . I’ve also found it very hard and difficult, especially after sessions dealing with my emotions.
02/014
It’s been emotionally draining, but not negative. Feeling that I am not alone has been the biggest
thing. Spending time with the research team and trusting the person doing the psychoeducation.
01/42
It was emotionally painful at times because it brought up some issues from the past that were
painful – but I was able to deal with them.
03/027
Starting to admit things . . . helping me confront stuff. Helped me pinpoint issues. I have said I didn’t
want to come but that’s only confrontation and I know it’s going to be okay.
01/47
After [psychoeducation] sessions you can feel quite vulnerable and confused about what you’ve
talked about.
02/014
You are talking about things that are painful, but its part and parcel of working through an issue.
No pain, no gain.
02/009
Has felt intense and hard. Has helped me to see things differently.
03/029
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Daunting at first. I’ve found it difficult to say about all the bad bits . . .
02/029
Anxious, frightened initially about the questions. Still anxious but not as frightened.
03/093
When the truth hit me it made me feel emotional – I find emotions hard to deal with.
03/062
Overwhelming . . .
03/11
Theme 4: positive orientation – optimism, trust and motivation
Overall, the detailed IPDE assessment and psychoeducation sessions helped to prepare people and orient
them for the next step. Many speakers articulated a positive motivation to build on their skills:
That there is hope, it’s not mysterious. What personality disorder is and the common aspects that
affect lives. That I can do something about it.
03/123
When you speak out loud about things it makes it real and it makes you look at it, made me want to
change it and make it better. I can make better choices.
02/098
Started to think about different ways of dealing with problems.
03/01
Learned that I have the skills to help myself.
03/04
Helped me really think about what things are a problem for me. Useful having that fed back to me.
Some questions make me think of things I haven’t thought of before. How my natural personality is
holding me back. Become more comfortable that I am not the only one with these problems.
[Improved motivation by] showing me what I can get out of the sessions.
01/51
. . . things aren’t so bad as I thought they were.
02/056
Take a step back and look at what I thought were major problems, aren’t at all. Feel confident about
sharing that [in problem-solving groups to follow].
01/46
It’s made me less apprehensive about going to somewhere new and talking to new people. It’s good
I’ve met you [therapist] before the groups start or you’re meeting new people in the group and new
therapists at the same time, it can be daunting.
02/026
I feel more motivated to join the group process.
03/39
Looking forward to problem-solving.
03/01
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Theme 5: barriers to progress – doubts and uncertainties
Some participants found the information difficult to assimilate. The psychoeducation had not met their
expectations. These misgivings or mismatches in their sense of what constituted meaningful help were
barriers to progress.
I don’t know how it [psychoeducation] is helping me, I don’t. It released tension. I put it in my mind in
the beginning that I didn’t fancy it.
02/015
I’ve not really understood them. I thought it was counselling, but it’s not really . . .
01/094
I’ve been unsure of the structure of the individual sessions, not sure what to expect . . .
01/124
. . . I thought that the personality statements were badly worded – slightly too open to interpretations –
a bit vague.
01/099
Not really [benefited], just good to get started with some therapy.
01/102
I didn’t learn anything.
01/102
. . . I am a little confused about whether I learnt anything extra to what I already knew.
03/078
Can’t quite remember.
01/117
I felt bad at the time. Didn’t always agree with what was being said. Hard sometimes to recall
the information.
03/03
Can’t remember most things.
03/37
Going through everything and seeing it in black and white, had feeling of being weak.
02/099
They weren’t long enough. There are just too many things that stress me to discuss in the sessions –
need to be longer.
01/150
Learning more about myself and feeling worried.
02/108
It is not known if participants felt these impressions could have been raised and addressed during the
course of the individual psychoeducation sessions. These follow-up data suggest that they were not
resolved. This early feedback of potential difficulties could have been invaluable in engaging successfully
with participants who were having difficulties and helping to address them.
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Feedback after problem-solving therapy
Problem-solving therapy was a 12-session group intervention designed to teach people strategies for solving
interpersonal problems. In addition, individual support sessions were also made available to participants.
Six themes were found in this analysis, which are summarised in Box 2 and elaborated on below.
Theme 1: positive experience
Many participants found problem-solving therapy to be a structured, positive, relevant intervention for
them. They found that it was non-threatening and that by applying it they could take effective action
successfully. Several responses evidence the fact that many people had grasped the method and felt
encouraged about applying it.
It was a good course overall.
02/055
Just that I really enjoyed it. It helped me a lot, but you only get out what you put into it. You need to
remember to use the skills.
02/008
Not what I expected it to be. First group I’ve stayed ‘switched on’ for. I learned how to stand back and
think about something rather than just react.
03/82
I found it very beneficial to use those sessions [problem-solving]. The way it was presented I’ll give it 9/10.
02/023
. . . I think its been the most helpful thing I’ve had since been involved in mental health services.
Pitched well as it doesn’t assume too much about the person beforehand.
02/026
What you’re doing is brilliant. I think the course should be longer, like a rolling course or open door.
Once a week having an open door for people with problems to talk.
02/065
I think the group should be available more widely.
01/117
I really miss the place and coming here.
01/150
BOX 2 Themes pertaining to problem-solving therapy
Themes
1. Positive experience.
2. Limited engagement.
3. Learning outcomes.
4. Vulnerabilities triggered – feeling exposed and unsatisfied.
5. Peer support seen as a positive resource.
6. Needed more sessions to master new skills.
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Managed to attend groups consistently despite feeling stressed.
03/003
I like the fact that it wasn’t about me, the fact anything can be broken down into smaller pieces using
the steps.
01/098
Valuable experience, I learnt to mediate my responses, to learn to step back and just listen, not
comment or criticise.
01/099
It’s reinforced that by going through a process again and again it helps and you can get better at it.
01/110
I’ve learnt that groups aren’t as scary as they seem. And the fact that so many options come up and it
is helpful.
02/040
That I can control my impulsivity, that the glass is not always half empty, that I can be my own master,
I just need to work on my skills and techniques.
02/008
[I] feel more confident in solving problems and feel capable of managing difficulties in a structured way.
03/039
[I learnt] to solve problems in a different way. Something more structured – easy to follow. I recognise
the build up of a problem and can ID [identify] how I’m feeling then stop and work things out.
03/013
If you can stick at it long enough it gets better. Realise how it works and that everyone is there for
similar reasons and not feeling like an individual in a group.
01/104
My general opinion is it’s something you’ve got to want to participate in. No use sitting there and
having no input. Good to have other’s input and I’ve gained more confidence.
01/033
It was OK – didn’t think I’d like it at first but it was OK. Good idea and good to know there are things
that can help.
03/020
Had impact on me as it made me use my mind more – thinking of options.
03/029
Absolutely brilliant. Although difficult to participate in some of them, I felt the actual problem-solving
process was very, very useful.
02/023
It stopped me overdosing, it made me stop and think about things.
02/027
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[The process was] helpful, I liked the fact that the group wasn’t big and the way we dealt with one
thing at a time.
02/029
I think it brings a lot of mentally ill people together and gives them a bond in a group. It’s a good way
to come together to bring experiences together.
02/052
It’s a lot different than I thought; I was expecting it to more emotional but it’s been relaxed and
informal and I’ve got on with people better than I thought.
02/064
This was an encouraging and remarkable endorsement by a clinical population that is frequently
challenging to engage. There is also implicit confirmation that the PEPS therapists were providing a valuable
treatment that was not already routinely available. It looked as if for some participants it contained a
collaborative approach to defining personal problems and setting priorities for intervention that had been
identified as lacking in treatment plans, based purely on diagnostic assessments by clinicians.80
Theme 2: limited engagement
Another robust finding of this analysis was the theme of limited engagement in problem-solving therapy,
which seemed to include timing of the problem-solving therapy, resistance to the group format, sustaining
the commitment required to complete the course, sometimes speakers felt that participants could not
‘relate’ to their problem or vice versa, and a deterioration in mental state.
I would have got more out of it at a different time. I wasn’t 100% there as I had so much going on in
my head. If I had the chance I would like to try it again when all other things aren’t going on.
02/073
I am lucky that it wasn’t a group really, mostly just me who attended so . . .
01/84
I have learned a lot about myself, but due to physical health problems I’ve not got as much as I’d like
to due to not being able to attend group often. Helpful in future to keep the six steps in mind. Can
use it better when not it crisis – have been using problem-solving in recent separation of marriage.
03/01
Groups weren’t for me and I feel I’m missing out ‘cos I still need help. Didn’t like talking about other
people – they could listen to me and think I’m a bad character.
02/015
All female group can go off on a tangent. Shame that it wasn’t better attended – lost people over
course of the group.
01/57
May not have needed to be 12 weeks as same thing each week and group became smaller with time
. . . Useful when people related to your problem as a group. Sometimes if people did not relate to my
problem or made certain comments, it didn’t help, made me feel alone. But not always.
01/49
Maybe just that I found I couldn’t work with it over the last couple of weeks as I was in a really ‘bad’
place and couldn’t focus on it. I just couldn’t engage in it when I was feeling at my worst.
03/13
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It was getting to me because I wanted to go, but found it difficult to be around the group and I felt
bad then that I wasn’t attending.
02/068
I’m not sure I liked the group. I didn’t like that individuals were under the ‘spot light’ to bring
their problems.
01/86
I could have gained more out of it if it hadn’t been at the wrong time and the problems with transport
didn’t help. Things that were said and done in the group [had a bad effect]. I also felt inferior in the
group because they sometimes used big words.
02/073
I did enjoy coming to the group, but my depression came in the last few weeks and that’s why I didn’t
make it to sessions – wasn’t myself.
02/053
I didn’t give it a chance.
02/015
I didn’t like the fact that each week was about one person’s problem. I wanted more opportunity to
talk about my problems. I did relate to some of the other’s problems, but not to all.
01/38
I found it hard going that there were so many sessions. I think a break in the middle of 2 weeks would
have been good.
02/014
It seems likely that an obvious implication of this theme of insufficient engagement with a core component
of treatment was a lack of mastery of the skills required for independent and effective application of
problem-solving therapy to complex real-life problems.
Theme 3: learning outcomes
There was a strongly supported theme that problem-solving therapy did result in learning outcomes that
participants could articulate for themselves as evidenced in the following quotations:
I’m a lot more calmer, I don’t lash out as much now. I learnt to talk about things rather then bottling
things up then falling apart. I’ve now learnt I can talk things through, but I don’t always talk them
through with the right people.
01/94
I feel as though I got a new set of tools which I can use on a daily basis – I know I am not a freak!
02/830
Strategies for my goals and ambitions. Learning alternatives to self-harm. Being reminded of
importance of planning sleep and meals. Suggestions to keep diaries was useful. Also indirectly
learned from others what they had learned. Printouts helpful so you could remember things.
Learned about other resources – Crisis Line.
01/124
I’ve got in touch with Gofal [a Welsh mental heath and well-being charity] and other agencies to help
me get back into work and have support in place.
02/023
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The way we deconstructed the problem in stages was good, it took the excess away – by breaking it
down and intervening gently it made the problem seem more manageable. By looking at things
objectively it took away the emotional charge/shit feelings/scariness of the problem. I really benefited
from learning this tool, I try to implement it as much as I can.
01/78
Even though it has been so hard, by hanging on through that day and letting it run its course, you can
turn negative thoughts into positive thoughts. After 54 years I am finally starting to have positive
thoughts – even if it’s just one to get me through the day. Nobody has given us the tools before.
I have hope in my heart.
02/52
Really good philosophy and tools. It can be difficult and can fall by the wayside – need self-discipline.
I learned about myself and how others perceive things – I was able to work out things logically –
learnt a structure [for] soul searching. I realise I am a bit of an attention/reassurance seeker. I recognise
I can manipulate to get my own way and how this can affect others. I can use Stop & Think more
positively. The more I use Stop & Think, the easier I’ll find it. I want to be able to incorporate it into
everyday life.
03/36
. . . a fusion of individual CBT [cognitive–behavioural therapy] in a group setting, but it wouldn’t have
worked without the supplementary sessions . . . the group alone does not hold it. By listening to other
group member’s problems and how they react to them . . . that was a learning curve for me to see
myself in others. Hard journey to start a path of acceptance and self-compassion. I learned to mediate
my responses, to learn to step back and just listen . . . usually my impulses are very quick and I’m out
there without thinking . . .
01/99
. . . made me use my mind more – thinking of options. Group was caring and understanding.
Good using six steps – put a different light on it. Made me try different things rather than just giving
up. Understood more about self and built my confidence to ask questions and challenge others/offer
others support. I want to use it more than I do, but that’s up to me to practise it so it feels easier to
engage automatically.
03/29
These quotes provide convincing indications that adult learners had been engaged actively in meaningful
learning with unequivocal signs of skills being brought within the participants’ reach. Traits associated
with self-direction were being nurtured, including being methodical and disciplined, logical and analytical,
collaborative and interdependent, open, as well as increasingly motivated and confident, as is consistent
with the work of Candy.81
Theme 4: vulnerabilities triggered – feeling exposed and unsatisfied
This theme related to having difficult feelings and negative social interactions, making unfavourable
comparisons with others and being unable to reconcile the dissonance between what they expected and
what problem-solving therapy actually involved. There were some indications of the socioeconomic or
cultural differences in which their own lifestyle seemed far removed from the problems being addressed.
For a few, it was too contrived, formal and academic.
After [problem-solving therapy] group taking feelings home with you with no one to share them with.
Listening to other people’s problems, felt overwhelmed. Good to feel not alone, but sometimes it felt
too much. Walked away with a lot spinning around in your head. Wanting to forget a lot of it. I felt I
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was the one with the problem (like when the psychiatrist wrote an inaccurate report). Nowhere else to
go. Still lacked confidence. Some people dropped off. Wondering what happened to them. Concerned
they were alright.
01/133
I didn’t like it at all. I’m a private person and didn’t want my dirty laundry to be aired. It was not for
me. It blew my mind and I couldn’t face it. It benefited me in opening my eyes and knowing it’s not
for me.
02/15
Sometimes I didn’t think any one listened to me and I would get upset . . .
01/148
Sessions would confuse my head coming from my lifestyle. My lifestyle is quite rough. I also struggle
with being a bit quiet. And sometimes people having a laugh and I felt I wasn’t part of it. I needed to
contribute, express more [but could not].
01/150
Groups shouldn’t be run over the Christmas months, should start in the new year as Christmas is
distressing for people so they might/do miss lots of groups over the weeks due to being unwell.
Should have been in a nicer environment, the room was too small. The research is a bit formal like it
was a test or too academic.
01/104
The intensity of the group [had bad effects]. I started drinking a lot. It consumed my thoughts.
I think if I hadn’t had other therapeutic [one-to-one] support during this time I would have made
suicide attempts.
01/099
Made me regress, [I] know you (therapist) were correct, but I couldn’t change. Confirmed how I felt
already. I felt depressed.
01/121
Some emotional factors, practical approach and the steps sometimes means you don’t have the facility
to talk to a lot about why problems have come about. Would be best to have the groups alongside a
more emotional focused group.
01/133
. . . as soon as the groups finished things went downhill again.
03/072
They were good but I don’t think it was good how it was set up. It was too planned with someone
bringing a problem the following week, situation of ‘it’s not my turn’ to talk about my problem.
So you are thinking of your own problem when someone is talking about theirs. The steps were too
long. Sometimes you didn’t know your problem or what you wanted so you’d spend a long time on
that bit and it dragged it out too much and I lost concentration . . .
(01/094)
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Theme 5: peer support seen as a positive resource
The content of this theme related to overcoming negative stereotypes, vicarious learning from peers,
being less judgemental, and overcoming social isolation.
Realised that others who have this diagnosis and that people with BPD [borderline PD] are not
monsters. It was helpful to meet other people with BPD who are employed . . . I had a lot of
personality issues at work and it is hard to keep a job. It was useful to meet other people who have
personality disorders and can keep a job.
01/104
I’ve enjoyed it. Meeting people who are the same as me.
02/027
I feel I got a lot emotionally out of the group. I have been using my skills and I don’t feel angry if it
doesn’t work, I just try something else. I am now part of a support group made up of ‘stop and think’
group members.
03/082
Huge meeting others with personality disorder, having others care, listen, take notice. Learnt to be less
judgemental of others.
03/011
I found it reassuring that I wasn’t alone in the way I dealt with things. Others have problems too and
being able to share. Got good helpful ideas off others.
03/013
Met a member of the group which developed into a friendship. Good to know I’m not on my own,
others could identify with things I was saying, vice versa.
03/020
Sharing of info with other group members. Feel less isolated, ability to look at things differently
breaking the cycle.
03/023
Sharing experiences with others and getting their support. Would feel more confident in engaging in
other group work.
03/076
I made friends and learnt how to listen and negotiate with other group members.
03/083
I liked everyone in the group, I enjoyed it sociably, I liked the people very much.
01/098
Being in a group with people helped me be more sociable in my personal life.
01/100
Rewarding that when I put in options some people thought they were really good options.
And some people came back to the group and said it worked, rewarding to be listened to.
01/133
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It was nice being with people with different experiences – the social aspects. I feel more comfortable
making small talk, having done it in a safe environment. Other people come up with things that you
don’t think of.
02/026
Listening to others stories I can relate to, can put a context into it without needing to talk about it.
Having another view point of comparison, having someone say ‘yes I can relate to this’.
02/064
The main thing I’ve learnt is that other people are dealing with similar problems and using a technique
that works.
02/065
[I learnt] that there are options to problems. I was expecting mad people in the group but actually they
were all quite normal which made me feel less threatened in a group setting.
01/104
Group was understanding, good using the six steps.
03/029
Theme 6: needed more sessions to master new skills
Many participants felt that more opportunities to master social problem-solving skills were needed.
They wanted to be able to repeat the course and were worried that, after the course was over, there
would be nothing to replace it.
What you’re doing is brilliant – I think the course should be longer, like a rolling course of open door.
Once a week, having an open door for people with problems to talk.
02/65
More sessions as just warming up.
03/37
If I had the chance, I’d like to try it again when . . . other things aren’t going on.
02/73
Group could be longer. Just got used to people and was only half-way there when it stopped.
03/038
I hope we can have somewhere to go like this along the way in the future.
02/52
Found support sessions 1 : 1 valuable.
03/01
My only worry is that when this is all gone, I’m left with nothing again and that scares me.
02/32
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Themes related to psychoeducation with problem-solving therapy based on
feedback at 72-week follow-up
The following six themes were found in the interview data on final reflections by participants on PEPS
therapy. They are summarised in Box 3 and then examples of quotes follow.
Theme 1: psychoeducation with problem-solving is a valid treatment
Participants found PEPS to be credible, to mobilise their own resources, to provide positive, collaborative
experiences with staff and peers, and to provide hope of adopting a self-directed approach to improving
their lives.
Really good, well structured. Different depending on who got [participates] in it. Very useful for me.
Skills based versus analysis, analytic introspective based. I think this is better for people with a
personality disorder. Skills based model really useful. Differing and varying opinions useful because
people had similar disorders, you could compare issues. Strategies for my goals and ambitions.
Learning alternatives to self-harm. Being reminded of importance of planning sleep and meals.
Suggestions to keep diaries was useful. Also indirectly learned from others what they had learned.
Printouts helpful so you could remember things. Learned about other resources – Crisis Line.
01/124
I think everyone who was offered the chance to go to PEPS therapy doesn’t know how lucky they are.
To go there and know what’s wrong with you and understand why you’re different and that you’ve
got to work towards improving yourself. People don’t understand mental health, if you keep it in your
head what you’ve learnt here – remember the people you met here and one part of the program will
keep you alive.
02/052
[PEPS was] very good, it explained a lot to me.
02/058
Living again, not just existing, PEPS saved my life!
03/004
I hope it gets rolled out at the end of the study.
03/023
BOX 3 Themes related to PEPS therapy
Themes
1. PEPS is a valid treatment.
2. Both psychoeducation and problem-solving therapy are necessary parts of it.
3. Peer support and not being the only one with difficult problems was reassuring.
4. Barriers to PEPS working.
5. Consistency of staff and process important for security and sustained participation.
6. Lack of ‘dose’ – needed more sessions and supervised practice.
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A lot easier to be in and keep employment when one has tools to manage . . . Also [applies to]
everyday life. I’ve had long history of self-harming. Now when I get these urges, I dismiss them.
Before, I felt I had to cut myself. Now I can step back, it’s worked for me. When born, not given a
handbook. By listening to others [in PEPS] who have same problem and trying what’s worked for
them, it’s helpful. Amazing what a little care and compassion can do. To hear another person say,
‘I can understand how you feel’ means a lot . . . Helped me be more open with my wife. I feel
confident knowing she cares about me. If I have a [bad] day, I can tell her. Before would have bottled
that up and would have felt like cutting myself. I used to wear a mask, now more open and honest.
Know people care about me. No longer embarrassed about who or what I am.
01/127
I did have a benefit. I was thinking in a different way, stopped putting myself down as much and
though more positively.
01/084
Felt like I could help other people who were going through things that I’d been through. It’s changed
my whole attitude. If I think about all of my overdosing, it just seems like selfishness and not being
prepared to deal with what I get myself into.
02/027
More confident dealing with things. Deal with things a lot better now than previously; used to have
lots of meltdowns. Confidence to deal with things better and be around strangers.
02/029
Having ill people together, we came up with better answers – I think we need each other. Still need
each other, need courses like PEPS, can mend each other, laugh and feel more positive. I think I deal
with things much better since the course.
02/052
No longer making the same mistakes again and again, now coming up new counselling/solutions to
[my] problems
02/056
Helped with social, recently discovered I have Asperger’s.
02/064
They [therapists] were lovely, really patient and understanding. Doctors normally make me feel crap
and like they are looking down their nose at me. It was really important that PEPS people didn’t make
me feel like that.
02/029
It’s a way of life now. Thank you for changing my life. It’s been an amazing experience and I’m very
grateful for everyone who played a part in helping me get better.
02/056
Although I have given Q7 [rate the usefulness of PEPS] as a ‘1’, it is because I’ve let it slip. I do think it
is really useful and works. I just need to find a way of reminding myself.
01/117
Learnt how to talk to people comfortably and overcome paranoia of people judging you.
03/001
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These responses demonstrate that participants experienced PEPS therapy as combining interesting
knowledge of their difficulties with practical coping skills and positive attitudes towards their future recovery.
Theme 2: both psychoeducation and problem-solving were necessary parts of
psychoeducation with problem-solving
This theme demonstrated that many participants had grasped the rationale for PEPS and valued both
component parts of it.
I think they work together, they complement each other – you need both. Whole structure
very helpful.
01/098
Liked the individual ones – felt I could open up better one to one. Group sessions were fine, liked
listening to other problems. I’ve never been good in large groups, was nice that it was a small group.
Both parts useful in different ways, useful to have both, worked well together.
02/009
Both worked well together both equally useful.
02/020
Both useful and worked well together.
03/004
The two come hand in hand. If I had to chose, when everyone works in the group together and
sharing our experiences was the best part.
02/052
Went hand in hand, couldn’t have one without the other.
02/056
Worked well together. The more educated you are the more able you are to deal with your problems.
02/062
Both worked well. One to one gave me confidence to go into the groups, confidence got me ready
for the group.
03/001
Worked well together. One to one brought me outside myself and helped me understand myself
which helped me face going to the groups.
03/013
I like being one-to-one, more direct and just about me; but then in the group It helps you to see other
people’s views and hear other people who are worse off. [Both] useful for different things, worked
well side-by-side. Also nice to have opportunity for individual support sessions.
02/004
Preferred the group because you realised you’re not the only one that behaves like that. Help each
other to deal with things and individual session were alright.
02/005
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Found psych-ed great, therapist was really understanding and non-judgemental, prefer one to one.
Not a lot of people in the group was good. More attention to each person and good if nervous
around big groups.
02/006
I think it should incorporate the two. I liked that we met the therapist and had a chance to discuss
problems to work on. First day with the group is really hard, much easier when you at least know
the therapist.
02/008
Theme 3: peer support and not being only one with personality disorder or
difficult problems to solve was reassuring
[Benefited from] the support factor, wish they were still ongoing.
02/078
I met a couple of other girls that I’m still in touch with and call them when I’m having a bad day.
01/042
Had someone to discuss things and plan things with, it was nice to have support.
01/050
Being around others that knew where I was coming from and didn’t judge me. Really appreciated it.
03/013
Good to know other people’s views on problems, see things from different angles. Good way to start
discussions and share experiences and let off steam.
02/006
That I’m not alone was such a huge relief. Even when you’ve got the same problem as someone,
it’s not exactly the same but you understand each other better.
02/008
Theme 4: barriers
Participants highlighted various reasons why they gave up on PEPS. Group factors were a major reason,
the size, composition and ‘feel’ of groups led many to reject this format. Some people realised that their
personal mental health vulnerabilities were triggered by PEPS. Some participants were not yet in a
reflective space, they felt caught in a spotlight and drawing attention to any perceived shortcomings was
too much for them to cope with.
Not saying it didn’t work, but drop-outs in the group were unsettling. Changes in the group affected
me; maybe a bigger group could have helped with this. More men as largely women group.
03/125
Didn’t attend problem-solving groups, couldn’t be in a room with strangers.
02/058
Only went to half of one group session – didn’t feel comfortable.
02/015
Only attend the individual session, found those helpful. Couldn’t attend group session due to
other commitments.
01/150
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Sometimes it can be awkward, everyone has different problems. Individual more helpful; didn’t find
groups helpful.
01/063
Didn’t like the groups – would have been better if had more time to work with the therapist.
01/086
Might be a good idea to have a service user involved in explaining personality disorder – only they
understand what it feels like. Would like refresher sessions of problem-solving and maybe include new
information on what helps.
02/008
I think my weak point is that I let it slip. I don’t keep things up I need things put on a plate for me or
I don’t do it.
01/084
Sometimes main message was lost. Noticed I was distracted by those who were less confident reading
and writing. Wondered if it put people off, unsure if others got as much out of it.
03/004
I do think I’ve benefited but I’ve been really ill lately and I have a bad memory.
02/014
I struggle with paranoia and found that I couldn’t understand how others were finding the sessions
useful. I judged myself and them but I have learnt that I shouldn’t judge them as it is acceptable that
they could find it useful even if I didn’t.
01/099
Group sessions didn’t feel comfortable enough and being pushed too far into the deep end, made me
want to give up.
02/039
When you are at your lowest sometimes wish you hadn’t gone because you know there isn’t a
booklet to help you.
02/052
It drew attention to my bad attributes which meant I would leave group sessions feeling low and
negative about myself. Also found that I would take on other people’s negative thoughts and start
thinking those about myself.
01/002
Everything all together was overwhelming and I was unwell for a period afterwards. The premise of
group was to bring a problem you wanted to work on. That exposure mixed with the immediate
finality when the sessions ended was difficult.
03/123
Only went to one group session as didn’t get on with some of the participants.
03/118
It’s a good idea but not the group meetings; I prefer one to one. I don’t like talking about my
problems in front of other people especially if I don’t know them. They might take me the wrong way.
I’ve had bad experiences with this in the past.
02/015
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One to one were very good; didn’t like the group session everyone knowing my business.
02/039
Personally it didn’t work, especially the group therapy. Went because the GP told me to but they were
a waste of time.
01/063
Wasn’t very impressed with it, it didn’t seem to benefit me. I didn’t like the way the groups were.
I didn’t like the way it used different people to talk each week – ‘spotlighted you’ I didn’t feel
comfortable opening up to strangers.
01/086
Theme 5: consistency of staff and process important for security and
sustained participation
Psychoeducation with problem-solving staff were valued for being sensitive and skilled. The format seemed
acceptable to many participants:
Thought the therapists were really good, the way they explained things – not judgemental.
02/005
Routine helped me, consistent time and place.
02/008
Staff helpful and supportive, everyone got the chance to give input.
02/008
Therapists were very nice and down to earth.
02/009
From a workforce perspective, the fact that many people with PDs engaged with the staff and the process
suggests that treatment specifically designed for people with PD need not be extremely intensive and costly.
Theme 6: lack of ‘dose’
A dominant theme in the feedback received on PEPS therapy was that people had not had sufficient
exposure to the method and supervised practice in using it until it became a part of their own skill set that
they could apply independently.
I think others found it difficult being open and dealing with their problems in front of others. I found it
useful but ideally it might be useful to have a short refresher course a few months later.
02/014
Needed longer than 3 months in the group, worked well together.
01/084
Once sessions were over, I was like a zombie. I couldn’t do anything for a few days.
03/82
Not long enough – only just got into it and then it’s finished.
03/024
Looking for a short-term intervention to a long-term issue. Could have been better to hold the
12 sessions over 12 months, 12 weekly sessions were too much to process.
03/123
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Better to spread therapy over 12 months, time frame was too short, very intense and full on. If over a
longer period may be able to take things in better as remembering was difficult.
03/125
Didn’t last long enough. Waited a long time hear if in the group, then given only 2 weeks’ notice.
Little follow-up.
03/036
Not enough time to go through everyone in the group and follow-up every problem. Problems never
felt finished – so not solved.
03/024
It could have been longer, could have used the support for a bit longer.
02/009
Fabulous staff, could have lasted longer.
02/066
Pity it’s still not going on.
02/078
Groups felt like going back to school. [The process was] not long enough, needed more weeks.
03/024
After a while I slipped back into my old ways, would be good if it could keep going for longer maybe
once a month.
02/006
I believe the spike in adverse events was due to the model not sustaining the support. It gave people
help and then left them.
01/099
Ended to soon, only got to work on one problem. Would have been good to have chance to
say more.
01/100
Content was good but not enough time to do everything.
03/123
12 weeks is not enough, should have been extended for as long as the person needs.
01/063
These comments suggest that this intervention was offered as a separate, stand-alone treatment. This is
not ideal. Participants missed having maintenance sessions to consolidate and reinforce their acquisition of
new skills. There seems to have been no carry over to ongoing mental health services participants were
receiving. A probable implication is that as soon as the intervention was over, there was risk of it being
eroded because it was not practised and improved. It was expecting a great deal of individuals with severe
mental health problems to organise themselves to use a complex method unaided and unsupervised after
the problem-solving course had been delivered. These data suggest that some participants floundered
when the research intervention was suddenly stopped.
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Themes related to usual treatment based on feedback at 72-week follow-up
Treatment as usual was provided by participants’ usual-care teams in accordance with normal practice.
What constituted treatment as usual in the trial was variable. A summary of services mentioned by
respondents in their feedback is given in Table 31. This analysis found two themes pertaining to
treatments and support received as ‘usual treatment’:
1. helpful aspects of usual treatment
2. unhelpful aspects of usual treatment.
Theme 1: helpful usual treatment
Participants highlighted the usefulness of the practical help and support, being listened to and believed,
and a sense that staff were caring and competent.
It’s been helpful, they gave me advice on staying positive and keeping my mind occupied.
01/34
Psychiatrist and social worker. Treatment from psychiatrist was excellent; [I] thought [the] social worker
was very bad.
02/03
Floating support worker has been a huge help. Advocate has been hugely helpful in appointments
[with] CPN [community psychiatric nurse] and psychiatrist – felt more believed and listened to.
03/07
TABLE 31 Services mentioned by participants describing usual treatment
Service Qualifiers
Outpatient psychiatry Regular follow-ups over several years
Inpatient admissions As required
Art therapy Weekly
Psychology As agreed
Psychotherapy As agreed
Keyworker from CMHT or voluntary agency Regularly (fortnightly or monthly) as planned or when requested
Drug and alcohol team Not specified
Counselling As agreed
Planned meetings with GP Regularly arranged
Community psychiatric nurse Usually fortnightly or as agreed
Social worker In role of keyworker usually fortnightly or as agreed
Day centre Several days a week over the duration of several years
Crisis or emergency services As required
Occupational therapy As agreed
Advice on benefits As required
Mentalisation groups Weekly for several months
Mindfulness course As per referral
Mental health advocacy As required
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Felt I could talk to my counsellor and they understood.
01/44
GP doesn’t listen or states the obvious. Mental health team have been great. CPN has brought
forward appointments with the psychiatrist – monitoring me closely. Health-care assistant tries to
motivate me to do things. They try to help even when I don’t think they can – don’t feel brushed off.
02/07
GP, psychiatrist and care co-ordinator – everyone was very kind, everyone was doing their best.
I felt like I was being looked after.
03/10
I don’t know [what benefits I have had from treatment as usual] maybe a bit of community support
has kept me out of hospital.
01/82
GP and CPN have been brilliant.
03/25
Yes, the psychologist I had was very good and understanding. She taught me different techniques and
helped me to understand how my mind works.
01/87
I guess so – I’ve been quite stable. Art therapy helped me to understand my emotions and control
them better.
01/93
Medication and CPN for past 18 months. CPN doesn’t always respond quick enough. Finally got meds
[medications] balance right. CPN helps with problem-solving.
03/34
Mental health team have been really good. I only wish what is on offer now with psychology and
psycho-education was available 20 years ago as I might have been a lot better.
01/111
There was no mention of specific PD services or care pathways. People valued knowing who was
responsible for their care and how to contact them as a minimum.
Theme 2: unhelpful aspects of usual treatment
Individuals whose personal histories include being marred by close relationships picked up on staff
attitudes and willingness to take action to help them. Some participants were affected by cut-backs.
It was concerning to hear that some people felt that unless they deteriorated or experienced crises they
were not taken seriously.
Waiting lists for treatment – art therapy are really bad. Also took a long time to see a psychiatrist and
the mental health team. Quite scary to be kept waiting, to be left alone in those situations.
01/140
It’s all been very confusing. I was receiving support albeit intermittent[ly], but I moved house about a
year ago and now my local GP will not refer me to services as he wants proof that I have previously
been given a diagnosis of borderline personality disorder.
01/115
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Only given six sessions with my mental health team. Not enough. Actually it’s worse at the end.
Just about the time you feel you have developed rapport, the sessions end. Now I don’t even want to
start. I don’t see use in having to keep re-explaining myself, to start building rapport with someone
who will stop seeing me in a few sessions.
01/131
Don’t seem that bothered, seems as if they don’t have enough time – suggest things and then it takes
ages for anything to happen.
02/11
Medication and seeing a professional every 4 months. Had a crisis – told there was no-one available to
talk to [me]. Requested a copy of the notes the lead professional had made. They did not corroborate
her experience of meetings. Felt ‘talked down to’ confronted the professional, put in a complaint.
03/14
Nothing, no treatment received. Medication – came off it in March this year [2012].
01/28
Some counselling through GP, but was stopped as funding was pulled. [GP/CMHT] really bad, not
sympathetic, not aware of other services. Not at all bothered – didn’t see [my] desperation. Told [my]
only hope was the crisis team.
02/25
Don’t feel I’ve had much treatment. Sessions with psychiatry. See GP regularly. Psychiatrist hasn’t
given me suggestions or further support. Feel passed back [and] forth between GP and psychiatrist.
Therapist at GP and sessions at ‘Workshop and Co’ all of which stopped, so I feel abandoned.
01/01
Psychologist then discharged and had no one. [It] took my daughter being placed on child protection
list to have help.
02/30
Nothing since CPN at start of PEPS. Would have liked PEPS. Questionnaires made her think more –
raised awareness [was] helpful.
03/33
Nothing – psychiatrist every 3 months waiting for psychologist. Bad experience of crisis team – [I felt]
intimidated [they] didn’t understand. Fear of A&E [accident and emergency] – too many germs.
Daughter is my carer. Self-management – felt categorised.
02/33
Unsatisfactory at all stages – both GP and CMHT. Difficulty being referred by GP basically told to make
my own arrangements. CMHT not at all concerned. Just wanted numbers going through their doors.
No longer have hope to speak to my GP. I just can’t depend on anyone at the moment. Before I had
the feeling in the back of my head I could speak to my GP. Now I don’t have that feeling anymore.
01/108
I didn’t receive any treatment for my mental health.
01/40
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Struggling for a long time. No service for what she needs help with. Refused psychotherapy as [she
was] deemed ‘not safe’. But not safe without psychotherapy either. Struggling with change of CPN.
No progress. Feels that what she says is acknowledged, but no support or way to deal with it after
that [is offered].
03/107
Difficult to get care other than when I’m in crisis . . .
01/104
None – only see GP for alcohol related problems.
03/128
Discussion
The aim of this analysis was to provide information on participants’ experiences of usual treatment and
PEPS therapy, with their perceived benefits and limitations. The majority of codes related to feedback on
treatment aspects participants valued, as well as on obstacles they encountered. For many participants,
having a thorough assessment of their personality traits and receiving detailed feedback on the meaning of
the results made them feel valued and helped them to understand the challenges they faced if they were
to overcome problems and recover valued roles. Furthermore, they grasped the rationale of the treatment
to follow and saw the psychoeducation as pretherapy preparation, which was generally helpful in orienting
them to the intervention to follow. Good staff performance emerged with a difficult-to-treat group feeling
that they were listened to, cared for, supported and treated reliably and skilfully. The structure, training
and supervision adopted by PEPS provide useful feedback to services wishing to develop specific care
pathways for people with a PD.
Overall, this analysis provided strong indications that PEPS provided self-knowledge in a way that
empowered participants to become agents of change. PEPS had an impact on their attitudes, which
changed from frequently being disaffected to being engaged, hopeful and motivated to put effort into
acquiring skills.
Several well-supported codes in this analysis related to challenges that needed to have been resolved in
order for learning to progress from positive interest to successful acquisition of complex social and
cognitive skills. Early signs were present that some people were being lost at the beginning of the process
when they did not grasp the notion of how their own clusters of habits interfered with their social
functioning and problem-solving. Unfortunately, subsequent learning could not proceed until individuals
grasped the rationale. Given their personal experiences of being marred by their relationships, the
transition from individual to group format was too difficult for many in this clinical population. Instead of
labelling the problem-solving a group, it might have been less threatening to have presented it as a safe,
non-invasive course. The analysis harvested important feedback on perceptions influencing motivation to
engage or reject involvement in a group intervention including size, composition (including sex), efficiency
in completing problem-solving cycles, group norms (arriving late, rejecting some contributions) and
cohesion. PEPS did provide positive, even corrective, group experiences where groups were smaller,
provided valuable suggestions for problem-solving options and challenged negative stereotypes about
people meeting criteria for a PD. Unfortunately many people floundered at this stage and did not engage
in group-based problem-solving. Follow-up, providing ongoing feedback on attempts to apply the skills
and opportunities to repeat the course, emerged as being essential for the approach to become embedded
in services and in people’s lives.
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Closer links to educational research and knowledge about adult learning might have informed more
accurate perceptions of prior learning needed for this quite sophisticated intervention to have met its
outcome standards for proven efficacy. Clearly coping with high anxiety in social situations was relevant to
many participants, but was not the focus of PEPS therapy.
The limitations of this analysis include the second-hand accounts of participants’ accounts captured on
semistructured interview sheets. Some questions were repetitive and did not draw out meaningful
elaborations or invite participants to provide more individualised responses. Future studies might benefit
from using focus groups. These could use interview data to differentiate those people who were
enthusiastic about the skills-based approach that they had been offered from those whose experience of
PEPS had led them to reject this treatment approach. Focus group data could help us to understand what
factors differentiated the groups and what might be done to increase access to clearly structured,
evidence-based interventions.
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Chapter 7 Discussion
Summary of findings
Clinical effectiveness
The findings of this trial showed that PEPS therapy plus usual treatment was no more effective than usual
treatment alone on either the primary outcome or a range of secondary outcome measures. Specifically,
no superior effect of PEPS therapy plus usual treatment over usual treatment alone at the 72-week
follow-up on the primary outcome of social functioning, measured by the SFQ (adjusted difference in
means –0.73 points, 95% CI –1.83 to 0.38 points; p= 0.19). The change score on the SFQ required to
indicate the minimum degree of clinical significance was a reduction of 2 points. The CI of the difference
in means crossed zero and did not include –2; thus, the null finding is unequivocal. Scores on the SFQ
reduced in both arms of the trial from baseline to the 72-week follow-up, indicating some overall
positive change. This may be attributable to being in a trial, bearing in mind that participants in the
usual-treatment arm underwent a number of assessments that are not typical of usual treatment, although
this observation can also be explained by regression to the mean. While the CI for the whole sample did
not include zero, nor did it include –2 points (95% CI –1.54 to –0.32 points), hence any effect did not
reach the requirement for minimum clinical significance.
At the 72-week follow-up, no treatment effects were evident for any of the secondary outcomes, namely
scheduled and unscheduled health service use collected from GP records, mood measured by the HADS, or
on the client’s assessment of change on the three problems they considered most important. The process
of change, which was to improve social problem-solving skills as assessed by the SPSI-R, showed no group
differences at the post-treatment point of measurement. There was consistency across all measures; there
were no significant differences between the PEPS group and the usual-treatment group on any measure.
Furthermore, there were no obvious effects at different points in follow-up.
The baseline characteristics of the two groups were similar, apart from a slightly higher proportion of
participants with complex PD in the PEPS arm. Subgroup analysis of the SFQ at the 72-week follow-up
showed no difference in outcome for complex versus simple PD. There was no difference for people with
borderline PD.
About half of the people in the PEPS arm did not receive the full dose of treatment. Analysis of the
primary outcome by compliance suggested a better outcome for those who received an adequate amount
of treatment.
Cost-effectiveness
Psychoeducation with problem-solving shows slightly lower costs and higher QALYs, but differences are
not large or significant and CIs are wide. There is a 64% likelihood that the intervention is cost-effective at
the threshold used by NICE.
Adverse events
The stoppage of this trial because of concerns about safety is, to our knowledge, unique in trials of
complex psychosocial interventions.82 The DMEC, after studying unblinded data, alerted the TSC to the
higher rate of adverse events in the PEPS arm of the trial. The TSC advised that recruitment to the trial be
stopped, that treatment should discontinue and that all participants should be alerted to this safety signal.
The TSC also firmly advised that follow-up should continue.
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It quickly became apparent that stopping a trial of a complex psychosocial intervention because of reports
of adverse events was both unique and potentially harmful to the participants, and would require
additional, specific procedures to be implemented. We worked closely with the NCTU, in consultation with
the TSC and site coinvestigators, to develop procedures for safe stoppage. These included advising the
sponsor, advising clinical teams, writing information sheets for participants, devising clinically safe stopping
procedures, contacting all participants and conferring with the research ethics committee.83
By the end of the trial, both the number of adverse events, including serious adverse events, and the
number of people reporting them were greater in the PEPS arm. Four deaths were recorded in the PEPS
arm: two of these were from natural causes and two were suicides. The nature and circumstances of these
deaths did not seem related to the therapy. The number of hospitalisations and the number of people
hospitalised were greater in the PEPS arm. The majority of this difference is accounted for by incidents of
self-harm and drug and alcohol overdose. Although there was a tendency for PEPS participants to report
more adverse events, even after allowing for greater follow-up in the PEPS arm, the results are inconclusive
(adjusted incidence rate ratio 1.24, 95% CI 0.93 to 1.64). It should also be acknowledged that the
assumption underlying this analysis, that the occurrence of adverse events follows a Poisson distribution
(that is, equally likely to occur at any time following randomisation), may not hold true.
Participant views
Interpretation of the findings is assisted by what the participants told us about their experiences of PEPS
and usual treatment. Participants valued the one-to-one psychoeducation sessions, which built rapport and
increased knowledge and understanding of PD, as intended. The problem-solving approach was also seen
as helpful. There is, therefore, the important suggestion that service users’ perceptions of treatment being
helpful may not translate into clinically meaningful effects for this group of people.
There were mixed feelings about group work: some felt supported by working with peers, whereas others
felt the group setting to be challenging. There was a consistent view that the treatment was too short
and the lack of follow-up support was considered a serious shortcoming. Opinions about usual treatment
were variable: some individuals were positive about treatment received, while others felt dismissed and
neglected. Worryingly, there was a view that the way to access services was to evidence a decline or bring
about a crisis (e.g. harm oneself).
Strengths and limitations
Study design
This was a pragmatic trial with broad inclusion criteria (i.e. any PD). As such, it presents results that are
generalisable to regular clinical practice in secondary care mental health services.
Treatment fidelity
Treatment fidelity is the extent to which an intervention is delivered as specified in the protocol. Without a
high degree of fidelity, there is no way to determine whether unsuccessful outcomes reflect a failure of the
model or failure to implement the model as intended.84 A number of strategies were in place to maximise
treatment fidelity. The PEPS intervention was specified in treatment manuals, containing information
about the theory underpinning the treatment, the content of sessions, and the duration and frequency
of sessions. Therapists were qualified mental health nurses or psychology graduates with clinical
experience. Therapists were centrally trained by experienced clinicians and regular supervision was
provided. Audiotapes of treatment delivery were scrutinised by the trainers to ensure that each therapist
was adhering to the treatment specification and individuals were rated on competence checklists. None of
the therapists failed to meet the competence criteria on any of the measures.
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Measures
Validated outcome and process measures were used in this trial. With regard to secondary outcomes of
service usage, the original idea was that service use might not decline as a result of treatment but that
better use of the services offered might result. That is, treated individuals might attend scheduled
appointments and thereby avoid crises that required emergency, unscheduled appointments. In the event,
it was not easy to ascertain which appointments were scheduled and which were not, apart from the most
obvious ones such as emergency department visits.
Sample size
The power calculation for this trial was based on a pilot study conducted with a comparable sample.
As stated in the trial protocol,85 to detect a mean difference in SFQ score of 2 points (SD 4.53 points) at
the 72-week follow-up with a two-tailed significance level of 1% and power of 80% with equal allocation
to two arms, the requirement was 120 patients in each arm of the trial. Allowing for 30% drop-out, the
aim was to randomise 340 participants in total (i.e. 170 participants per arm). The study fell marginally
short of its target of 70% follow-up, with an overall follow-up at the 72-week end point being 68%.
There was a difference in the follow-up rate between the usual-treatment arm (62% follow-up) and the
PEPS treatment arm (73% follow-up), with the target being met in the latter. The numbers, however, were
somewhat short of the desired 120 participants per arm at 94 in the usual-treatment arm and 113 in the
PEPS arm. This was partly because the trial was stopped before 340 people could be randomised, with
only 306 randomised before recruitment was halted. Furthermore, although this was one of the largest
economic evaluations conducted in PD, the sample size may have been too limited to pick up important
effects on the use and cost of specific services. Nonetheless, this trial has demonstrated that it is possible
to recruit a large number of difficult-to-engage, community-dwelling individuals into a clinical trial and to
retain a large proportion of recruits to an end point 72 weeks after randomisation. Further, the achieved
sample size, although smaller than the target, still yielded sufficient precision to exclude a clinically
meaningful effect.
Bias
Care was taken to minimise bias through independent randomisation, ensuring as far as possible that
researchers collecting follow-up data were blinded to allocation, and conducting data entry and cleaning
while blind to intervention status. However, researchers were unblinded in some cases, with more cases in
the PEPS arm than in the usual-treatment arm (32% vs. 13%). Nonetheless, in the PEPS arm, the mean
72-week follow-up score on the primary outcome (the SFQ) was higher (i.e. in the undesired direction) for
the unblinded cases, indicating no bias in favour of the PEPS group.
On average, non-completers in the PEPS arm remained in the trial for longer than non-completers in the
usual-treatment arm. This, combined with the higher overall completion rates in the PEPS arm, contributes
to more observed person-years of follow-up in the PEPS arm (203 person-years) than with usual treatment
(178 person-years).
Bias in adverse event recording
Adverse event recording may have been subject to bias. Recording of adverse events during the trial
depended on self-disclosure or a report by a member of the clinical team. The difference in reports of
adverse events between arms could be explained in ways other than PEPS causing harm directly. These
include differential reporting, for a number of reasons. Those in the PEPS arm were more in contact with
therapists and so had more opportunity to report adverse events, and may also have felt more able to
admit adverse events candidly. Similarly, there may be a greater degree of identification by staff of
problems experienced by participants in the PEPS arm. In addition, clinicians may have been more likely to
advise the research therapists about adverse events for those in PEPS therapy, whereas they managed the
usual-treatment participants themselves, and so this may appear as more adverse events in the PEPS arm
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during the treatment phase. Alternatively, PEPS may encourage help-seeking, increasing the likelihood of
hospitalisation, in which case adverse events would not be literally ‘adverse’. More systematic and objective
recording of adverse events would have been desirable. Advance consent had not been obtained to access
Health and Social Care Information Centre records, and gaining consent to do so from participants in the
follow-up period proved difficult because of limited contact and availability.
Uptake of the intervention
Of those randomised to the PEPS arm, 4% (n= 6) received no intervention at all, 51% (n= 78) received a
partial intervention (i.e. ≤ 5 group sessions) and 45% (n= 70) received the intervention as per protocol
(i.e. ≥ six group sessions). In the pilot study, of the 87 people allocated to PEPS, 13% (n= 11) never
attended, 1% (n= 1) attended psychoeducation only, 21% (n= 18) attended psychoeducation and fewer
than five group sessions, and 66% (n= 57) attended psychoeducation and five or more group sessions.
So, in the definitive study, fewer people received no treatment but also fewer received an adequate
quantity of treatment. The planned 12-session group intervention actually lasted, on average, six sessions.
That is, most participants did not receive the full treatment. CACE analysis attempts to estimate the effect
of the intervention among those in the PEPS arm who adhered compared with those in the usual-care arm
who would have adhered had they been allocated to receive it. As expected, when the proportion
adherent is around 50%, the CACE estimates are approximately twice that of analyses that take no
account of amount of intervention received. However the 95% CIs are wide and none of the sensitivity
analyses lend strong support for different conclusions from the primary analysis.
Of the psychoeducation sessions offered (on average 3.4), 90% were taken up. Clearly, individual
psychoeducation is far better attended than subsequent group sessions and the overall group
non-completion rate is high. This difference may be explained in a number of ways. Participants’
enthusiasm for treatment may be stronger at the start of treatment and wane with time, they may prefer
individual sessions or the content of psychoeducation may be more relevant to their problems.
To our knowledge, there is no review of treatment uptake and completion specifically in RCTs of
psychological interventions. However, reviews of treatment completion of psychological therapies for PD
using evaluations of any design indicate non-completion rates as low as zero and as high as 80%, with
median or mean non-completion rates of between 29% and 35%.33,86,87 Although the PEPS therapy
non-completion rates appear higher than average, studies of non-completion use many different
definitions of what constitutes non-completion of therapy and so comparisons may be misleading.
Personality disorder types
The treatment was offered to people with any type of PD. This was a pragmatic approach in that services
often cannot offer separate treatments for different disorders and so treatments are offered only for the
most common disorders (typically borderline PD) and people with the less common PDs may not be offered
treatment at all. However, it may be that people with certain types of disorder have done better than
others. Although the trial was not powered to conduct subgroup analyses, examination of those with
borderline PD, which was the most prevalent disorder at baseline, showed no difference on the primary
outcome at follow-up.
Non-standard usual treatment
The content of usual treatment was not standardised in this trial. Imposing standard treatment on the
large number of services contributing to this trial was not considered a feasible option. Practice varied
widely across services, and usual treatment was not a clearly prescribed procedure. Some participants
commented that usual treatment could be well planned, holistic and reliably delivered, but in other cases it
was unfocused, dismissive and unreliable. This issue (i.e. highly variable usual treatment) affected both
those in the PEPS plus usual-treatment arm and those in usual treatment alone. The variability of usual
treatment and the unclear treatment pathways for people with PD may have, in part, accounted for the
loss to follow-up.
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Observations about participants
Overall, participants in this trial were heavy users of health services, costing approximately £8000 per
annum (based on the baseline data). This is comparable to the estimated treatment costs for schizophrenia
but substantially more than the costs for bipolar disorder.88 This is reflected in low quality of life, with
QALYs of around 0.57 over the entire follow-up (i.e. out of possible 1.5 QALYs). The prevalence of PD in
mental health services in England is at least 40%.89 Coid et al.1 have estimated a population prevalence of
4.4% in those aged 16–74 years and this would imply total health costs of around £16B per year.
Interpretation
We found no evidence to support the use of PEPS therapy alongside standard care within the UK NHS for
improving social functioning of adults with PD living in the community. This differs from the pilot study,
in which a significant improvement was found in the primary outcome of social functioning, measured, as
in this trial, by the SFQ at the end of treatment, which was a mean of 24 weeks post baseline (range
21–28 weeks).43 The between-group difference on the SFQ at the end point was –1.06 points (95% CI
–1.99 to –0.18 points). In the pilot study, there were also significant improvements on the SPSI-R, although
no significant improvements in service use.
A number of explanations can be put forward for the lack of significant effects observed in this full-scale
trial compared with the pilot study. The full trial was superior in its design and methods: it was multisite,
there was a larger number of participants (providing greater precision of estimated between-group
differences) the follow-up period was considerably longer and the methods of imputing missing data were
more sophisticated. Hence, greater confidence can be placed in these results. Evidence from meta-analyses
shows that demonstration projects have larger effects than programmes delivered more widely, and high
methodological rigour is related to smaller outcomes.90 Pilot projects may produce larger effects because
they are more manageable in size and they are innovative, hence they may benefit from closer supervision,
higher programme fidelity and a greater motivational drive from the closely involved chief investigator.
Evidence for the effectiveness of psychological treatments for PD is marred by methodological weakness.
Systematic review authors have concluded that many of the trials of PD treatments are of poor quality,
have small sample sizes and use a wide range of non-comparable outcomes with different degrees of
clinical importance (e.g. self-reported changes in personality beliefs vs. days in hospital).11,91,92 This variation
makes it difficult to draw firm conclusions about any one treatment, and there is a place for specifying
core outcome measures of agreed importance to all.93
Most of the treatments for PD that are evidenced as effective are of relatively long duration and are
delivered by highly trained personnel, and hence are costly to deliver and are consequently of restricted
availability. The question of whether or not brief interventions work for PD has been investigated recently,94
with insufficient available evidence to provide an answer. The null findings of the PEPS trial suggest that the
intervention may have been too brief to have had an effect, at least as a stand-alone treatment divorced
from good clinical care. This point of view was articulated by participants in the PEPS trial.
Although social problem-solving was addressed as a common need among people with PD, this may
not be the case. Alternatively, this particular aspect of treatment may not have been a priority for all
participants. Hence, brief ‘one-size-fits-all’ treatments appear not to be the way forward, but rather
clinicians should base treatment plans on a thorough case formulation. Assessment and case formulation
would also reveal who might benefit from group sessions and who might be averse to working in groups.
Information from participants tells us that some participants enjoyed the support gained from other group
members, whereas others found it difficult to discuss their own problems or to listen to others discussing
their problems. This is reflected in the differential attendance rates for individual and group components.
However, many interventions for people with PD are group based and it may be that there is a need to
offer some pretherapy training in group-work skills so that people find it easier to engage.95
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
Crudely set in the company of similar trials reporting the same outcome, PEPS is the largest and longest
trial and, to our knowledge, most methodologically rigorous. A synthesis of these trials is presented in
Figure 6. Although the synthesis of all trials does still suggest a modest effect, despite the PEPS data, the
overall result is dominated by small bias-prone studies. In Figure 7 the studies are sorted by time, with a
real trend across time showing that the more recent the study the less the effect of the intervention.
This may be because of improvements in study design and conduct over the past 15 years.
Recently evidence has been accruing from trials that structured clinical management achieves equally good
outcomes as specific treatments for PD.98–101 Commenting upon this, Bateman102 speculated that in the
past general psychiatric treatment, or treatment as usual, may actually have inadvertently been harmful
and specialist treatments may have shown benefit primarily by minimising harm, possibly through
preventing unco-ordinated care. Service users and providers have also highlighted the importance of
co-ordinating and integrating psychological treatments within teams that can provide additional support
for patients at times of crisis.30 In the PEPS trial, treatment was delivered as a stand-alone therapy rather
than being integrated into a co-ordinated package of care.
In the PEPS trial, although there was a higher number of adverse events reported in the treatment arm,
it is also the case that the number of reported events was high in the usual-care arm: 76 adverse events
reported by 39 people (26%) over a period of 72 weeks. One explanation for a higher number of reported
events in the treatment arm of the PEPS trial is that the treatment stopped without any structured
follow-up, thus leaving participants unsupported after a period of treatment. To have one’s support
withdrawn may well be more damaging than to have had little or no support in the first place. As reported
by participants, some individuals may be driven to dramatic and harmful gestures to access services.
DISCUSSION
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Chapter 8 Conclusions
Implications for health care
The conclusion here is that PEPS therapy should not be promoted for people in secondary mental health
services who are diagnosed with PD, at least not in the absence of a structured, comprehensive clinical
care package. Harm is most likely to be caused by leaving people unsupported after the conclusion of brief
interventions rather than by PEPS itself. However, any use of brief problem-solving interventions in practice
should be conducted only with rigorous collection of data on adverse effects, in the context of the need
for better awareness and measurement of adverse events in psychotherapy practice as a whole.
It seems reasonable to say that no specific treatment should be delivered to this group of individuals in the
absence of good clinical care. This is an important and topical message when the Improving Access to
Psychological Therapies initiative is being extended to people with ‘severe mental illness’, which includes
PD.103 Structured clinical management of people with PDs is an important aspect of treatment, it is not an
alternative to specific treatments but rather the bedrock on which these treatments may be offered.
Some participants expressed reservations about group sessions, both in terms of the content being
challenging and also concerning anxieties about being with other people. Others found group work to
be an informative process and the support of others was deemed helpful. A general message is a
greater investment in preparing people for group treatment may be worthwhile to prevent treatment
non-completion.104 The higher costs of group versus individual sessions may make individual preparation
sessions cost-effective (£476 vs. £119, respectively).
Psychoeducation with problem-solving was also reported to have equipped a workforce of mental
health professionals to offer consistently skilled responses to people presenting with PD. Although this
intervention did not achieve the standard for significance, a positive working alliance and a willingness
among many people with PD to master well-defined skills suggests that a promising start was made
to developing general staff competencies and engaging people with PD in services.
Implications for researchers
Defining and reporting adverse effects of psychological therapies
The issue of defining and recording adverse events in trials of complex psychosocial interventions has been
highlighted as of crucial importance. Consideration of potential harms has not been given adequate
attention in clinical trials of psychosocial interventions with people with PDs or participants with other
types of problems.82,105,106 Specification of the nature of possible harms and identification of the type of
person who may be susceptible to harm is important information to collect to establish risk–benefit
balances that ought to be available to clinical services to inform the choice of treatments provided and to
patients to help them make decisions about consenting to psychosocial treatment. Linden107 has offered
definitions of a range of unwanted events and adverse treatment reactions and has constructed a checklist
for recording the existence, severity and treatment-relatedness of these events that may be of value for
systematic observation of harms in clinical trials. Jonsson et al.105 offer suggestions for collecting and
reporting adverse effects in RCTs, including providing a plan for how harms will be detected within the
protocol for ethical review, using structured assessment methods such as checklists or rating scales, active
and regular monitoring, and reporting the absence of harms as well as the occurrence of harms. At the
consent stage it is worth asking participants for permission to access official records that may assist in
the identification of adverse events, including centrally held NHS data via the Health and Social Care
Information Centre.
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Processes for stopping trials of psychological therapies
Consideration should be given in advance to procedures for stopping trials of psychosocial interventions,
should this be necessary. The difficult and traumatic halting of PEPS was made more challenging by the
need for additional, very specific procedures to be implemented. It was important that this was undertaken
both swiftly and safely, and the procedure we followed has already been presented.83 We hope to fully
publish this experience to guide funders, sponsors, participants, trial units and triallists.
Recommendations for research
Methodological research
Measuring adverse events in psychological therapies
There is clearly a place for systematic research into the definition and prevalence of adverse effects of
psychological therapies. We know of some ongoing work in Sheffield [www.shef.ac.uk/scharr/sections/hsr/
mh/mhresearch/adeptproject (accessed 25 April 2016)] and await results of this important initiative.
Procedures for stopping trials of psychosocial interventions
We have discovered that there is not clarity around this issue. We suggest that Delphi work could inform a
working party to draw on collective experience and consideration of specific examples in order to inform
policy and the design and conduct of trials.
Core outcomes
There is a need to define and gain consensus for a core outcome data set for trials such as PEPS. We think a
Core Outcome Measures in Effectiveness Trials initiative (COMET; www.comet-initiative.org), specific to
psychological interventions for people with borderline personality difficulties is indicated, or this area of
evaluative research will continue to be dogged by use of different measures, used with no agreed consistency.
Service delivery analysis
Pathways of care for people with personality disorder
Service research into defining and implementing pathways of care for people with PD is urgently needed.
Given emerging evidence that good clinical care is as effective as ‘active’ treatments,95,98–100 more should
be done to understand the barriers to, and facilitators of, the implementation of good care. Both
qualitative and quantitative investigation is indicated.
Economics
Economic evaluations of interventions for people with personality disorder
Evidence from this study shows that people with PD are heavy users of mental health services and have
poor quality of life in comparison with people with other disorders. Overall, participants in this trial had
annual costs of around £8000 (based on the baseline data) and QALYs were around one-third of those of
people with full health. Evaluations of treatments for people with PD should continue to address both
costs and quality of life.
Evaluations
James Lind initiative
There are several ongoing James Lind initiatives in mental health care. It would seem that there could
be a priority-setting exercise conducted for questions of relevance to the care of people with
borderline-type problems.
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Disaggregation of psychoeducation and problem-solving therapy
Although PEPS therapy as a whole was not effective, there were differences in uptake of the individual
psychoeducation sessions and the group problem-solving sessions. Individual psychoeducation sessions
were well attended, and this component of the intervention may be worth evaluating separately.
However, care should be taken to embed this in good clinical care.
Active comparator
As good-quality clinical care has established effectiveness, future trials ought to be a comparison between
good-quality routine clinical care versus good-quality clinical care plus the experimental intervention.
This would answer the question as to what additional value was conferred by the intervention over and
above that from good-quality routine clinical care. This type of design has not been employed, to date,
in PD treatment trials. This would require specification and monitoring of good-quality clinical care.
In addition, the impact of continuation of care after the end of the experimental treatment could be tested.
Adverse events
We plan to investigate adverse events further by accessing centrally held NHS data on deaths and
hospitalisations for all PEPS trial participants. Because we do not have consent from all participants to do
this, accessing this information without participant consent requires approval from the Health Research
Authority Confidentiality Advisory Group. In light of the trial stoppage for safety reasons, we have a clear
justification for requesting approval.
Other interventional research
This is a grossly under-researched area. There is a place for a broad overview of all evaluative studies in this
area, to produce a map of where randomised research exists and where it does not. The number and
power of studies in this area would then become obvious. In this way, guidance on what systematic
reviews are possible can be created and, where relevant to NHS practice, those interventions in everyday
practice that have not been fairly tested in trials could then be randomised within the context of
routine care.
Final statement
This rigorous trial has established that PEPS therapy is not an effective treatment for improving social
functioning in community adults with PD. This is despite PEPS being based on solid theoretical and
empirical foundations,43,56 on therapy components with demonstrated effectiveness in dealing with a range
of psychological problems31,36,37 and which has been deemed helpful by those who have received it.49
This is not the first psychosocial intervention that has appeared promising – theoretically, empirically
and by favourable participant judgement – but has proved in rigorous trials to be ineffective or even
harmful.108,109 Information from this study indicates that people with PD have poor quality of life and are
heavy users of health and social services. It is important to continue to seek effective management and
treatment for this group of troubled individuals. Good-quality research is the only way to provide evidence
of what is genuinely effective, or ineffective, and is the best way to serve patients, their family and friends,
and our wider society. Such research is expensive, but the costs of not conducting such research may
well be greater.
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Appendix 1 Psychoeducation facilitators’ manual
Reproduced with permission from Banerjee P, D’Silva K, Huband N, Duggan C. Psychoeducation forPeople with Personality Disorder. Unpublished manual. Nottingham, UK: Nottinghamshire Healthcare
NHS Trust; 2009.
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Brief structured interview 
 (given at beginning of the psychoed sessions) 
 
Name: ___________________________  Date: _____________ 
 
 
I want to ask about you and your personality. There are just six short questions. 
 
 
Question 1 
What does the word ‘personality’ mean to you?  
 
 
 
Question 2 
Do you think your personality causes you problems? In what way? 
 
 
 
Question 3 
Do you think your personality causes problems for other people? In what 
way? 
 
 
 
Question 4 
Would you like to change the way you handle problems? 
 
 
 
Question 5 
Some people are diagnosed as having a personality disorder. Do you know 
what a personality disorder is? 
 
 
 
Question 6 
Have you ever been told you might have a personality disorder? 
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All About Problems and Personality 
 
 
What are personality problems? 
 
We all have problems, and especially problems with other people. These problems 
crop up from time to time and we all try to deal with them. 
 
Some people seem to find a way of dealing with each new problem they find. They 
have the knack of getting their problems sorted. Lucky them. 
 
For others, it’s more difficult. They try to sort their problems, but their ‘personality’ 
seems to get in the way. They find themselves doing things much the same way each 
time. Perhaps making the same mistakes again. It is like repeating the same patterns 
of behaviour again and again and their problems don’t get sorted properly. They are 
often unhappy. Those around them are often unhappy as well. If you are one of these 
people, you will want something to change. 
 
 
So what is my ‘personality’ and how does it mess things up? 
 
Personality is just the way you usually think, feel and behave. It’s just how you are.  
 
Your personality may get in the way of getting your problems sorted. You find you 
think, feel and behave much the same way every time. And because of how you think, 
feel and behave, things continue to go wrong. 
  
Why does this happen? 
 
We think some people just haven’t been given the skills to get things sorted. Not really 
their fault. 
 
Maybe nobody gave them the right skills. Maybe they were unable to learn the skills. 
So their personality (their usual way of thinking, feeling and doing) takes over. And it 
doesn’t work too well. So problems don’t get sorted out. And the problems keep 
coming back.  
 
This project is all about learning new skills that can help stop this happening. Breaking 
the cycle. 
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What is personality disorder? 
 
A person is said to have a personality disorder if  their personality causes distress or 
difficulties for themselves or others, and this happens over and over again. 
 
A personality disorder must have the three Ps. It must be: 
 
 
Problematic  It causes distress or difficulties for the person or for 
other people. It can lead to problems with relationships, 
with employment, and with the law. 
 
 
Persistent   This way of thinking, feeling and behaving is long-
standing. The difficulties tend to appear in late childhood 
and teenage years and continue into adult life. 
 
Pervasive  This way of thinking, feeling and behaving occurs in 
many situations. 
 
 
 
What can be done to help? 
 
You have agreed to take part in the “Stop & Think!” treatment. This can help you to 
change some of your ways of thinking, feeling and behaving. But only if that is what 
you want. 
 
These changes can allow a person to have a better quality of life. These changes 
can allow them to function better with other people. At the end of the day, it’s up to 
you.  
 
 
What do I have to do to make this work? 
 
First, you need to be clear about what bits of your thinking, feeling and behaving you 
really want to change. The Stop & Think! worker will help you decide. 
 
In the next session, you’ll look at a list of problems. You’ll tick those problems that 
apply to you. Then you’ll go away and pick the 5 you most want to change. 
 
Once you’ve chosen these, you can go ahead and join the group. The Stop & Think! 
worker will explain what the group work involves. We don’t pretend it’ll be easy – 
changing and learning new things never is. But it might be worth a bit of effort. 
 
It’s all about you learning new skills to help yourself get a better quality of life. 
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Problems Checklist (Client Version) 
 
 
Do you have any of these problems?  
If you do, which of them would you most like to change? 
 
 
 
 
(1) Problems making it hard to want any close relationships 
Finds it hard to trust people - sometimes finds it hard to trust friends  
Often thinks: “that person is out to get me” 
Doesn’t like confiding in others in case they can’t be trusted 
Often notices other people’s casual comments; thinks “they’re having a go at me” 
Finds it hard to forgive people - often bears a grudge 
Gets annoyed if others are critical or make comments 
Quick to be suspicious that a loved-one is not being faithful 
Believes strongly in magic and supernatural forces  
Sees and notices things that most other people don’t see and notice 
Has very few close friends 
Gets uncomfortable with people - worries that they might be a threat 
Experiences things that other people often don’t seem to know about 
Has thoughts that other people don’t seem to have 
Says things that other people regard as strange 
Does things that seem sensible, but which others think rather unusual 
Dresses in a way that others think is odd  
Is suspicious - feels that others are out to get them 
Doesn’t want close relationships and doesn’t like them 
Usually prefers doing things alone 
Doesn’t have much interest in sex 
Finds it hard to enjoy anything  
Has very few close friends 
Isn’t impressed by other people’s praise 
Isn’t bothered by other people’s critical comments  
Sometimes seen by others as rather cold and unemotional 
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(2) Problems making it hard to keep close relationships 
Often has a need to flirt - can be seductive 
Worries a lot about own appearance and whether people notice  
Has a way of showing feelings that people say is very dramatic  
Unhappy if not the one who stands out in the crowd 
Has feelings that often change suddenly and unexpectedly 
Tends to talk dramatically - doesn’t bother with the details 
Easily influenced by people and situations 
Often feels very close to new people after spending very little time with them 
Often skipped school (before age 15) 
Ran away from home overnight more than once (before age 15) 
Often started fights (before age 15) 
Used a weapon more than once (before age 15) 
Was sometimes cruel to animals or was cruel to people (before age 15) 
Sometimes destroyed other people’s property or started fires (before age 15) 
Often lied (before age 15) 
Stole from people (before age 15) 
Finds it hard to hold down a steady job 
Finds it hard to stay out of trouble 
Often gets into fights  
Not good at paying bills or debts 
Often lies or cons people 
Often takes chances - does reckless things  
After breaking the law, feels there was good reason for the crime - is not sorry 
Finds it hard to plan ahead 
Often uses people - takes advantage of them 
Sees self as important - gets annoyed when people don’t respect this 
Has problems that are different from those other people have 
Thinks a lot about being famous, powerful or attractive 
Feels a real need to be treated as a special person 
Needs to be admired - much happier when the centre of attention  
Finds it hard to be concerned about how other people feel 
Often feels jealous of others – or that others are jealous 
All relationships seem to be intense - lots of ups and downs  
Sometimes acts suddenly - doesn’t care that this might be self-damaging 
Can experience sudden mood swings - these can be very powerful 
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Has angry outbursts - things can get smashed, sometimes people get hit 
Often behaves as if suicidal - has episodes of self-harm 
Finds it hard to decide what’s important in life  
Uncertain about self-image - often thinks “Who am I?” 
Finds it hard to control angry outbursts 
Usually feels empty - often feels bored 
When stressed, finds people and surroundings don’t seem real anymore 
Can make frantic efforts to stop someone close from leaving 
When stressed, can feel very paranoid  
Finds it hard to plan ahead  
 
 
(3) Problems making it hard to form close relationships 
Finds it hard to make decisions - needs reassurance and advice from others 
Likes others to make important decisions and take responsibility 
Finds it hard to disagree with someone - scared of losing their support  
Lacks self-confidence - finds it difficult to do things without others helping 
Offers to do unpleasant things for other people - to make sure of their support  
When alone, feels helpless and unable to care for self 
If a close relationship ends, quickly seeks another relationship for care and support 
Worries a lot about being left to manage alone 
Feels inferior to others 
Won’t get involved with people unless sure of being liked 
Avoids mixing with others - scared they will criticise or disapprove  
Very careful and guarded in close relationships  
Worries a lot about being rejected by others  
Doesn’t function well with new people - feels very inadequate 
Avoids new social situations - worries about being embarrassed 
Thinks too much about rules, details and lists  
Finds being a perfectionist makes it very difficult to get things done  
Needs to concentrate on work all the time - enjoys being very productive 
Has definite ideas about right and wrong - feels things must always be correct 
Unable to throw away objects that others might see as useless or worthless  
Finds it hard to work with others, especially if they want to do things a different way  
Doesn’t like spending money unnecessarily - or wasting it on gifts 
Doesn’t like change - sometimes seen as inflexible and stubborn 
Sometimes does things slowly or badly on purpose 
Feels other people don’t understand and don’t appreciate 
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Gets out of doing things by pretending to have forgotten they need doing 
Doesn’t like people in authority - often criticises them 
Often grumpy and argumentative 
Gets annoyed and envious when others seem to get a better deal out of life 
Complains about having bad luck and often blames others for this – then changes and 
blames self 
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Problems Checklist (Clinician Version) 
 
 
 
 
Do you have any of these problems? 
If you do, which of them would you most like to change? 
 
 
 
Paranoid problems - make it hard to want any close relationships 
Finds it hard to trust people - sometimes finds it hard to trust friends  
Often thinks: “that person is out to get me” 
Doesn’t like confiding in others in case they can’t be trusted 
Often notices other people’s casual comments; thinks “they’re having a go at me” 
Finds it hard to forgive people - often bears a grudge 
Gets annoyed if others are critical or make comments 
Quick to be suspicious that a loved-one is not being faithful 
 
 
Schizotypal problems - make it hard to want any close relationships 
 Believes strongly in magic and supernatural forces  
 Sees and notices things that most other people don’t see and notice 
 Has very few close friends 
 Gets uncomfortable with people - worries that they might be a threat 
 Experiences things that other people often don’t seem to know about 
 Has thoughts that other people don’t seem to have 
 Says things that other people regard as strange 
 Does things that seem sensible, but which others think rather unusual 
 Dresses in a way that others think is odd  
 Is suspicious - feels that others are out to get them 
Schizoid problems - make it hard to want any close relationships 
 Doesn’t want close relationships and doesn’t like them 
 Usually prefers doing things alone 
 Doesn’t have much interest in sex 
 Finds it hard to enjoy anything  
 Has very few close friends 
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 Isn’t impressed by other people’s praise 
 Isn’t bothered by other people’s critical comments  
 Sometimes seen by others as rather cold and unemotional 
 
 
Histrionic problems  - make it hard to keep close relationships 
Often has a need to flirt - can be seductive 
Worries a lot about own appearance and whether people notice  
Has a way of showing feelings that people say is very dramatic  
Unhappy if not the one who stands out in the crowd 
Has feelings that often change suddenly and unexpectedly 
Tends to talk dramatically - doesn’t bother with the details 
Easily influenced by people and situations 
Often feels very close to new people after spending very little time with them 
 
 
Antisocial problems (before age 15) - make it hard to keep close relationships 
 Often skipped school 
 Ran away from home overnight more than once 
 Often started fights 
 Used a weapon more than once 
 Was sometimes cruel to animals or was cruel to people 
 Sometimes destroyed other people’s property or started fires 
 Often lied 
 Stole from people  
 
 
Antisocial problems (since age 15) - make it hard to keep close relationships 
 Finds it hard to hold down a steady job 
 Finds it hard to stay out of trouble 
 Often gets into fights  
 Not good at paying bills or debts 
 Often lies or cons people 
 Often takes chances - does reckless things  
 After breaking the law, feels there was good reason for the crime - is not sorry 
 Finds it hard to plan ahead 
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Narcissistic problems -  make it hard to keep close relationships 
Often uses people - takes advantage of them 
Sees self as important - gets annoyed when people don’t respect this 
Has problems that are different from those other people have 
Thinks a lot about being famous, powerful or attractive 
Feels a real need to be treated as a special person 
Needs to be admired - much happier when the centre of attention  
Finds it hard to be concerned about how other people feel 
Often feels jealous of others – or that others are jealous 
 
Borderline problems - make it hard to keep close relationships 
 All relationships seem to be intense - lots of ups and downs  
 Sometimes acts suddenly - doesn’t care that this might be self-damaging 
 Can experience sudden mood swings - these can be very powerful 
 Has angry outbursts - things can get smashed, sometimes people get hit 
 Often behaves as if suicidal - has episodes of self-harm 
 Finds it hard to decide what’s important in life  
 Uncertain about self-image - often thinks “Who am I?” 
 Finds it hard to control angry outbursts 
 Usually feels empty - often feels bored 
 When stressed, finds people and surroundings don’t seem real anymore 
 Can make frantic efforts to stop someone close from leaving 
 When stressed, can feel very paranoid  
 Finds it hard to plan ahead  
 
Dependent problems -  make it hard to form close relationships 
 Finds it hard to make decisions - needs reassurance and advice from others 
 Likes others to make important decisions and take responsibility 
 Finds it hard to disagree with someone - scared of losing their support  
 Lacks self-confidence - finds it difficult to do things without others helping 
 Offers to do unpleasant things for other people - to make sure of their support  
 When alone, feels helpless and unable to care for self 
 If a close relationship ends, quickly seeks another relationship for care and support 
 Worries a lot about being left to manage alone 
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Avoidant problems -  make it hard to form close relationships 
Feels inferior to others 
Won’t get involved with people unless sure of being liked 
Avoids mixing with others - scared they will criticise or disapprove  
Very careful and guarded in close relationships  
Worries a lot about being rejected by others  
Doesn’t function well with new people - feels very inadequate 
Avoids new social situations - worries about being embarrassed 
 
Obsessive-compulsive problems - make it hard to form close relationships 
Thinks too much about rules, details and lists  
Finds being a perfectionist makes it very difficult to get things done  
Needs to concentrate on work all the time - enjoys being very productive 
Has definite ideas about right and wrong - feels things must always be correct 
Unable to throw away objects that others might see as useless or worthless  
Finds it hard to work with others, especially if they want to do things a different way  
Doesn’t like spending money unnecessarily - or wasting it on gifts 
Doesn’t like change - sometimes seen as inflexible and stubborn 
 
 
Passive-aggressive problems - make it hard to form close relationships 
 Sometimes does things slowly or badly on purpose 
 Feels other people don’t understand and don’t appreciate 
 Gets out of doing things by pretending to have forgotten they need doing 
 Doesn’t like people in authority - often criticises them 
 Often grumpy and argumentative 
 Gets annoyed and envious when others seem to get a better deal out of life 
 Complains about having bad luck and often blames others for this – then changes and 
blames self 
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Psychoeducation - end of course summary 
 
 
Name Date of Birth ID no 
Start date      /      /         end      /     /        Course competed   Yes/No 
Therapist. signature 
  
Diagnosis ? IPDE score 
? agreed diagnosis 
Clients view of diagnosis  (include a statement of whether the client agrees with the diagnosis and if they 
do not agree list which aspects they do not agree with and why) 
 
Aims of Psychoeducation 
 
 
 
 
 
 
 
Overview of psychoeducation (provide a brief summary of the psychoeducation sessions; you might like 
to relate it to the aims above.) 
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Name Date of Birth ID no 
Summary of problems (expand on the list of agreed problems taking into account the discussion you have 
had around the problems using examples if necessary to show the effect that the problems have on the clients 
lifestyle and interpersonal functioning.) 
 
Problems the client has identified that they want to change 
 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
Other problems the client would like to change but not included as treatment goals 
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135

Appendix 2 Psychoeducation participant booklet
Reproduced with permission from Banerjee P, D’Silva K, Huband N, Duggan C. Psychoeducation forPeople with Personality Disorder. Unpublished manual. Nottingham, UK: Nottinghamshire Healthcare
NHS Trust; 2009.
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Information processing
limitations and biases
Cognitive deficits
e.g., poor verbal ability
Temperament
e.g., impulsivity 
Poor social 
problem solving
Dysfunction
e.g., interpersonal
difficulties; poor
coping
Affect
e.g., anxiety, 
distress, anger,
depression
Substance use
Self-schema
Failure, poor self-control 
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 Client Post-Intervention Interview Schedule for Stop & Think! 
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 Stop & Think! is a group programme for people who have problems controlling their emotions or 
behaviour, to the extent that this makes them unhappy or causes problems with other people in their 
lives. The problems of people who are eligible for Stop & Think! relate to personality difficulties. That 
means that they have traits that sometimes make life difficult. Traits that can cause problems include 
impulsivity, irritability, aggressiveness, and poor self-worth.  Stop & Think! aims to help people cope 
with these difficulties and solve life’s problems more effectively. 
 
Stop & Think! teaches people a strategy for solving problems.  Stop & Think! involves answering six 
key questions: 
 
Feeling bad?   
Some people have difficulty recognising unpleasant feelings such as anger, depression, and boredom.  
Either they react without thinking to the unpleasant feelings or they just put up with them. What they 
don’t do is try to identify what the problem is and work out an effective action plan. Stop & Think! 
helps you recognise unpleasant feelings and start problem solving. 
 
What’s my problem? 
You can’t solve a problem unless you can say what it is.  Some people have difficulty defining their 
problems clearly and breaking down big problems into smaller, manageable ones.  Stop & Think! 
teaches you to define your problems clearly and break big problems into smaller chunks. 
 
What’s my goal? 
To solve a problem, you need to know what you’re aiming for, otherwise you’ll never know if you’ve 
arrived!  Stop & Think! teaches you to set clear, achievable goals. 
 
What are my options?  
There are usually a number of ways of achieving a goal.  Be creative and think of a lot of options. This 
gives you more than one way to solve a problem.  Creativity is good, but you also need common sense.  
Stop & Think! teaches you to be creative in thinking of possible solutions to a problem.  Then you learn 
to think of what would likely happen if you took action, and you weed out the bad ideas.   
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What’s my plan? 
The good ideas that you are left with are then put into order as an action plan.  This action plan isn’t 
going to be effective if it stays on paper, so you need to carry out this plan. 
 
How am I doing? 
Action plans need to be checked to see if they are working.  Have you achieved your goal?  If 
so, well done!  If not, what got in the way? What can you do next? 
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 Please look at the statements below and tick the reply that comes closest to how you have been recently.   
 
 
I complete my tasks at work and home satisfactorily 
      Most of the time    
      Quite often    
      Sometimes    
      Not at all    
 
I find my tasks at work and at home very stressful 
      Most of the time    
      Quite often    
      Sometimes    
      Not at all    
 
I have no money problems 
      No problems at all   
      Slight worries only   
      Definite problems    
      Very severe problems   
 
I have difficulties in getting and keeping close relationships 
      Severe difficulties    
      Some problems    
      Occasional problems   
      No problems at all   
 
I have problems in my sex life 
      Severe problems    
      Moderate problems   
      Occasional problems   
      No problems at all   
 
I get on well with my family and other relatives 
      Yes, definitely    
      Yes, usually    
      No, some problems   
      No, severe problems   
 
I feel lonely and isolated from other people 
      Almost all the time   
      Much of the time    
      Not usually    
      Not at all    
 
I enjoy my spare time 
      Very much    
      Sometimes    
      Not often    
      Not at all    
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 Scoring: 
 
I complete my tasks at work and home satisfactorily 
      Most of the time   0 
      Quite often   1 
      Sometimes   2 
      Not at all   3 
 
I find my tasks at work and at home very stressful 
      Most of the time   3 
      Quite often   2 
      Sometimes   1 
      Not at all   0 
 
I have no money problems 
      No problems at all  0 
      Slight worries only  1 
      Definite problems   2 
      Very severe problems  3 
 
I have difficulties in getting and keeping close relationships 
      Severe difficulties   3 
      Some problems   2 
      Occasional problems  1 
      No problems at all  0 
 
I have problems in my sex life 
      Severe problems   3 
      Moderate problems  2 
      Occasional problems  1 
      No problems at all  0 
 
I get on well with my family and other relatives 
      Yes, definitely   0 
      Yes, usually   1 
      No, some problems  2 
      No, severe problems  3 
 
I feel lonely and isolated from other people 
      Almost all the time  3 
      Much of the time   2 
      Not usually   1 
      Not at all   0 
 
I enjoy my spare time 
      Very much   0 
      Sometimes   1 
      Not often   2 
      Not at all   3 
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 Fe
el
in
g 
ba
d?
 
An
 u
nd
er
-d
ev
el
op
ed
 re
sp
on
se
 s
ho
ws
 a
 
la
ck
 
o
f a
w
a
re
n
e
ss
 o
f e
m
o
tio
ns
 (e
.g.
, ‘I
 
do
n'
t k
n
o
w
’). 
Th
e
re
 is
 a
n 
in
ab
ilit
y 
to
 
n
a
m
e
 (e
.g.
, ‘I
 ju
st 
fee
l b
ad
’) a
nd
 ow
n 
e
m
o
tio
ns
 (e
.g.
, ‘I
t’s
 hi
m
 
th
at
 m
a
ke
s 
m
e
 
fe
e
l li
ke
 th
is’
). A
 lim
ite
d 
ra
ng
e 
of
 
e
m
o
tio
ns
 is
 e
xp
re
ss
ed
. E
m
o
tio
ns
 a
re
 
n
o
t l
in
ke
d 
to
 p
hy
si
ca
l s
e
n
sa
tio
ns
 o
r 
co
gn
itiv
e 
ch
an
ge
s.
 T
he
 fo
cu
s 
is
 
o
n
 
be
ha
vio
ur
s 
ra
th
er
 th
an
 e
m
o
tio
ns
 o
r 
fe
e
lin
gs
, a
nd
 fe
e
lin
gs
 a
re
 d
es
cr
ib
ed
 a
s 
be
ha
vio
ur
s 
(e.
g.,
 ‘I 
fe
lt 
lik
e
 p
un
ch
in
g 
so
m
e
o
n
e
’). 
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Fe
el
in
g 
ba
d?
 
A 
we
ll-
de
ve
lo
pe
d 
re
sp
on
se
 c
le
ar
ly 
id
en
tif
ie
s 
an
d 
ow
n
s 
di
ffi
cu
lt 
em
ot
io
ns
. 
Th
is 
is 
sig
nif
ie
d 
by
 
st
at
em
en
ts
 o
f ‘
I f
ee
l 
…
…
’.
 
Em
ot
io
ns
 (e
.g.
, a
ng
ry,
 
sa
d,
 
an
xio
us
) a
re 
cle
arl
y i
de
nt
ifie
d 
an
d 
ar
e 
lin
ke
d 
wi
th
 p
hy
sic
al
 s
en
sa
tio
ns
 (e
.g.
, 
te
ns
e,
 h
ea
rt 
ra
cin
g,
 fe
el
in
g 
a 
lum
p 
in
 
st
om
ac
h) 
an
d c
og
nit
ive
 ch
an
ge
s (
e.g
., 
m
in
d 
ra
cin
g,
 fo
cu
s 
on
ly 
on
 o
ne
 th
in
g,
 
co
nf
u
sio
n).
 Th
er
e 
is 
re
co
gn
itio
n 
th
at
 
th
es
e 
em
ot
io
ns
 a
nd
 fe
el
in
gs
 a
re
 lin
ke
d 
to
 
th
e 
pr
ob
le
m
.
 
Th
er
e 
is 
re
co
gn
itio
n 
th
at
 
‘fe
el
in
g 
ba
d’ 
is 
a 
cu
e 
to
 in
itia
te
 p
ro
ble
m
 
so
lvi
ng
. 
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 W
ha
t's
 m
y 
pr
ob
le
m
? 
 An
 u
nd
er
-d
ev
el
op
ed
 re
sp
on
se
 is
 a
 v
ag
ue
, 
u
n
fo
cu
se
d 
or
 g
lob
al 
pr
ob
lem
 
(e.
g.,
 ‘M
y 
re
la
tio
ns
hi
ps
 a
re
 te
rri
bl
e’
); o
r a
 lis
t o
f 
pr
ob
le
m
s;
 o
r a
 p
ro
bl
em
 
th
at
 is
 h
ist
or
ica
l, 
al
th
ou
gh
 e
xp
re
ss
ing
 cu
rre
nt
 d
iffi
cu
lt 
em
ot
io
ns
 re
la
tin
g 
to
 a
 p
as
t p
ro
ble
m
 
is 
ac
ce
pt
ab
le
. R
es
po
ns
ib
ilit
y f
or
 th
e 
pr
ob
le
m
 
is 
pl
ac
ed
 e
lse
wh
er
e 
(e.
g.,
 ‘T
he
y d
on
’t 
tre
at
 m
e 
fa
irl
y’)
. T
he
 p
ro
bl
em
 
is 
no
t r
el
at
ed
 to
 th
e 
em
ot
io
ns
 id
en
tif
ie
d.
 T
he
 p
ro
bl
em
 
is 
ba
se
d 
on
 
as
su
m
pt
io
ns
 (e
.g.
, ‘I
 am
 
sin
gle
d 
ou
t f
or
 
u
n
fa
ir 
tre
at
m
en
t’).
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W
ha
t's
 m
y 
pr
ob
le
m
? 
A 
we
ll-
de
ve
lo
pe
d 
re
sp
on
se
 is
 a
 d
es
cr
ip
tio
n 
of
 
a 
sp
ec
ific
 
cu
rr
en
t o
r a
nt
ici
pa
te
d 
pr
ob
le
m
 
th
at
 re
la
te
s 
to
 fe
el
in
g 
ba
d.
 T
he
 d
es
cr
ip
tio
n 
is 
cle
ar
 a
nd
 c
on
cis
e 
w
hi
le
 id
en
tif
yin
g 
th
e 
cr
ux
 o
f a
 p
ro
bl
em
.
 
It 
do
es
 n
ot
 fo
cu
s 
on
 th
e 
su
pe
rfi
cia
l a
sp
ec
ts
 o
f a
 p
ro
bl
em
,
 
bu
t r
at
he
r 
th
e 
fo
cu
s 
is 
on
 p
ro
bl
em
at
ic 
iss
ue
s 
th
at
 a
re
 
pa
rt 
of
 
a 
pa
tte
rn
 fo
r 
th
e 
in
di
vid
ua
l (e
.g.
, 
ra
th
er
 th
an
 fo
cu
s 
on
 a
 m
in
or
 a
lte
rc
at
io
n,
 
th
e 
fo
cu
s 
m
igh
t b
e 
up
on
 a
 p
at
te
rn
 o
f a
ng
ry
 
re
sp
on
di
ng
 w
he
n 
th
wa
rte
d).
   
W
ha
t d
o 
I w
an
t?
 
 An
 u
nd
er
-d
ev
el
op
ed
 re
sp
on
se
 is
 u
nc
le
ar
 
(e.
g.,
 ‘I 
wa
nt
 to
 b
e 
be
tte
r’),
 un
sp
ec
ific
 
(e.
g.,
 ‘I 
w
an
t t
o 
be
 h
ap
py
’) a
nd
 un
rea
list
ic 
(e.
g.,
 ‘I 
w
an
t t
o 
st
op
 fe
el
in
g 
an
gr
y’)
.
 
Th
e 
fo
cu
s 
is 
on
 
w
ha
t o
th
er
 p
eo
pl
e 
sh
ou
ld
 d
o 
ra
th
er
 th
an
 
w
ha
t t
he
 p
er
so
n 
hi
m
/h
er
se
lf 
sh
ou
ld
 d
o.
 T
he
 
go
al 
is 
no
t r
ela
te
d 
to
 th
e 
pr
ob
lem
 
ex
pr
es
se
d 
he
nc
e 
it 
wi
ll n
ot
 s
ol
ve
 th
e 
pr
ob
le
m
 
or
 
am
el
io
ra
te
 u
np
le
as
an
t f
ee
lin
gs
.
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W
ha
t d
o 
I w
an
t?
 
A 
we
ll-
de
ve
lo
pe
d 
re
sp
on
se
 is
 a
n 
im
po
rta
nt
, s
pe
cif
ic 
an
d 
re
al
ist
ic 
go
al 
(e.
g.,
 
‘I 
wa
nt
 to
 le
ar
n 
wa
ys
 
to
 c
on
tro
l m
y a
ng
er
 
be
tte
r’).
 Th
e g
oa
l s
ho
uld
 fo
cu
s 
on
 
ch
an
gin
g 
on
e’s
 o
wn
 b
eh
av
iou
r a
nd
 n
ot
 o
n 
th
e 
ex
pe
ct
at
io
n 
th
at
 o
th
er
s 
wi
ll c
ha
ng
e.
 
W
he
n 
ac
hi
ev
ed
, t
he
 g
oa
l s
ho
uld
 
am
el
io
ra
te
 th
e 
id
en
tif
ie
d 
pr
ob
le
m
 
an
d 
he
nc
e 
re
du
ce
 th
e 
fre
qu
en
cy
 
or
 in
te
ns
ity
 
of
 
u
n
pl
ea
sa
nt
 fe
el
in
gs
.  
   
W
ha
t a
re
 m
y 
o
pt
io
ns
? 
An
 u
nd
er
-d
ev
el
op
ed
 re
sp
on
se
 s
ho
ws
 fe
w
 
op
tio
ns
 o
r o
pt
io
ns
 th
at
 a
re
 a
ll v
ar
ia
tio
ns
 o
f 
th
e 
sa
m
e 
th
in
g.
 T
he
 o
pt
io
ns
 m
ay
 
be
 a
 
re
he
ar
se
d 
se
t, 
wi
th
 n
o 
re
al
 th
ou
gh
t g
ive
n 
to
 
th
e 
sp
ec
ific
 
pr
ob
le
m
 
u
n
de
r d
isc
us
sio
n 
(e.
g.,
 
'S
pe
ak
 
to
 s
ta
ff’
). T
he
 o
pt
io
ns
 a
re
 v
ag
ue
 (e
.g.
, 
‘R
el
ax
’). 
Th
er
e 
is 
a 
pr
ed
om
in
an
ce
 o
f 
u
n
re
as
on
ab
le
 o
pt
io
ns
. T
he
 o
pt
io
ns
 d
o 
no
t 
re
la
te
 to
 th
e 
ex
pr
es
se
d 
pr
ob
le
m
.
 
Th
e 
ba
la
nc
e 
of
 
ad
va
nt
ag
es
 a
nd
 d
isa
dv
an
ta
ge
s i
s 
n
ot
 a
dd
re
ss
ed
 a
nd
 th
e 
ef
fe
ct
s 
on
 o
th
er
 
pe
op
le
 a
re
 n
ot
 a
ck
n
ow
le
dg
ed
. 
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W
ha
t a
re
 m
y 
o
pt
io
ns
? 
A 
we
ll-
de
ve
lo
pe
d 
re
sp
on
se
 s
ho
ws
 a
 
di
ve
rs
e 
ra
ng
e 
of
 
op
tio
ns
. T
he
 lis
t c
an
 
in
clu
de
 o
pt
io
ns
 th
at
 m
ay
 
n
ot
 b
e 
ad
vis
ab
le
 
to
 a
ct
 u
po
n 
(e.
g.,
 se
lf-h
ar
m
,
 
vio
le
nc
e 
to
 
ot
he
rs
), b
ut 
m
os
t w
ill 
be
 p
ot
en
tia
lly
 
u
se
fu
l 
op
tio
ns
. T
he
 o
pt
io
ns
 w
ill 
re
la
te
 to
 th
e 
ex
pr
es
se
d 
pr
ob
le
m
.
 
Th
e 
m
ajo
r 
ad
va
nt
ag
es
 a
nd
 d
isa
dv
an
ta
ge
s t
o 
se
lf 
an
d 
ot
he
rs
 o
f e
ac
h 
op
tio
n 
ar
e 
id
en
tif
ie
d.
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 W
ha
t i
s 
m
y 
pl
an
? 
 An
 u
nd
er
-d
ev
el
op
ed
 a
ct
io
n 
pl
an
 is
 a
n 
u
n
co
or
di
na
te
d 
lis
t o
f a
ct
io
ns
 th
at
 h
av
e 
no
 
cle
ar
 p
ro
gr
es
sio
n.
 T
he
 p
la
n 
is 
a 
re
pe
at
 o
f t
he
 
lis
t o
f o
pt
io
ns
 g
en
er
at
ed
. T
he
 it
em
s 
on
 th
e 
pl
an
 a
re
 v
ag
ue
 (e
.g.
, ‘I
 w
ill i
mp
ro
ve
 m
y s
el
f 
co
nf
id
en
ce
’) a
nd
 ou
tco
me
s 
ar
e 
no
t 
m
ea
su
ra
bl
e.
 T
he
 p
la
n 
do
es
 n
ot
 in
clu
de
 
im
m
ed
ia
te
ly 
ac
tio
na
bl
e 
co
pi
ng
 st
ra
te
gie
s o
r 
th
e 
pl
an
 fo
cu
se
s 
on
ly 
on
 im
m
ed
ia
te
 c
op
in
g 
st
ra
te
gie
s.
 T
he
re
 is
 n
o 
re
fe
re
nc
e 
to
 th
e 
re
so
ur
ce
s 
ne
ed
ed
 fo
r s
up
po
rti
ng
 th
e 
pla
n.
 
Th
e 
pl
an
 d
oe
s 
no
t r
el
at
e 
to
 th
e 
ex
pr
es
se
d 
pr
ob
le
m
.
 
Th
e 
ac
tio
ns
 a
re
 a
nt
iso
cia
l o
r 
da
m
ag
ing
.  
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W
ha
t i
s 
m
y 
pl
an
? 
 A 
we
ll-
de
ve
lo
pe
d 
ac
tio
n 
pl
an
 fo
cu
se
s 
up
on
 
a 
sm
al
l li
st
 
of
 
th
em
ed
 a
ct
io
ns
 (e
.g.
, 
pr
ev
en
tio
n,
 c
op
in
g,
 n
eg
ot
iat
ion
). I
n e
ac
h 
th
em
e,
 a
 s
m
al
l n
um
be
r o
f a
ct
io
ns
 s
ho
ul
d 
be
 lis
te
d.
 T
he
se
 s
ho
ul
d 
be
 S
M
AR
T,
 
i.e
., 
sp
ec
ific
,
 
m
ea
su
ra
bl
e,
 a
ch
ie
va
bl
e,
 re
al
ist
ic,
 
an
d 
tim
e-
lim
ite
d.
 T
he
re
 s
ho
ul
d 
be
 a
ct
io
ns
 
w
ith
 im
m
ed
ia
te
, s
ho
rt-
te
rm
,
 
an
d 
lo
ng
er
-
te
rm
 
ou
tc
om
es
.
 
An
y s
u
pp
or
t n
ee
de
d 
to
 
en
ac
t t
he
 p
la
n 
is 
sp
ec
ifie
d.
 S
om
e 
pl
an
s 
sh
ou
ld
 b
e 
ch
al
le
ng
ing
 a
nd
 a
im
 
to
 a
dd
re
ss
 
th
e 
pr
ob
le
m
’s
 c
au
se
s.
 T
he
 a
ct
io
n 
pl
an
 
re
la
te
s 
to
 th
e 
ex
pr
es
se
d 
pr
ob
le
m
.
 
Th
er
e 
ar
e 
no
 a
nt
iso
cia
l o
r d
am
ag
ing
 a
cti
on
s.
 
 
Ho
w
 
am
 I 
do
in
g?
 
An
 u
nd
er
-d
ev
el
op
ed
 a
pp
ra
isa
l is
 
ru
sh
ed
, 
su
pe
rfi
cia
l, 
an
d 
un
cle
ar
. T
he
 p
la
n 
ha
s 
no
t 
be
en
 ta
ck
le
d 
an
d 
no
 g
oo
d 
re
as
on
s a
re
 g
ive
n 
fo
r 
in
ac
tio
n.
 A
lte
rn
at
ive
ly,
 
th
er
e 
is 
cla
im
 
to
 a
n 
im
m
ed
ia
te
 a
nd
 c
om
pl
et
e 
su
cc
es
s 
(e.
g.,
 ‘T
he
 
fir
st
 s
te
p 
so
lve
d 
al
l m
y p
ro
bl
em
s’
). 
Su
cc
es
se
s 
m
ay
 
ha
ve
 b
ee
n 
ac
hi
ev
ed
 b
ut
 a
re
 
n
ot
 re
co
gn
ise
d.
 F
ail
ur
es
 a
re
 vi
ew
ed
 a
s a
 
sh
or
tc
om
in
g 
of
 
th
e 
pl
an
 a
nd
 th
er
e 
is 
no
 
co
m
m
itm
en
t t
o 
pe
rs
ist
 w
ith
 th
e 
pl
an
, 
ex
am
in
e 
th
e 
re
as
on
s 
fo
r 
la
ck
 
of
 
su
cc
es
s,
 o
r 
fin
d 
al
te
rn
at
ive
 s
tra
te
gie
s. 
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Ho
w
 
am
 I 
do
in
g?
 
 A 
we
ll-
de
ve
lo
pe
d 
ap
pr
ai
sa
l is
 
ho
ne
st
. I
t 
re
po
rts
 o
n 
al
l a
sp
ec
ts
 o
f t
he
 p
la
n 
an
d 
in
di
ca
te
s 
wh
ich
 a
ct
io
ns
 h
av
e 
be
en
 c
ar
rie
d 
ou
t a
nd
 w
hi
ch
 h
av
e 
no
t. 
Th
e 
su
cc
es
s 
or
 
ot
he
rw
ise
 o
f e
ac
h 
ac
tio
n 
is 
as
se
ss
ed
 a
nd
 
th
e 
ob
st
ac
le
s 
to
 im
pl
em
en
ta
tio
n 
of
 
th
e 
pl
an
 a
re
 id
en
tif
ie
d.
 T
he
 re
as
on
s 
fo
r 
la
ck
 
of
 
su
cc
es
s 
w
ith
 a
sp
ec
ts
 
of
 
th
e 
pl
an
 a
re
 
id
en
tif
ie
d 
an
d 
al
te
rn
at
ive
 s
tra
te
gie
s a
re
 
co
n
sid
er
ed
. S
uc
ce
ss
 is
 a
ck
n
ow
le
dg
ed
 in
 
te
rm
s 
of
 in
cr
em
en
ta
l a
ch
ie
ve
m
en
t t
ow
ar
ds
 
th
e 
id
en
tif
ie
d 
go
al.
 A
 cl
ea
r i
nt
en
t is
 
ex
pr
es
se
d 
to
 c
on
tin
ue
d 
wo
rk
 
on
 th
e 
pl
an
.  
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 Client Post-Intervention Interview Schedule for Stop & Think! 
 
Participant Identification .............................    Date ............................... 
 
The purpose of this interview is to gather your views on the Stop & Think! group sessions.  The 
Stop & Think! sessions were those where you learned a way of tackling and solving problems.  
 
1. First, I am interested in hearing your general opinions of the Stop & Think! sessions. 
So, before I ask you any questions that might get you thinking about specific things, 
would you please give me your general opinions of the Stop & Think! sessions?  
 
 
 
2. Please tell me the main things you learned in the Stop & Think! sessions: 
 
 
 
3. Besides gaining knowledge, I am interested in whether you got anything else out of the 
Stop & Think! sessions. Did you benefit in any way? 
 
 
 
3a. If you did benefit, could you please try to tell me how Stop & Think! had this good 
effect?  
 
 
 
4. Do you think Stop & Think! had any bad effects? 
 
 
 
4a. If so, could you please try to tell me how Stop & Think! had a bad effect?  
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5. May I ask you to rate how useful you found the Stop & Think! sessions overall? 
10 Very useful indeed  
9 
8 
7 
6 
5 
4 
3 
2 
1 
0  Not at all useful  
 
 
 
 
 
6. Do you have any other comments? 
 
 
 
 
 
 
 
Thank you for your help. 
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Stop & Think!
Bad feelings?
What’s my problem?
What do I want?
 
 
What are my options?
Good outcomes Bad outcomes  
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 What’s my plan?
Action                                                                           Date               Helper
How am I doing?
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  Stop & Think! 
 
************************
 
 
Feeling bad? 
 
 
What’s my problem? 
 
 
 What do I want? 
 
 
 What are my options? 
 
 
What’s my plan? 
 
 
How am I doing? 
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 Appendix 8. 
 
 
 
 
 
  
 
Thoughts 
Emotional 
feelings 
Physical 
feelings 
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Appendix 4 Competence rating scale:
International Personality Disorder Examination
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
205
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
206
Appendix 5 Competence rating scale:
psychoeducation
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Appendix 6 Competence rating scale:
problem-solving therapy
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Appendix 7 Psychoeducation therapist fidelity
rating
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Appendix 8 Record check data collection forms
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Appendix 9 Unblinding script
Final version 2.0: 3 December 2010
At the start of the study, the following information should be given:
The study involves looking at two different treatments for personality disorder. To find out which
treatment is best we are asking you to complete some questionnaires and interviews with me. Both you
and your mental health team will know what treatment you are receiving, but to make sure the results
are fair, it is important that I don’t know which treatment group you are in until you have finished
taking part in the research. I will remind you not to tell me this information each time I contact you
about the research.
Each time the research assistant assesses the participant, a reminder about the need for blinding should
be issued.
There is a particular risk of unblinding at the administration of the CSRI at the second follow-up. A specific
instruction is recommended at this point:
I am going to ask you about the services you have received in the past 6 months. Remember, it is
important that I don’t know which treatment group you were in. So, you should not tell me whether
or not you received PEPS sessions (i.e. psychoeducation and Stop & Think sessions). Just don’t mention
these and tell me only about your use of other services.
DOI: 10.3310/hta20520 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 52
© Queen’s Printer and Controller of HMSO 2016. This work was produced by McMurran et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
225

Appendix 10 Summary of trial amendments
Stage of the trial
Amendment
reference
Protocol version
and date Summary of changes
Amendments
implemented before
recruitment started
Substantial
amendment 1
(15 June 2010)
Version 2.0, dated
15 June 2010
The protocol was amended to include revised
eligibility criteria, clarification of arrangements for
the trial DMEC, a change to the follow-up
schedule and addition of the service use record
check as a secondary outcome measure
Amendments
implemented during
the recruitment phase
Substantial
amendment 2
(17 August 2010)
Version 3.0, dated
17 August 2010
The planned requirement for a standardised form
of treatment as usual was removed from
the protocol
Substantial
amendment 3
(4 October 2010)
Version 4.0, dated
4 October 2010
The protocol was amended to include additional
competence checks for the IPDE and delivery of
psychoeducation, and to clarify the publication
policy. In addition, the amendment included a
procedure for providing feedback of the
participants’ IPDE results at final follow-up and to
allow provision of a summary of the trial results
after the final report
Substantial
amendment 4
(1 April 2011)
Version 5.0, dated
1 April 2011
In response to advice from the TSC and DMEC
the definition of recordable adverse events was
expanded and simplified to ensure that all
potentially relevant adverse events were recorded.
The reporting procedure was also clarified
Substantial
amendment 5
(17 August 2011)
N/A The decision was taken to allow problem-solving
therapy to be offered in mixed-sex groups. The
participant information sheet was updated to
remove the reference to single-sex groups
Substantial
amendment 6
(02 February 2012)
N/A The interview schedule at final follow-up for
participants in the treatment as usual arm was
updated to remove references to standardised
treatment as usual as per the changes
implemented in Substantial amendment 2
Substantial
amendment 7
(5 July 2012)
N/A Following the decision to provide IPDE feedback to
participants who requested this, at the end of their
involvement in the trial the study team developed a
procedure and supporting documents to ensure
that this feedback was provided sensitively and
within an appropriate context to avoid causing
distress or worry to participants. The procedure,
letters and report template for the provision of
IPDE results were submitted for review
Substantial
amendment 8
(26 November 2012)
N/A Retrospective approval was sought from the
Research Ethics Committee for implementation of
the trial changes as an urgent safety measure,
following the decision to stop recruitment and
delivery of the trial intervention
Amendments
implemented during
the follow-up phase
Substantial
amendment 9
(3 April 2013)
Version 6.0, dated
3 April 2013
This amendment included proposals for a number
of measures to improve follow-up completion,
including the introduction of payments to
participants, the facility to post the SFQ to
participants for completion and submission of a
participant newsletter
N/A, not applicable.
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Appendix 11 Schedule of Data Monitoring and
Ethics Committee and Trial Steering Committee
meetings
DMEC meetings TSC meetings
2010
19 October 2010 17 March 2010
2011
15 February 2011 23 March 2011
22 June 2011
16 September 2011
2012
28 February 2012 13 January 2012
15 October 2012 16 March 2012
15 August 2012
1 November 2012
Plus subsequent joint TSC/TMG meetings regarding early stopping
2013
9 January 2013
20 March 2013
6 December 2013
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Appendix 12 Unit costs used in economic
evaluation
Service Unit cost Source
GP £4 per minute of patient contact Curtis (2013)110
Psychiatrist £362 per face-to-face contact
Other doctor £135 per 30 minutes of patient contact
Psychologist £134 per hour of client contact
Drug and alcohol advisor £54 per clinic consultation
Other counsellor/therapist £63 per hour of client contact
Home treatment/crisis team member £37 per hour per team member
Assertive outreach team member £49 per hour of patient contact
Early intervention team member £37 per hour
Social worker £226 per hour of face-to-face contact
Mental health nurse £74 per hour of face-to-face contact
Occupational therapist £44 per hour
Accident and emergency service £125 per attendance
Drug/alcohol service £38 per user session
Community mental health centre £38 per user session
Day care centre/day hospital £38 per user session
Drop-in centre £38 per user session
Self-help/support group £38 per user session
Class/group at a leisure centre £38 per user session
Adult education class £38 per user session
Other day care activity provided by team £38 per user session
Inpatient admission £345 per day (psychiatric); £577 per day (other) Department of Health
(2012)111
Contact with police £1 per minute Bedfordshire Police Authority
(2009)112
Night detained in a police cell £414 per night Heslin et al. (2016)113
National average wage £26,500 per year Office for National Statistics
(2013)114
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Appendix 13 Intervention costs
Individual psychoeducation sessions
Delivered by a band 6 mental health nurse, psychology graduate or other mental health professional.
1-hour session.
Unit cost= £119 per session.
Problem-solving group session
Delivered by two band 6 mental health nurses, psychology graduates or other mental health professionals.
2-hour sessions.
Average of 7.5 participants.
Unit cost= £63 per session.
Individual support as part of group therapy
Delivered by a band 6 mental health nurse, psychology graduate or other mental health professional.
1-hour session.
Unit cost= £119 per session.
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Appendix 14 Qualitative interview schedule:
post intervention – psychoeducation
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Appendix 15 Qualitative interview schedule:
post intervention – problem-solving therapy
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Appendix 16 Qualitative interview schedule:
72-week follow-up – psychoeducation with
problem-solving therapy
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Appendix 17 Qualitative interview schedule:
72-week follow-up – usual treatment
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